UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED ~~March 31,~~June 30, 2023

OR

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM _____TO

COMMISSION FILE NUMBER: 814-00802

HORIZON TECHNOLOGY FINANCE CORPORATION

(Exact name of registrant as specified in its charter)

Delaware		27-2114934
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)
312 Farmington Avenue
Farmington, CT		06032
(Address of principal executive offices)		(Zip Code)

(860) 676‑8654

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☐☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b‑2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☐
Emerging growth company	☐


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act	☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b‑2 of the Exchange Act). Yes ☐ No ☒

The number of shares of the registrant’s common stock traded under the symbol “HRZN” on the Nasdaq Global Select Market, $0.001 par value per share, outstanding as of ~~May 2,~~August 1, 2023 was ~~28,656,554.~~32,103,683.

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Ticker symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	HRZN	The Nasdaq Stock Market LLC
4.875% Notes due 2026	HTFB	The New York Stock Exchange
6.25% Notes due 2027	HTFC	The New York Stock Exchange

Table of Contents

	*March 31,*			*December 31,*			*June 30,*			*December 31,*
	*2023*			*2022*			*2023*			*2022*
	(Unaudited)						(Unaudited)
Assets
Non-affiliate investments at fair value (cost of $724,162 and $721,248, respectively)	$	714,466		$	720,026
Non-affiliate investments at fair value (cost of $723,633 and $721,248, respectively)							$	714,485		$	720,026
Non-controlled affiliate investments at fair value (cost of $0 and $0, respectively) (Note 5)		846			—			906			—
Total investments at fair value (cost of $724,162 and $721,248, respectively) (Note 4)		715,312			720,026
Total investments at fair value (cost of $723,633 and $721,248, respectively) (Note 4)								715,391			720,026
Cash		19,844			20,612			24,395			20,612
Investments in money market funds		23,698			7,066			25,865			7,066
Restricted investments in money market funds		2,987			2,788			2,904			2,788
Interest receivable		13,843			13,573			14,893			13,573
Other assets		2,554			2,761			3,960			2,761
Total assets	$	778,238		$	766,826		$	787,408		$	766,826

Liabilities
Borrowings (Note 7)	$	439,645		$	434,078		$	418,016		$	434,078
Distributions payable		9,365			9,159			10,592			9,159
Base management fee payable (Note 3)		1,059			1,065			1,063			1,065
Incentive fee payable (Note 3)		2,978			1,392			118			1,392
Other accrued expenses		3,508			2,684			2,200			2,684
Total liabilities		456,555			448,378			431,989			448,378

Commitments and contingencies (Notes 3 and 8)

Net assets
Preferred stock, par value $0.001 per share, 1,000,000 shares authorized, zero shares issued and outstanding as of March 31, 2023 and December 31, 2022		—			—
Common stock, par value $0.001 per share, 100,000,000 shares authorized, 28,544,822 and 27,920,838 shares issued and 28,377,357 and 27,753,373 shares outstanding as of March 31, 2023 and December 31, 2022, respectively		30			29
Preferred stock, par value $0.001 per share, 1,000,000 shares authorized, zero shares issued and outstanding as of June 30, 2023 and December 31, 2022								—			—
Common stock, par value $0.001 per share, 100,000,000 shares authorized, 32,263,724 and 27,920,838 shares issued and 32,096,259 and 27,753,373 shares outstanding as of June 30, 2023 and December 31, 2022, respectively								34			29
Paid-in capital in excess of par		393,312			385,921			437,561			385,921
Distributable earnings (loss)		(71,659	)		(67,502	)
Distributable loss								(82,176	)		(67,502	)
Total net assets		321,683			318,448			355,419			318,448
Total liabilities and net assets	$	778,238		$	766,826		$	787,408		$	766,826
Net asset value per common share	$	11.34		$	11.47		$	11.07		$	11.47

							*For the Three Months Ended*						*For The Six Months Ended*
	*For the Three Months Ended*						*June 30,*						*June 30,*
	*March 31,*						*2023*			*2022*			*2023*			*2022*
	*2023*			*2022*
Investment income
Interest income on non-affiliate investments	$	27,399		$	13,853		$	26,624		$	17,720		$	54,023		$	31,573
Fee income on non-affiliate investments		638			351			1,493			868			2,131			1,219
Total investment income		28,037			14,204			28,117			18,588			56,154			32,792
Expenses
Interest expense		7,120			3,424			7,179			4,225			14,299			7,649
Base management fee (Note 3)		3,201			2,244			3,207			2,523			6,408			4,767
Performance based incentive fee (Note 3)		2,978			1,424			118			2,145			3,094			3,570
Administrative fee (Note 3)		440			362			368			374			808			735
Professional fees		658			577			447			271			1,106			848
General and administrative		445			344			546			362			992			706
Total expenses		14,842			8,375			11,865			9,900			26,707			18,275
Net investment income before excise tax		13,195			5,829			16,252			8,688			29,447			14,517
Provision for excise tax		184			100			179			106			363			206
Net investment income		13,011			5,729			16,073			8,582			29,084			14,311
Net realized and unrealized loss
Net realized (loss) gain on non-affiliate investments		(168	)		30			(16,529	)		271			(16,697	)		301
Net realized (loss) gain on investments		(168	)		30
Net unrealized depreciation on non-affiliate investments		(8,383	)		(2,287	)
Net realized loss on controlled affiliate investments								—			(1,200	)		—			(1,200	)
Net realized loss on investments								(16,529	)		(929	)		(16,697	)		(899	)
Net unrealized appreciation (depreciation) on non-affiliate investments								548			(1,436	)		(7,835	)		(3,723	)
Net unrealized appreciation on non-controlled affiliate investments		846			—			60			—			906			—
Net unrealized appreciation on controlled affiliate investments		—			50			—			1,400			—			1,450
Net unrealized depreciation on investments		(7,537	)		(2,237	)
Net unrealized appreciation (depreciation) on investments								608			(36	)		(6,929	)		(2,273	)
Net realized and unrealized loss		(7,705	)		(2,207	)		(15,921	)		(965	)		(23,626	)		(3,172	)
Net increase in net assets resulting from operations	$	5,306		$	3,522		$	152		$	7,617		$	5,458		$	11,139
Net investment income per common share	$	0.46		$	0.26		$	0.54		$	0.35		$	1.00		$	0.62
Net increase in net assets resulting from operations per common share	$	0.19		$	0.16		$	0.01		$	0.31		$	0.19		$	0.48
Distributions declared per share	$	0.33		$	0.30		$	0.33		$	0.30		$	0.66		$	0.60
Weighted average shares outstanding		28,227,100			21,904,160			29,747,290			24,301,762			28,987,948			23,109,584

					*Paid-In Capital*												*Paid-In Capital*
	*Common Stock*				*in Excess of*		*Distributable*			*Total Net*			*Common Stock*				*in Excess of*		*Distributable*			*Total Net*
	*Shares*		*Amount*		*Par*		*Earnings*			*Assets*			*Shares*		*Amount*		*Par*		*Earnings*			*Assets*
Balance at December 31, 2021		21,217,460	$	22	$	301,359		(56,046	)	$	245,335
Issuance of common stock, net of offering costs		2,750,171		3		38,184		—			38,187
Net increase in net assets resulting from operations, net of excise tax:
Net investment income, net of excise tax		—		—		—		5,729			5,729
Net realized gain on investments		—		—		—		30			30
Net unrealized depreciation on investments		—		—		—		(2,237	)		(2,237	)
Issuance of common stock under dividend reinvestment plan		9,506		—		145		—			145
Distributions declared		—		—		—		(7,200	)		(7,200	)
Balance at March 31, 2022		23,977,137		25		339,688		(59,724	)		279,989			23,977,137	$	25	$	339,688		(59,724	)	$	279,989

Balance at December 31, 2022		27,753,373		29		385,921		(67,502	)		318,448
Issuance of common stock, net of offering costs		605,848		1		7,173		—			7,174			868,230		1		10,340		—			10,341
Net increase in net assets resulting from operations, net of excise tax:
Net investment income, net of excise tax		—		—		—		13,011			13,011			—		—		—		8,582			8,582
Net realized loss on investments		—		—		—		(168	)		(168	)		—		—		—		(929	)		(929	)
Net unrealized depreciation on investments		—		—		—		(7,537	)		(7,537	)		—		—		—		(36	)		(36	)
Issuance of common stock under dividend reinvestment plan		18,136		—		218		—			218			11,737		—		145		—			145
Distributions declared		—		—		—		(9,463	)		(9,463	)		—		—		—		(7,487	)		(7,487	)
Balance at June 30, 2022														24,857,104		26		350,173		(59,594	)		290,605

Balance at March 31, 2023		28,377,357	$	30	$	393,312	$	(71,659	)	$	321,683			28,377,357		30		393,312		(71,659	)		321,683
Issuance of common stock, net of offering costs														3,698,175		4		43,998		—			44,002
Net increase in net assets resulting from operations, net of excise tax:
Net investment income, net of excise tax														—		—		—		16,073			16,073
Net realized loss on investments														—		—		—		(16,529	)		(16,529	)
Net unrealized appreciation on investments														—		—		—		608			608
Issuance of common stock under dividend reinvestment plan														20,727		—		251		—			251
Distributions declared														—		—		—		(10,669	)		(10,669	)
Balance at June 30, 2023														32,096,259	$	34	$	437,561	$	(82,176	)	$	355,419

	*For the three months ended March 31,*						*For the six months ended June 30,*
	*2023*			*2022*			*2023*			*2022*
Cash flows from operating activities:
Net increase in net assets resulting from operations	$	5,306		$	3,522		$	5,458		$	11,139
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used in) operating activities:
Amortization of debt issuance costs		478			336			950			705
Net realized loss (gain) on investments		168			(30	)
Net realized loss on investments								16,697			899
Net unrealized depreciation on investments		7,537			2,237			6,929			2,273
Purchase of investments		(47,008	)		(94,485	)		(87,553	)		(253,720	)
Principal payments received on investments		39,756			14,145			64,496			87,473
Payment-in-kind interest on investments		(1,204	)		—			(2,154	)		—
Proceeds from sale of investments		6,520			21,280			8,506			43,426
Equity received in settlement of fee income								(89	)		—
Changes in assets and liabilities:
Decrease (increase) in interest receivable		840			(866	)		65			(1,019	)
Increase in end-of-term payments		(1,017	)		(1,285	)		(1,291	)		(1,911	)
Decrease in unearned income		(1,148	)		(81	)
(Decrease) increase in unearned income								(2,291	)		232
Decrease in other assets		98			652			(717	)		(620	)
Increase (decrease) in other accrued expenses		824			(274	)
(Decrease) increase in other accrued expenses								(484	)		91
(Decrease) increase in base management fee payable		(6	)		79			(2	)		165
Increase (decrease) in incentive fee payable		1,586			(591	)
(Decrease) increase in incentive fee payable								(1,274	)		130
Net cash provided by (used in) operating activities		12,730			(55,361	)		7,246			(110,737	)
Cash flows from financing activities:
Proceeds from issuance of 2027 Notes								—			50,000
Repayment of 2019 Asset-Backed Notes		(4,783	)		(12,352	)		(11,765	)		(20,702	)
Proceeds from issuance of common stock, net of offering costs		7,174			38,187			51,175			48,529
Advances on Credit Facilities		10,000			25,000			30,000			119,000
Repayment of Credit Facilities		—			(20,000	)		(35,000	)		(40,000	)
Debt issuance costs		(19	)		(550	)		(729	)		(2,170	)
Distributions paid		(9,039	)		(6,227	)		(18,229	)		(13,306	)
Net cash provided by financing activities		3,333			24,058			15,452			141,351
Net increase (decrease) in cash, cash equivalents and restricted cash		16,063			(31,303	)
Net increase in cash, cash equivalents and restricted cash								22,698			30,614
Cash, cash equivalents and restricted cash:
Beginning of period		30,466			47,281			30,466			47,281
End of period	$	46,529		$	15,978		$	53,164		$	77,895

Supplemental disclosure of cash flow information:
Cash paid for interest	$	6,623		$	3,044		$	13,409		$	6,535
Supplemental non-cash investing and financing activities:
Warrant investments received and recorded as unearned income	$	141		$	1,174		$	656		$	1,845
Distributions payable	$	9,365		$	7,193		$	10,592		$	7,457
End-of-term payments receivable	$	10,799		$	6,522		$	11,074		$	7,149
Non-cash income	$	3,944		$	1,424		$	7,182		$	2,378

	*March 31,*				*June 30,*
	*2023*		*2022*		*2023*		*2022*
Cash	$	19,844	$	12,452	$	24,395	$	54,353
Investments in money market funds		23,698		2,011		25,865		21,959
Restricted investments in money market funds		2,987		1,515		2,904		1,583
Total cash, cash equivalents and restricted cash	$	46,529	$	15,978	$	53,164	$	77,895

Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*			*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*		*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*			*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Non-Affiliate Investments — 222.1% (8)
Non-Affiliate Debt Investments — 212.8% (8)
Non-Affiliate Debt Investments — Life Science — 95.7% (8)
Non-Affiliate Investments — 201.1% (8)
Non-Affiliate Debt Investments — 192.3% (8)
Non-Affiliate Debt Investments — Life Science — 82.9% (8)
Avalo Therapeutics, Inc. (2)(5)(12)	Biotechnology	Term Loan		14.25	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025	$	2,913	$	2,860	$	2,779	Biotechnology	Term Loan		14.50	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025	$	2,055	$	2,011	$	1,938
		Term Loan		14.25	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025		2,885		2,832		2,752		Term Loan		14.50	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025		2,028		1,982		1,910
		Term Loan		14.25	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025		1,442		1,416		1,375		Term Loan		14.50	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025		1,014		991		955
		Term Loan		14.25	%	Prime		6.25	%		9.50	%		-			3.00	%	February 1, 2025		2,885		2,829		2,749		Term Loan		14.50	%	Prime		6.25	%		9.50	%		-			3.00	%	February 1, 2025		2,028		1,980		1,907
		Term Loan		14.25	%	Prime		6.25	%		9.50	%		-			3.00	%	February 1, 2025		2,885		2,829		2,749		Term Loan		14.50	%	Prime		6.25	%		9.50	%		-			3.00	%	February 1, 2025		2,028		1,980		1,907
		Term Loan		14.25	%	Prime		6.25	%		9.50	%		-			3.00	%	April 1, 2025		1,442		1,412		1,370		Term Loan		14.50	%	Prime		6.25	%		9.50	%		-			3.00	%	April 1, 2025		1,014		987		951
		Term Loan		14.25	%	Prime		6.25	%		9.50	%		-			3.00	%	April 1, 2025		1,442		1,412		1,370		Term Loan		14.50	%	Prime		6.25	%		9.50	%		-			3.00	%	April 1, 2025		1,014		987		951
Castle Creek Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		12.88	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,895		4,895	Biotechnology	Term Loan		13.13	%	Prime		4.88	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,899		4,899
		Term Loan		12.88	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,967		4,967		Term Loan		13.13	%	Prime		4.88	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,971		4,971
		Term Loan		12.88	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		3,000		2,977		2,977		Term Loan		13.13	%	Prime		4.88	%		9.55	%		13.50	%		5.50	%	May 1, 2026		3,000		2,982		2,982
		Term Loan		12.88	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,967		4,967		Term Loan		13.13	%	Prime		4.88	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,971		4,971
		Term Loan		12.88	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,970		4,970		Term Loan		13.13	%	Prime		4.88	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,971		4,971
		Term Loan		12.88	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		3,000		2,980		2,980		Term Loan		13.13	%	Prime		4.88	%		9.55	%		13.50	%		5.50	%	May 1, 2026		3,000		2,982		2,982
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		12.57	%	Libor		4.72	%		9.75	%		-			5.00	%	June 1, 2024		1,979		1,965		1,965	Biotechnology	Term Loan		12.97	%	Prime		4.72	%		9.75	%		-			5.00	%	June 1, 2024		1,979		1,968		1,968
		Term Loan		12.57	%	Libor		4.72	%		9.75	%		-			5.00	%	June 1, 2024		1,979		1,966		1,966		Term Loan		12.97	%	Prime		4.72	%		9.75	%		-			5.00	%	June 1, 2024		1,979		1,969		1,969
		Term Loan		12.57	%	Libor		4.72	%		9.75	%		-			5.00	%	November 1, 2025		5,000		4,930		4,930		Term Loan		12.97	%	Prime		4.72	%		9.75	%		-			5.00	%	November 1, 2025		5,000		4,936		4,936
		Term Loan		12.57	%	Libor		4.72	%		9.75	%		-			5.00	%	May 1, 2026		5,000		4,921		4,921		Term Loan		12.97	%	Prime		4.72	%		9.75	%		-			5.00	%	May 1, 2026		5,000		4,930		4,930
Evelo Biosciences, Inc. (2)(5)(12)	Biotechnology	Term Loan		12.25	%	Prime		4.25	%		11.00	%		-			4.25	%	January 1, 2028		10,000		9,880		9,880	Biotechnology	Term Loan		12.50	%	Prime		4.25	%		11.00	%		-			4.25	%	January 1, 2028		10,000		9,887		9,887
		Term Loan		12.25	%	Prime		4.25	%		11.00	%		-			4.25	%	January 1, 2028		15,000		14,819		14,819		Term Loan		12.50	%	Prime		4.25	%		11.00	%		-			4.25	%	January 1, 2028		15,000		14,830		14,830
		Term Loan		12.25	%	Prime		4.25	%		11.00	%		-			4.25	%	January 1, 2028		6,000		5,928		5,928		Term Loan		12.50	%	Prime		4.25	%		11.00	%		-			4.25	%	January 1, 2028		6,000		5,932		5,932
		Term Loan		12.25	%	Prime		4.25	%		11.00	%		-			4.25	%	January 1, 2028		6,000		5,928		5,928		Term Loan		12.50	%	Prime		4.25	%		11.00	%		-			4.25	%	January 1, 2028		6,000		5,932		5,932
		Term Loan		12.25	%	Prime		4.25	%		11.00	%		-			4.25	%	January 1, 2028		4,000		3,952		3,952		Term Loan		12.50	%	Prime		4.25	%		11.00	%		-			4.25	%	January 1, 2028		4,000		3,955		3,955
		Term Loan		12.25	%	Prime		4.25	%		11.00	%		-			4.25	%	January 1, 2028		4,000		3,952		3,952		Term Loan		12.50	%	Prime		4.25	%		11.00	%		-			4.25	%	January 1, 2028		4,000		3,955		3,955
Greenlight Biosciences, Inc. (2)(5)(12)	Biotechnology	Term Loan		13.75	%	Prime		5.75	%		9.00	%		-			3.00	%	July 1, 2025		4,500		4,371		4,352	Biotechnology	Term Loan		14.00	%	Prime		5.75	%		9.00	%		-			3.00	%	July 1, 2025		4,000		3,886		3,859
		Term Loan		13.75	%	Prime		5.75	%		9.00	%		-			3.00	%	July 1, 2025		2,250		2,187		2,177		Term Loan		14.00	%	Prime		5.75	%		9.00	%		-			3.00	%	July 1, 2025		2,000		1,944		1,931
IMV Inc. (2)(5)(12)	Biotechnology	Term Loan		13.75	%	Prime		5.75	%		9.00	%		-			5.00	%	July 1, 2025		5,000		4,951		4,759
IMV Inc. (5)(12)(13)(15)																										Biotechnology	Term Loan		14.00	%	Prime		5.75	%		9.00	%		-			5.00	%	July 1, 2025		5,035		4,988		2,814
		Term Loan		13.75	%	Prime		5.75	%		9.00	%		-			5.00	%	July 1, 2025		2,500		2,476		2,380		Term Loan		14.00	%	Prime		5.75	%		9.00	%		-			5.00	%	July 1, 2025		2,500		2,476		1,397
		Term Loan		13.75	%	Prime		5.75	%		9.00	%		-			5.00	%	January 1, 2026		5,000		4,953		4,761		Term Loan		14.00	%	Prime		5.75	%		9.00	%		-			5.00	%	January 1, 2026		5,000		4,953		2,795
		Term Loan		13.75	%	Prime		5.75	%		9.00	%		-			5.00	%	January 1, 2026		5,000		4,953		4,761		Term Loan		14.00	%	Prime		5.75	%		9.00	%		-			5.00	%	January 1, 2026		5,000		4,953		2,794
KSQ Therapeutics, Inc. (2) (12)	Biotechnology	Term Loan		12.75	%	Prime		4.75	%		8.50	%		-			5.50	%	May 1, 2027		6,250		6,082		6,082
KSQ Therapeutics, Inc. (2)(12)																										Biotechnology	Term Loan		13.00	%	Prime		4.75	%		8.50	%		-			5.50	%	May 1, 2027		6,250		6,188		6,188
		Term Loan		12.75	%	Prime		4.75	%		8.50	%		-			5.50	%	May 1, 2027		6,250		6,182		6,182		Term Loan		13.00	%	Prime		4.75	%		8.50	%		-			5.50	%	May 1, 2027		6,250		6,188		6,188
Native Microbials, Inc (2) (12)	Biotechnology	Term Loan		13.25	%	Prime		5.25	%		8.50	%		-			5.00	%	November 1, 2026		3,750		3,707		3,707
Native Microbials, Inc (2)(12)																										Biotechnology	Term Loan		13.50	%	Prime		5.25	%		8.50	%		-			5.00	%	November 1, 2026		3,750		3,711		3,711
		Term Loan		13.25	%	Prime		5.25	%		8.50	%		-			5.00	%	November 1, 2026		2,500		2,472		2,472		Term Loan		13.50	%	Prime		5.25	%		8.50	%		-			5.00	%	November 1, 2026		2,500		2,475		2,475
PDS Biotechnology Corporation (2)(5)(12)	Biotechnology	Term Loan		13.75	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		10,000		9,714		9,714	Biotechnology	Term Loan		14.00	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		10,000		9,727		9,727
		Term Loan		13.75	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		3,750		3,702		3,702		Term Loan		14.00	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		3,750		3,707		3,707
		Term Loan		13.75	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		3,750		3,702		3,702		Term Loan		14.00	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		3,750		3,707		3,707
Provivi, Inc. (2)(12)	Biotechnology	Term Loan		13.17	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		4,667		4,606		4,606	Biotechnology	Term Loan		13.61	%	Prime		5.36	%		9.50	%		-			5.50	%	December 1, 2024		4,667		4,605		4,605
		Term Loan		13.17	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		4,667		4,606		4,606		Term Loan		13.61	%	Prime		5.36	%		9.50	%		-			5.50	%	December 1, 2024		4,667		4,605		4,605
		Term Loan		13.17	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,287		2,287		Term Loan		13.61	%	Prime		5.36	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,289		2,289
		Term Loan		13.17	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,287		2,287		Term Loan		13.61	%	Prime		5.36	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,289		2,289
		Term Loan		13.17	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,282		2,282		Term Loan		13.61	%	Prime		5.36	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,284		2,284
		Term Loan		13.17	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,282		2,282		Term Loan		13.61	%	Prime		5.36	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,284		2,284

Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*		*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*		*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*		*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Stealth Biotherapeutics Inc. (2)(12)	Biotechnology	Term Loan		13.50	%	Prime		5.50	%		8.75	%		-		6.00	%	October 1, 2025		5,000		4,922		4,922	Biotechnology	Term Loan		13.75	%	Prime		5.50	%		8.75	%		-		6.00	%	October 1, 2025		4,750		4,680		4,680
		Term Loan		13.50	%	Prime		5.50	%		8.75	%		-		6.00	%	October 1, 2025		2,500		2,461		2,461		Term Loan		13.75	%	Prime		5.50	%		8.75	%		-		6.00	%	October 1, 2025		2,375		2,338		2,338
Aerobiotix, LLC (2)(12)	Medical Device	Term Loan		14.25	%	Prime		6.25	%		9.50	%		-		6.00	%	April 1, 2026		2,500		2,467		2,361	Medical Device	Term Loan		14.50	%	Prime		6.25	%		9.50	%		-		6.00	%	April 1, 2026		2,500		2,471		2,358
		Term Loan		14.25	%	Prime		6.25	%		9.50	%		-		6.00	%	April 1, 2026		2,500		2,467		2,361		Term Loan		14.50	%	Prime		6.25	%		9.50	%		-		6.00	%	April 1, 2026		2,500		2,471		2,358
Ceribell, Inc. (2)(12)	Medical Device	Term Loan		11.25	%	Prime		3.50	%		8.25	%		-		5.50	%	October 1, 2024		5,000		4,977		4,977	Medical Device	Term Loan		11.75	%	Prime		3.50	%		8.25	%		-		5.50	%	October 1, 2024		5,000		4,981		4,981
		Term Loan		11.25	%	Prime		3.50	%		8.25	%		-		5.50	%	October 1, 2024		5,000		4,977		4,977		Term Loan		11.75	%	Prime		3.50	%		8.25	%		-		5.50	%	October 1, 2024		5,000		4,981		4,981
		Term Loan		11.25	%	Prime		3.50	%		8.25	%		-		5.50	%	October 1, 2024		2,500		2,481		2,481		Term Loan		11.75	%	Prime		3.50	%		8.25	%		-		5.50	%	October 1, 2024		2,500		2,485		2,485
		Term Loan		11.25	%	Prime		3.50	%		8.25	%		-		5.50	%	October 1, 2024		2,500		2,481		2,481		Term Loan		11.75	%	Prime		3.50	%		8.25	%		-		5.50	%	October 1, 2024		2,500		2,485		2,485
Cognoa, Inc. (2)(12)	Medical Device	Term Loan		13.50	%	Prime		5.50	%		8.75	%		-		6.00	%	August 1, 2026		5,000		4,940		4,940	Medical Device	Term Loan		13.75	%	Prime		5.50	%		8.75	%		-		6.00	%	August 1, 2026		5,000		4,948		4,948
		Term Loan		13.50	%	Prime		5.50	%		8.75	%		-		6.00	%	August 1, 2026		2,500		2,470		2,470		Term Loan		13.75	%	Prime		5.50	%		8.75	%		-		6.00	%	August 1, 2026		2,500		2,474		2,474
Conventus Orthopaedics, Inc. (2)(12)	Medical Device	Term Loan		12.67	%	Libor		8.00	%		9.25	%		-		10.36	%	July 1, 2025		3,960		3,904		3,904	Medical Device	Term Loan		13.07	%	Prime		4.82	%		9.25	%		-		10.36	%	July 1, 2025		3,960		3,910		3,910
		Term Loan		12.67	%	Libor		8.00	%		9.25	%		-		10.36	%	July 1, 2025		3,960		3,904		3,904
Corinth Medtech, Inc. (2)(12)	Medical Device	Term Loan		13.00	% (11)	Prime		5.25	%		8.50	%		-		20.00	%	June 30, 2023		2,528		2,528		2,528
		Term Loan		13.00	% (11)	Prime		5.25	%		8.50	%		-		20.00	%	June 30, 2023		2,528		2,528		2,528
		Term Loan		13.00	% (11)	Prime		5.25	%		8.50	%		-		50.00	%	June 30, 2023		200		200		200		Term Loan		13.07	%	Prime		4.82	%		9.25	%		-		10.36	%	July 1, 2025		3,960		3,910		3,910
CSA Medical, Inc. (2)(12)	Medical Device	Term Loan		12.87	%	Libor		8.20	%		10.00	%		-		5.00	%	January 1, 2024		1,250		1,239		1,239	Medical Device	Term Loan		13.34	%	Prime		5.09	%		10.00	%		-		5.00	%	January 1, 2024		875		867		867
		Term Loan		12.87	%	Libor		8.20	%		10.00	%		-		5.00	%	January 1, 2024		83		83		83		Term Loan		13.34	%	Prime		5.09	%		10.00	%		-		5.00	%	January 1, 2024		58		58		58
		Term Loan		12.87	%	Libor		8.20	%		10.00	%		-		5.00	%	March 1, 2024		1,600		1,587		1,587		Term Loan		13.34	%	Prime		5.09	%		10.00	%		-		5.00	%	March 1, 2024		1,200		1,191		1,191
InfoBionic, Inc. (2)(12)	Medical Device	Term Loan		14.00	%	Prime		6.25	%		9.50	%		-		4.00	%	October 1, 2024		2,771		2,715		2,715	Medical Device	Term Loan		14.50	%	Prime		6.25	%		9.50	%		-		4.00	%	October 1, 2024		2,771		2,724		2,724
		Term Loan		14.00	%	Prime		6.25	%		9.50	%		-		4.00	%	June 1, 2025		1,000		977		977		Term Loan		14.50	%	Prime		6.25	%		9.50	%		-		4.00	%	June 1, 2025		1,000		979		979
Magnolia Medical Technologies, Inc. (2)(12)	Medical Device	Term Loan		12.75	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,946		4,946	Medical Device	Term Loan		13.25	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,953		4,953
		Term Loan		12.75	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,946		4,946		Term Loan		13.25	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,953		4,953
		Term Loan		12.75	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,940		4,940		Term Loan		13.25	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,948		4,948
		Term Loan		12.75	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,941		4,941		Term Loan		13.25	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,949		4,949
		Term Loan		12.75	%	Prime		5.00	%		9.75	%		-		4.00	%	January 1, 2027		5,000		4,920		4,920		Term Loan		13.25	%	Prime		5.00	%		9.75	%		-		4.00	%	January 1, 2027		5,000		4,927		4,927
		Term Loan		12.75	%	Prime		5.00	%		9.75	%		-		4.00	%	January 1, 2027		5,000		4,920		4,920		Term Loan		13.25	%	Prime		5.00	%		9.75	%		-		4.00	%	January 1, 2027		5,000		4,927		4,927
Robin Healthcare, Inc. (2)(12)	Medical Device	Term Loan		13.50	%	Prime		5.50	%		10.25	%		-		4.00	%	November 1, 2026		3,500		3,413		3,413	Medical Device	Term Loan		13.75	%	Prime		5.50	%		10.25	%		-		4.00	%	November 1, 2026		3,500		3,417		3,417
		Term Loan		13.50	%	Prime		5.50	%		10.25	%		-		4.00	%	November 1, 2026		3,500		3,463		3,463		Term Loan		13.75	%	Prime		5.50	%		10.25	%		-		4.00	%	November 1, 2026		3,500		3,467		3,467
Scientia Vascular, Inc. (2)(12)	Medical Device	Term Loan		12.50	%	Prime		4.75	%		8.50	%		-		5.00	%	January 1, 2027		3,750		3,601		3,601	Medical Device	Term Loan		13.00	%	Prime		4.75	%		8.50	%		-		5.00	%	January 1, 2027		3,750		3,659		3,659
		Term Loan		12.50	%	Prime		4.75	%		8.50	%		-		5.00	%	January 1, 2027		3,750		3,710		3,710		Term Loan		13.00	%	Prime		4.75	%		8.50	%		-		5.00	%	January 1, 2027		3,750		3,714		3,714
																										Term Loan		13.50	%	Prime		5.25	%		9.00	%		-		5.00	%	March 1, 2027		5,000		4,928		4,928
Sonex Health, Inc. (2)(12)	Medical Device	Term Loan		14.25	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,478		2,478	Medical Device	Term Loan		14.75	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,481		2,481
		Term Loan		14.25	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,478		2,478		Term Loan		14.75	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,481		2,481
		Term Loan		14.25	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,478		2,478		Term Loan		14.75	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,481		2,481
		Term Loan		14.25	%	Prime		6.50	%		9.75	%		-		8.00	%	April 1, 2026		2,500		2,459		2,459		Term Loan		14.75	%	Prime		6.50	%		9.75	%		-		8.00	%	April 1, 2026		2,500		2,463		2,463
		Term Loan		14.25	%	Prime		6.50	%		9.75	%		-		8.00	%	May 1, 2026		2,500		2,458		2,458		Term Loan		14.75	%	Prime		6.50	%		9.75	%		-		8.00	%	May 1, 2026		2,500		2,462		2,462
Spineology, Inc. (2)(12)	Medical Device	Term Loan		15.00	%	Prime		7.00	%		10.25	%		-		1.00	%	October 1, 2025		5,000		4,969		4,969	Medical Device	Term Loan		15.25	%	Prime		7.00	%		10.25	%		-		1.00	%	October 1, 2025		5,000		4,972		4,972
		Term Loan		15.00	%	Prime		7.00	%		10.25	%		-		1.00	%	April 1, 2026		2,500		2,483		2,483		Term Loan		15.25	%	Prime		7.00	%		10.25	%		-		1.00	%	April 1, 2026		2,500		2,485		2,485

Portfolio Company (1)(3)		*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*		*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*			*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*		*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Swift Health Systems Inc. (2)(12)		Medical Device	Term Loan		13.00	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,457		3,457		Medical Device	Term Loan		13.50	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,460		3,460
			Term Loan		13.00	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,457		3,457			Term Loan		13.50	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,460		3,460
			Term Loan		13.25	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,447		3,447			Term Loan		13.50	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,450		3,450
			Term Loan		13.25	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,447		3,447			Term Loan		13.50	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,450		3,450
Total Non-Affiliate Debt Investments — Life Science	Total Non-Affiliate Debt Investments — Life Science																						309,108		307,749	Total Non-Affiliate Debt Investments — Life Science																						302,687		294,452
Non-Affiliate Debt Investments — Sustainability — 25.8% (8)
Aerofarms, Inc. (2)(12)		Other Sustainability	Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		3.00	%	April 1, 2026		3,750		3,704		3,585
Non-Affiliate Debt Investments — Sustainability — 23.4% (8)
Aerofarms, Inc. (12)																											Other Sustainability	Term Loan		15.00	%	Prime		6.75	%		10.00	%		-		3.00	%	April 1, 2026		3,750		3,710		3,585
			Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		3.00	%	April 1, 2026		3,750		3,704		3,585			Term Loan		15.00	%	Prime		6.75	%		10.00	%		-		3.00	%	April 1, 2026		3,750		3,710		3,585
Nexii Building Solutions, Inc. (2)(12)		Other Sustainability	Term Loan		15.00	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,383		7,245
Nexii Building Solutions, Inc. (2)(12)(15)																											Other Sustainability	Term Loan		15.25	%	Prime		7.00	%		10.25	%		-		2.50	%	August 27, 2025		7,500		7,395		7,024
																												Term Loan		15.25	%	Prime		7.00	%		10.25	%		-		2.50	%	August 27, 2025		7,500		7,395		7,024
																												Term Loan		15.25	%	Prime		7.00	%		10.25	%		-		2.50	%	August 27, 2025		7,500		7,395		7,024
			Term Loan		15.00	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,383		7,245			Term Loan		15.25	%	Prime		7.00	%		10.25	%		-		2.50	%	June 8, 2026		5,000		4,922		4,675
			Term Loan		15.00	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,383		7,245			Term Loan		15.25	%	Prime		7.00	%		10.25	%		-		2.50	%	June 8, 2026		5,000		4,922		4,675
			Term Loan		15.00	%	Prime		7.00	%		10.25	%		-		2.50	%	July 1, 2026		5,000		4,912		4,820			Term Loan		15.25	% (11)	Prime		7.00	%		10.25	%		-		-		September 30, 2023		680		680		646
			Term Loan		15.00	%	Prime		7.00	%		10.25	%		-		2.50	%	July 1, 2026		5,000		4,912		4,820			Term Loan		15.25	% (11)	Prime		7.00	%		10.25	%		-		-		September 30, 2023		542		542		515
Soli Organic, Inc. (2)(12)		Other Sustainability	Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.75	%	April 1, 2026		5,000		4,935		4,935		Other Sustainability	Term Loan		15.00	%	Prime		6.75	%		10.00	%		-		2.75	%	April 1, 2026		5,000		4,942		4,942
			Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.75	%	April 1, 2026		2,500		2,467		2,467			Term Loan		15.00	%	Prime		6.75	%		10.00	%		-		2.75	%	April 1, 2026		2,500		2,471		2,471
			Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.75	%	May 1, 2026		5,000		4,932		4,932			Term Loan		15.00	%	Prime		6.75	%		10.00	%		-		2.75	%	May 1, 2026		5,000		4,940		4,940
			Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.75	%	May 1, 2026		2,500		2,466		2,466			Term Loan		15.00	%	Prime		6.75	%		10.00	%		-		2.75	%	May 1, 2026		2,500		2,470		2,470
			Term Loan		13.50	%	Prime		5.50	%		11.75	%		-		2.75	%	December 1, 2026		5,000		4,909		4,909			Term Loan		13.75	%	Prime		5.50	%		11.75	%		-		2.75	%	December 1, 2026		5,000		4,917		4,917
			Term Loan		13.50	%	Prime		5.50	%		11.75	%		-		2.75	%	December 1, 2026		2,500		2,454		2,454			Term Loan		13.75	%	Prime		5.50	%		11.75	%		-		2.75	%	December 1, 2026		2,500		2,458		2,458
Temperpack Technologies, Inc. (2)(12)		Other Sustainability	Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.50	%	June 1, 2025		3,750		3,706		3,706		Other Sustainability	Term Loan		15.00	%	Prime		6.75	%		10.00	%		-		2.50	%	June 1, 2026		3,750		3,709		3,709
			Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.50	%	June 1, 2025		3,750		3,720		3,720			Term Loan		15.00	%	Prime		6.75	%		10.00	%		-		2.50	%	June 1, 2026		3,750		3,723		3,723
			Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		7,500		7,431		7,431			Term Loan		15.00	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2026		7,500		7,436		7,436
			Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		3,750		3,715		3,715			Term Loan		15.00	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2026		3,750		3,718		3,718
			Term Loan		14.75	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		3,750		3,715		3,715			Term Loan		15.00	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2026		3,750		3,718		3,718
Total Non-Affiliate Debt Investments — Sustainability	Total Non-Affiliate Debt Investments — Sustainability																						83,831		82,995	Total Non-Affiliate Debt Investments — Sustainability																						85,173		83,255
Non-Affiliate Debt Investments — Technology — 83.2% (8)
Non-Affiliate Debt Investments — Technology — 75.9% (8)
Axiom Space, Inc. (2)(12)		Communications	Term Loan		13.75	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,459		7,459		Communications	Term Loan		14.25	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,462		7,462
			Term Loan		13.75	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,459		7,459			Term Loan		14.25	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,462		7,462
			Term Loan		13.75	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,459		7,459			Term Loan		14.25	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,462		7,462
Better Place Forests Co. (12)(13)		Consumer-related Technologies	Term Loan		14.25	%	Prime		6.25	%		9.50	%		-		1.85	%	July 1, 2025		5,000		4,951		3,467		Consumer-related Technologies	Term Loan		14.50	%	Prime		6.25	%		9.50	%		-		1.85	%	July 1, 2025		5,104		5,056		3,426
			Term Loan		14.25	%	Prime		6.25	%		9.50	%		-		1.85	%	October 1, 2025		2,500		2,474		1,733			Term Loan		14.50	%	Prime		6.25	%		9.50	%		-		1.85	%	October 1, 2025		2,500		2,474		1,677
																												Term Loan		14.50	%	Prime		6.25	%		9.50	%		-		100.00	%	September 30, 2023		150		150		102
																												Term Loan		14.50	%	Prime		6.25	%		9.50	%		-		100.00	%	September 30, 2023		250		250		169
																												Term Loan		14.50	%	Prime		6.25	%		9.50	%		-		100.00	%	September 30, 2023		250		250		169
CAMP NYC, Inc. (2)(12)		Consumer-related Technologies	Term Loan		15.25	%	Prime		7.25	%		10.50	%		-		3.00	%	May 1, 2026		3,500		3,464		3,464		Consumer-related Technologies	Term Loan		15.50	%	Prime		7.25	%		10.50	%		-		3.00	%	May 1, 2026		3,500		3,467		3,467
Clara Foods Co. (2)(12)		Consumer-related Technologies	Term Loan		13.50	%	Prime		5.75	%		9.00	%		-		5.50	%	August 1, 2025		2,333		2,318		2,318		Consumer-related Technologies	Term Loan		14.00	%	Prime		5.75	%		9.00	%		-		5.50	%	August 1, 2025		2,083		2,069		2,069
			Term Loan		13.50	%	Prime		5.75	%		9.00	%		-		5.50	%	August 1, 2025		2,333		2,318		2,318			Term Loan		14.00	%	Prime		5.75	%		9.00	%		-		5.50	%	August 1, 2025		2,083		2,069		2,069

Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*			*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*		*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*			*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Divergent Technologies, Inc. (2)(12)	Consumer-related Technologies	Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,520		3,520	Consumer-related Technologies	Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,602		3,602
																											Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,240		1,240
																											Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,720		3,720
																											Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,240		1,240
																											Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,720		3,720
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,239		1,239		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,240		1,240
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,717		3,717		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	January 1, 2028		3,750		3,705		3,705
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,239		1,239		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	January 1, 2028		3,750		3,700		3,700
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,717		3,717		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	April 1, 2028		3,750		3,705		3,705
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,239		1,239		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2028		3,750		3,698		3,698
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	January 1, 2028		3,750		3,701		3,701		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2028		3,750		3,698		3,698
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	January 1, 2028		3,750		3,701		3,701		Term Loan (14)		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2028		1,250		1,250		1,250
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	April 1, 2028		3,750		3,698		3,698		Term Loan (14)		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2028		1,250		1,250		1,250
Havenly, Inc. (2)(12)	Consumer-related Technologies	Term Loan		13.00	%	Prime		5.00	%		5.00	%		-			4.00	%	March 1, 2027		2,000		1,165		1,165	Consumer-related Technologies	Term Loan		13.25	%	Prime		5.00	%		5.00	%		-			4.00	%	March 1, 2027		2,000		1,250		1,250
		Term Loan		13.00	%	Prime		5.00	%		5.00	%		-			4.00	%	March 1, 2027		3,000		1,748		1,748		Term Loan		13.25	%	Prime		5.00	%		5.00	%		-			4.00	%	March 1, 2027		3,000		1,875		1,875
		Term Loan		11.50	%	Prime		3.50	%		10.50	%		-			7.78	%	February 1, 2028		2,813		2,813		2,813		Term Loan		11.75	%	Prime		3.50	%		10.50	%		-			7.78	%	February 1, 2028		2,813		2,813		2,813
		Term Loan		11.50	%	Prime		3.50	%		10.50	%		-			7.78	%	February 1, 2028		2,813		2,813		2,813
Interior Define, Inc. (2)(12)(13)	Consumer-related Technologies	Term Loan		14.50	%	Prime		6.50	%		9.75	%		-			4.00	%	January 1, 2026		3,246		3,162		—
		Term Loan		14.50	%	Prime		6.50	%		9.75	%		-			4.00	%	January 1, 2026		2,963		2,886		—		Term Loan		11.75	%	Prime		3.50	%		10.50	%		-			7.78	%	February 1, 2028		2,813		2,813		2,813
Lyrical Foods, Inc. (2)(12)	Consumer-related Technologies	Term Loan		10.50	%	Prime		2.50	%		8.00	%		-			-		September 1, 2027		2,598		2,586		2,330	Consumer-related Technologies	Term Loan		10.75	%	Prime		2.50	%		8.00	%		-			-		September 1, 2027		2,598		2,589		2,330
MyForest Foods Co. (2)(12)	Consumer-related Technologies	Term Loan		14.75	%	Prime		6.75	%		10.00	%		-			3.00	%	October 1, 2025		5,000		4,961		4,961	Consumer-related Technologies	Term Loan		15.00	%	Prime		6.75	%		10.00	%		-			3.00	%	October 1, 2025		4,667		4,635		4,635
		Term Loan		14.75	%	Prime		6.75	%		10.00	%		-			3.00	%	October 1, 2025		2,500		2,480		2,480		Term Loan		15.00	%	Prime		6.75	%		10.00	%		-			3.00	%	October 1, 2025		2,333		2,317		2,317
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Term Loan		13.50	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		5,169		5,121		4,883	Consumer-related Technologies	Term Loan		14.00	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		5,352		5,304		4,630
		Term Loan		13.50	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,067		2,050		1,955		Term Loan		14.00	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,141		2,124		1,854
		Term Loan		13.50	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,584		2,564		2,446		Term Loan		14.00	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,676		2,658		2,320
		Term Loan		13.50	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		3,101		3,076		2,934		Term Loan		14.00	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		3,211		3,189		2,784
		Term Loan		13.50	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,584		2,548		2,430		Term Loan		14.00	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,676		2,644		2,308
		Term Loan		13.50	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,584		2,548		2,430		Term Loan		14.00	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,676		2,644		2,308
		Term Loan		13.50	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		5,169		5,093		4,859		Term Loan		14.00	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		5,351		5,287		4,614
		Term Loan		13.50	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,584		2,545		2,428		Term Loan		14.00	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,676		2,642		2,306
Optoro, Inc. (2)(12)	Consumer-related Technologies	Term Loan		14.00	%	Prime		6.25	%		9.50	%		-			4.00	%	August 1, 2027		2,500		2,355		2,355	Consumer-related Technologies	Term Loan		14.50	%	Prime		6.25	%		9.50	%		-			4.00	%	August 1, 2027		2,500		2,400		2,400
																											Term Loan		14.50	%	Prime		6.25	%		9.50	%		-			4.00	%	July 1, 2028		1,875		1,779		1,779
Primary Kids, Inc. (2)(12)	Consumer-related Technologies	Term Loan		15.00	%	Prime		7.25	%		10.50	%		-			3.00	%	March 1, 2025		2,300		2,277		2,277	Consumer-related Technologies	Term Loan		15.50	%	Prime		7.25	%		10.50	%		-			3.00	%	March 1, 2025		2,000		1,980		1,980
		Term Loan		15.00	%	Prime		7.25	%		10.50	%		-			3.00	%	March 1, 2025		2,300		2,277		2,277		Term Loan		15.50	%	Prime		7.25	%		10.50	%		-			3.00	%	March 1, 2025		2,000		1,980		1,980
		Term Loan		15.00	%	Prime		7.25	%		10.50	%		-			3.00	%	September 1, 2025		2,900		2,870		2,870		Term Loan		15.50	%	Prime		7.25	%		10.50	%		-			3.00	%	September 1, 2025		2,600		2,573		2,573
Unagi, Inc. (2)(12)	Consumer-related Technologies	Term Loan		15.75	% (11)	Prime		7.75	%		11.00	%		-			-		May 1, 2027		1,065		1,041		1,041	Consumer-related Technologies	Term Loan		16.00	% (11)	Prime		7.75	%		11.00	%		-			-		May 1, 2027		1,108		1,086		868
		Term Loan		15.75	% (11)	Prime		7.75	%		11.00	%		-			-		May 1, 2027		533		520		520		Term Loan		16.00	% (11)	Prime		7.75	%		11.00	%		-			-		May 1, 2027		554		543		434
		Term Loan		15.75	% (11)	Prime		7.75	%		11.00	%		-			-		May 1, 2027		533		521		521		Term Loan		16.00	% (11)	Prime		7.75	%		11.00	%		-			-		May 1, 2027		554		543		434
Liqid, Inc. (2)(12)	Networking	Term Loan		14.00	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		2,833		2,793		2,793	Networking	Term Loan		14.50	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		2,333		2,300		2,300
		Term Loan		14.00	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		2,833		2,793		2,793		Term Loan		14.50	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		2,333		2,300		2,300
		Term Loan		14.00	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,417		1,395		1,395		Term Loan		14.50	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,167		1,149		1,149
		Term Loan		14.00	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,417		1,395		1,395		Term Loan		14.50	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,167		1,149		1,149
		Term Loan		14.00	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,417		1,371		1,371		Term Loan		14.50	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,167		1,129		1,129
BriteCore Holdings, Inc. (2)(12)	Software	Term Loan		14.50	%	Prime		6.75	%		10.00	%		-			5.00	%	March 1, 2026		2,500		2,488		2,488	Software	Term Loan		15.00	%	Prime		6.75	%		10.00	%		-			5.00	%	March 1, 2026		2,500		2,489		2,489
		Term Loan		14.50	%	Prime		6.75	%		10.00	%		-			5.00	%	March 1, 2026		2,500		2,488		2,488		Term Loan		15.00	%	Prime		6.75	%		10.00	%		-			5.00	%	March 1, 2026		2,500		2,489		2,489
		Term Loan		14.50	%	Prime		6.75	%		10.00	%		-			3.00	%	March 1, 2027		2,500		2,467		2,467		Term Loan		15.00	%	Prime		6.75	%		10.00	%		-			3.00	%	March 1, 2027		2,500		2,469		2,469
		Term Loan		14.50	%	Prime		6.75	%		10.00	%		-			3.00	%	March 1, 2027		2,500		2,467		2,467		Term Loan		15.00	%	Prime		6.75	%		10.00	%		-			3.00	%	March 1, 2027		2,500		2,469		2,469
Decisyon, Inc. (12)	Software	Term Loan		17.43	%	Prime		9.43	%		12.68	%		-			50.43	%	December 31, 2022		3,284		3,284		2,750

Portfolio Company (1)(3)		*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*			*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*			*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*		*Margin*			*Floor*			*Ceiling*		*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Dropoff, Inc. (2)(12)		Software	Term Loan		14.50	%	Prime		6.50	%		9.75	%		-			3.50	%	April 1, 2026		6,500		6,359		6,359		Software	Term Loan		14.75	%	Prime			6.50	%		9.75	%		-		3.50	%	April 1, 2026		6,500		6,370		6,370
			Term Loan		14.50	%	Prime		6.50	%		9.75	%		-			3.50	%	April 1, 2026		6,000		5,869		5,869			Term Loan		14.75	%	Prime			6.50	%		9.75	%		-		3.50	%	April 1, 2026		6,000		5,880		5,880
			Term Loan		14.50	%	Prime		6.50	%		9.75	%		-			3.50	%	August 1, 2026		2,500		2,442		2,442			Term Loan		14.75	%	Prime			6.50	%		9.75	%		-		3.50	%	August 1, 2026		2,500		2,447		2,447
Engage3, LLC (2)(12)		Software	Term Loan		14.00	%	Prime		6.25	%		9.75	%		-			4.50	%	July 1, 2027		3,750		3,680		3,680		Software	Term Loan		14.50	%	Prime			6.25	%		9.75	%		-		4.50	%	July 1, 2027		3,750		3,723		3,723
			Term Loan		14.00	%	Prime		6.25	%		9.75	%		-			4.50	%	July 1, 2027		3,750		3,720		3,720
Groundspeed Analytics, Inc. (2)(12)		Software	Term Loan		13.50	%	Prime		5.50	%		11.00	%		18.00	%		3.00	%	December 1, 2026		5,000		4,802		4,802
			Term Loan		13.50	%	Prime		5.50	%		11.00	%		18.00	%		3.00	%	December 1, 2026		5,000		4,953		4,953
			Convertible Note		15.00	%														September 10,2024		500		500		500			Term Loan		14.50	%	Prime			6.25	%		9.75	%		-		4.50	%	July 1, 2027		3,750		3,723		3,723
Kodiak Robotics, Inc. (2)(12)		Software	Term Loan		13.50	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		10,000		9,843		9,843		Software	Term Loan		13.75	%	Prime			5.50	%		10.25	%		-		4.00	%	April 1, 2026		10,000		9,860		9,860
			Term Loan		13.50	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		10,000		9,843		9,843			Term Loan		13.75	%	Prime			5.50	%		10.25	%		-		4.00	%	April 1, 2026		10,000		9,860		9,860
			Term Loan		13.50	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		5,000		4,921		4,921			Term Loan		13.75	%	Prime			5.50	%		10.25	%		-		4.00	%	April 1, 2026		5,000		4,930		4,930
			Term Loan		13.50	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		5,000		4,921		4,921			Term Loan		13.75	%	Prime			5.50	%		10.25	%		-		4.00	%	April 1, 2026		5,000		4,930		4,930
Lemongrass Holdings, Inc. (2)(12)		Software	Term Loan		14.50	%	Prime		6.50	%		9.75	%		-			2.50	%	March 1, 2026		5,000		4,953		4,953		Software	Term Loan		14.75	%	Prime			6.50	%		9.75	%		-		2.50	%	March 1, 2026		5,000		4,959		4,959
			Term Loan		14.50	%	Prime		6.50	%		9.75	%		-			2.50	%	March 1, 2026		2,500		2,477		2,477			Term Loan		14.75	%	Prime			6.50	%		9.75	%		-		2.50	%	March 1, 2026		2,500		2,480		2,480
Lytics, Inc. (2)(12)		Software	Term Loan		13.75	%	Prime		6.00	%		9.25	%		-			3.00	%	November 1, 2026		2,500		2,411		2,411		Software	Term Loan		14.25	%	Prime			6.00	%		12.25	%		-		3.00	%	November 1, 2026		2,500		2,414		2,414
			Term Loan		13.75	%	Prime		6.00	%		12.25	%		-			3.00	%	December 1, 2026		1,250		1,232		1,232			Term Loan		14.25	%	Prime			6.00	%		12.25	%		-		3.00	%	December 1, 2026		1,250		1,234		1,234
			Term Loan		13.75	%	Prime		6.00	%		12.25	%		-			3.00	%	April 1, 2027		1,000		984		984			Term Loan		14.25	%	Prime			6.00	%		12.25	%		-		3.00	%	April 1, 2027		1,000		985		985
Noodle Partners, Inc. (2)(12)		Software	Term Loan		13.00	%	Prime		5.00	%		12.00	%		-			3.00	%	March 1, 2027		10,000		9,733		9,733		Software	Term Loan		13.25	%	Prime			5.00	%		12.00	%		-		3.00	%	March 1, 2027		10,000		9,741		9,741
			Term Loan		13.00	%	Prime		5.00	%		12.00	%		-			3.00	%	March 1, 2027		5,000		4,928		4,928			Term Loan		13.25	%	Prime			5.00	%		12.00	%		-		3.00	%	March 1, 2027		5,000		4,932		4,932
			Term Loan		13.00	%	Prime		5.00	%		12.00	%		-			3.00	%	March 1, 2027		5,000		4,928		4,928			Term Loan		13.25	%	Prime			5.00	%		12.00	%		-		3.00	%	March 1, 2027		5,000		4,933		4,933
Reputation Institute, Inc. (2)(12)		Software	Term Loan		15.00	%	Prime		7.25	%		10.50	%		-			3.00	%	August 1, 2025		4,833		4,772		4,772		Software	Term Loan		15.50	%	Prime			7.25	%		10.50	%		-		3.00	%	August 1, 2025		4,333		4,278		4,278
Slingshot Aerospace, Inc. (2)(12)		Software	Term Loan		13.75	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,940		4,940		Software	Term Loan		14.00	%	Prime			5.75	%		9.75	%		-		5.00	%	August 1, 2026		5,000		4,946		4,946
			Term Loan		13.75	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,940		4,940			Term Loan		14.00	%	Prime			5.75	%		9.75	%		-		5.00	%	August 1, 2026		5,000		4,946		4,946
			Term Loan		13.75	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,875		4,875			Term Loan		14.00	%	Prime			5.75	%		9.75	%		-		5.00	%	August 1, 2026		5,000		4,882		4,882
			Term Loan		13.75	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,940		4,940			Term Loan		14.00	%	Prime			5.75	%		9.75	%		-		5.00	%	August 1, 2026		5,000		4,946		4,946
Supply Network Visibility Holdings LLC (2)(12)		Software	Term Loan		14.25	%	Prime		6.50	%		9.75	%		-			4.00	%	February 1, 2025		3,208		3,183		3,183		Software	Term Loan		12.50	%	Prime			4.25	%		12.00	%		-		2.50	%	June 1, 2028		2,500		2,456		2,456
			Term Loan		14.25	%	Prime		6.50	%		9.75	%		-			4.00	%	February 1, 2025		3,208		3,183		3,183			Term Loan		12.50	%	Prime			4.25	%		12.00	%		-		2.50	%	June 1, 2028		3,500		3,488		3,488
			Term Loan		14.25	%	Prime		6.50	%		9.75	%		-			4.00	%	December 1, 2025		2,500		2,475		2,475			Term Loan		12.50	%	Prime			4.25	%		12.00	%		-		2.50	%	June 1, 2028		2,500		2,491		2,491
			Term Loan		14.25	%	Prime		6.50	%		9.75	%		-			4.00	%	December 1, 2025		2,500		2,475		2,475			Term Loan		12.50	%	Prime			4.25	%		12.00	%		-		2.50	%	June 1, 2028		1,500		1,495		1,495
Viken Detection Corporation (2)(12)																												Software	Term Loan		12.25	%	Prime			4.00	%		11.75	%		-		3.50	%	June 1, 2027		5,000		4,762		4,762
																													Term Loan		12.25	%	Prime	��		4.00	%		11.75	%		-		3.50	%	June 1, 2027		2,500		2,461		2,461
																													Term Loan		12.25	%	Prime			4.00	%		11.75	%		-		3.50	%	June 1, 2027		2,500		2,461		2,461
Total Non-Affiliate Debt Investments — Technology	Total Non-Affiliate Debt Investments — Technology																							277,916		267,673	Total Non-Affiliate Debt Investments — Technology																							276,563		269,863
Non-Affiliate Debt Investments — Healthcare information and services — 8.1% (8)
Non-Affiliate Debt Investments — Healthcare information and services — 10.1% (8)
Hound Labs inc. (2) (12)		Diagnostics	Term Loan		14.00	%	Prime		6.00	%		9.25	%		-			3.50	%	June 1, 2026		2,500		2,388		2,388		Diagnostics	Term Loan		14.25	%	Prime			6.00	%		9.25	%		-		3.50	%	June 1, 2026		2,500		2,478		2,478
			Term Loan		14.00	%	Prime		6.00	%		9.25	%		-			3.50	%	June 1, 2026		2,500		2,476		2,476			Term Loan		14.25	%	Prime			6.00	%		9.25	%		-		3.50	%	June 1, 2026		2,500		2,478		2,478
			Term Loan		14.00	%	Prime		6.00	%		9.25	%		-			3.50	%	June 1, 2026		5,000		4,951		4,951
Secure Transfusion Services, Inc. (12)(13)		Other Healthcare	Term Loan		13.75	%	Prime		5.75	%		9.00	%		-			4.00	%	October 1, 2025		4,719		4,658		46
			Term Loan		13.75	%	Prime		5.75	%		9.00	%		-			4.00	%	December 31, 2025		2,217		2,182		5			Term Loan		14.25	%	Prime			6.00	%		9.25	%		-		3.50	%	June 1, 2026		5,000		4,957		4,957
BrightInsight, Inc. (2)(12)		Software	Term Loan		13.25	%	Prime		5.50	%		9.50	%		-			3.00	%	August 1, 2027		7,000		6,663		6,663		Software	Term Loan		13.75	%	Prime			5.50	%		9.50	%		-		3.00	%	August 1, 2027		7,000		6,670		6,670
			Term Loan		13.25	%	Prime		5.50	%		9.50	%		-			3.00	%	August 1, 2027		3,500		3,452		3,452			Term Loan		13.75	%	Prime			5.50	%		9.50	%		-		3.00	%	August 1, 2027		3,500		3,455		3,455
			Term Loan		13.25	%	Prime		5.50	%		9.50	%		-			3.00	%	August 1, 2027		3,500		3,452		3,452			Term Loan		13.75	%	Prime			5.50	%		9.50	%		-		3.00	%	August 1, 2027		3,500		3,455		3,455
			Term Loan		13.50	%	Prime		5.50	%		9.50	%		-			3.00	%	April 1, 2028		2,750		2,704		2,704			Term Loan		13.75	%	Prime			5.50	%		9.50	%		-		3.00	%	April 1, 2028		2,750		2,706		2,706
SafelyYou, Inc. (2)(12)																												Software	Term Loan		11.50	%	Prime			3.25	%		11.00	%		-		5.00	%	June 1, 2027		5,000		4,635		4,635
																													Term Loan		11.50	%	Prime			3.25	%		11.00	%		-		5.00	%	June 1, 2027		5,000		4,905		4,905
Total Non-Affiliate Debt Investments — Healthcare information and services	Total Non-Affiliate Debt Investments — Healthcare information and services																							32,926		26,137	Total Non-Affiliate Debt Investments — Healthcare information and services																							35,739		35,739
*Total Non- Affiliate Debt Investments*	*Total Non- Affiliate Debt Investments*																							703,781		684,554	*Total Non- Affiliate Debt Investments*																							700,162		683,309

					*Cost of*		*Fair*						*Cost of*		*Fair*
Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Number of Shares*		*Investments (6)(9)*		*Value (9)*		*Sector*	*Type of Investment (7)*	*Number of Shares*		*Investments (6)(9)*		*Value (9)*
Non-Affiliate Warrant Investments — 8.0% (8)
Non-Affiliate Warrants — Life Science — 2.1% (8)
Non-Affiliate Warrant Investments — 7.2% (8)
Non-Affiliate Warrants — Life Science — 1.8% (8)
Avalo Therapeutics, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		26,444		311		—	Biotechnology	Common Stock Warrant		26,444		311		—
Castle Creek Biosciences, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		7,404		214		329	Biotechnology	Preferred Stock Warrant		7,404		212		338
Corvium, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		661,956		53		—	Biotechnology	Preferred Stock Warrant		661,956		53		—
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		110,402		176		256	Biotechnology	Preferred Stock Warrant		110,402		175		264
Evelo Biosciences, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		463,915		126		—	Biotechnology	Common Stock Warrant		23,196		126		—
Greenlight Biosciences, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		47,452		366		—	Biotechnology	Common Stock Warrant		47,452		366		—
Imunon, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		19,671		66		—	Biotechnology	Common Stock Warrant		19,671		66		—
IMV Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		39,774		67		—
IMV Inc. (2)(5)(12)(15)									Biotechnology	Common Stock Warrant		39,774		67		—
KSQ Therapeutics, Inc. (2) (12)	Biotechnology	Preferred Stock Warrant		48,076		50		56	Biotechnology	Preferred Stock Warrant		48,076		50		58
Mustang Bio, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		252,161		141		—	Biotechnology	Common Stock Warrant		16,611		146		—
Native Microbials, Inc (2)(12)	Biotechnology	Preferred Stock Warrant		103,679		64		159	Biotechnology	Preferred Stock Warrant		103,679		64		163
PDS Biotechnology Corporation (2)(5)(12)	Biotechnology	Common Stock Warrant		299,848		160		937	Biotechnology	Common Stock Warrant		299,848		160		651
Provivi, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		254,609		401		128	Biotechnology	Preferred Stock Warrant		293,488		442		173
Rocket Pharmaceuticals Corporation (5)(12)	Biotechnology	Common Stock Warrant		7,051		17		2
Stealth Biotherapeutics Inc. (2)(12)	Biotechnology	Common Stock Warrant		318,181		264		28	Biotechnology	Common Stock Warrant		318,181		264		125
vTv Therapeutics Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		95,293		44		—	Biotechnology	Common Stock Warrant		95,293		44		—
Xeris Pharmaceuticals, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		126,000		72		9	Biotechnology	Common Stock Warrant		126,000		72		58
AccuVein Inc. (2)(12)	Medical Device	Common Stock Warrant		1,175		24		—	Medical Device	Common Stock Warrant		1,175		24		—
Aerin Medical, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		1,818,183		66		1,196	Medical Device	Preferred Stock Warrant		1,818,183		66		1,204
Aerobiotix, LLC (2)(12)	Medical Device	Preferred Stock Warrant		27,330		48		31	Medical Device	Preferred Stock Warrant		27,330		48		32
Canary Medical Inc. (2)(12)	Medical Device	Preferred Stock Warrant		12,153		86		1,862	Medical Device	Preferred Stock Warrant		12,153		86		1,319
Ceribell, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		145,483		69		206	Medical Device	Preferred Stock Warrant		145,483		69		211
Cognoa, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		775,000		144		173	Medical Device	Preferred Stock Warrant		4,106,174		145		178
Conventus Orthopaedics, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		7,972,222		221		221	Medical Device	Preferred Stock Warrant		7,972,222		221		229
CSA Medical, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		1,375,727		153		148	Medical Device	Preferred Stock Warrant		1,375,727		150		154
CVRx, Inc. (2)(5)(12)	Medical Device	Common Stock Warrant		47,410		76		72	Medical Device	Common Stock Warrant		47,410		76		278
Infobionic, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		317,647		124		51	Medical Device	Preferred Stock Warrant		317,647		124		52
Magnolia Medical Technologies, Inc. (2)(12)									Medical Device	Preferred Stock Warrant		809,931		194		390
Meditrina, Inc. (2)(12)									Medical Device	Preferred Stock Warrant		233,993		83		101
Robin Healthcare, Inc. (2)(12)									Medical Device	Preferred Stock Warrant		86,066		16		16
Scientia Vascular, Inc (2)(12)									Medical Device	Preferred Stock Warrant		27,036		57		64
Sonex Health, Inc. (2)(12)									Medical Device	Preferred Stock Warrant		1,098,805		98		125
VERO Biotech LLC (2)(12)									Medical Device	Preferred Stock Warrant		408		53		1
Swift Health Systems Inc. (2)(12)									Medical Device	Preferred Stock Warrant		135,484		71		84
Total Non-Affiliate Warrants — Life Science														4,199		6,268

						*Cost of*		*Fair*							*Cost of*		*Fair*
Portfolio Company (1)(3)		*Sector*	*Type of Investment (7)*	*Number of Shares*		*Investments (6)(9)*		*Value (9)*			*Sector*	*Type of Investment (7)*	*Number of Shares*		*Investments (6)(9)*		*Value (9)*
Magnolia Medical Technologies, Inc. (2)(12)		Medical Device	Preferred Stock Warrant		809,931		194		379
Meditrina, Inc. (2)(12)		Medical Device	Preferred Stock Warrant		233,993		83		98
Robin Healthcare, Inc. (2)(12)		Medical Device	Preferred Stock Warrant		86,066		16		15
Scientia Vascular, Inc (2)(12)		Medical Device	Preferred Stock Warrant		19,662		40		45
Sonex Health, Inc. (2)(12)		Medical Device	Preferred Stock Warrant		605,313		98		120
VERO Biotech LLC (2)(12)		Medical Device	Preferred Stock Warrant		408		53		1
Swift Health Systems Inc. (2)(12)		Medical Device	Preferred Stock Warrant		135,484		71		81
Total Non-Affiliate Warrants — Life Science							4,158		6,603
Non-Affiliate Warrants — Sustainability — 0.2% (8)
Aerofarms, Inc. (2)(12)		Other Sustainability	Preferred Stock Warrant		201,537		61		72		Other Sustainability	Preferred Stock Warrant		201,537		61		—
LiquiGlide, Inc. (2)(12)		Other Sustainability	Common Stock Warrant		61,359		39		53		Other Sustainability	Common Stock Warrant		61,359		36		56
Nexii Building Solutions, Inc. (2)(12)		Other Sustainability	Common Stock Warrant		204,195		490		1
Nexii Building Solutions, Inc. (2)(12)(15)											Other Sustainability	Common Stock Warrant		213,746		490		—
Soli Organic, Inc. (2)(12)		Other Sustainability	Preferred Stock Warrant		681		214		354		Other Sustainability	Preferred Stock Warrant		681		214		365
Temperpack Technologies, Inc. (2)(12)		Other Sustainability	Preferred Stock Warrant		34,604		118		259		Other Sustainability	Preferred Stock Warrant		34,604		121		266
Total Non-Affiliate Warrants — Sustainability	Total Non-Affiliate Warrants — Sustainability						922		739	Total Non-Affiliate Warrants — Sustainability						922		687
Non-Affiliate Warrants — Technology — 5.1% (8)
Non-Affiliate Warrants — Technology — 4.6% (8)
Axiom Space, Inc. (2)(12)		Communications	Common Stock Warrant		1,991		46		64		Communications	Common Stock Warrant		1,991		45		67
Intelepeer Holdings, Inc. (2)(12)		Communications	Preferred Stock Warrant		2,936,535		138		3,251		Communications	Preferred Stock Warrant		2,936,535		138		3,272
PebblePost, Inc. (2)(12)		Communications	Preferred Stock Warrant		598,850		91		170		Communications	Preferred Stock Warrant		598,850		92		139
Alula Holdings, Inc. (2)(12)		Consumer-related Technologies	Preferred Stock Warrant		20,000		93		64		Consumer-related Technologies	Preferred Stock Warrant		20,000		93		—
Aterian, Inc. (2)(5)(12)		Consumer-related Technologies	Common Stock Warrant		76,923		195		—		Consumer-related Technologies	Common Stock Warrant		76,923		195		—
Better Place Forests Co. (12)		Consumer-related Technologies	Preferred Stock Warrant		2,672		26		—		Consumer-related Technologies	Preferred Stock Warrant		10,690		26		—
Caastle, Inc. (2)(12)		Consumer-related Technologies	Preferred Stock Warrant		268,591		68		1,057		Consumer-related Technologies	Preferred Stock Warrant		268,591		67		1,058
CAMP NYC, Inc. (2)(12)		Consumer-related Technologies	Preferred Stock Warrant		17,605		22		—		Consumer-related Technologies	Preferred Stock Warrant		75,997		22		30
Clara Foods Co. (2)(12)		Consumer-related Technologies	Preferred Stock Warrant		46,745		30		124		Consumer-related Technologies	Preferred Stock Warrant		46,745		30		126
Divergent Technologies, Inc. (2)(12)		Consumer-related Technologies	Preferred Stock Warrant		33,742		70		237		Consumer-related Technologies	Preferred Stock Warrant		37,294		95		276
Havenly, Inc. (2)(12)		Consumer-related Technologies	Common Stock Warrant		1,312,500		2,942		2,674		Consumer-related Technologies	Common Stock Warrant		1,312,500		2,947		2,677
MyForest Foods Co. (2)(12)		Consumer-related Technologies	Preferred Stock Warrant		143		29		36		Consumer-related Technologies	Preferred Stock Warrant		250		29		61
NextCar Holding Company, Inc. (2)(12)		Consumer-related Technologies	Preferred Stock Warrant		1,261,253		197		17		Consumer-related Technologies	Preferred and Common Stock Warrant		1,237,370		197		—
Optoro, Inc. (2)(12)		Consumer-related Technologies	Preferred Stock Warrant		6,600		104		104		Consumer-related Technologies	Preferred Stock Warrant		11,550		182		182
Primary Kids, Inc. (2)(12)		Consumer-related Technologies	Preferred Stock Warrant		553,778		57		427		Consumer-related Technologies	Preferred Stock Warrant		553,778		57		595
Quip NYC Inc. (2)(12)		Consumer-related Technologies	Preferred Stock Warrant		6,191		325		532		Consumer-related Technologies	Preferred Stock Warrant		6,191		325		536
Unagi, Inc. (2)(12)		Consumer-related Technologies	Preferred Stock Warrant		171,081		32		111		Consumer-related Technologies	Preferred Stock Warrant		171,081		32		—
Updater, Inc.(2)(12)		Consumer-related Technologies	Common Stock Warrant		108,333		34		42		Consumer-related Technologies	Common Stock Warrant		108,333		34		11
CPG Beyond, Inc. (2)(12)		Data Storage	Preferred Stock Warrant		500,000		242		903		Data Storage	Preferred Stock Warrant		500,000		242		912
Silk, Inc. (2)(12)		Data Storage	Preferred and Common Stock Warrant		442,110		234		399		Data Storage	Preferred Stock Warrant		394,110		175		148
Global Worldwide LLC (2)(12)		Internet and Media	Preferred Stock Warrant		245,810		75		—		Internet and Media	Preferred Stock Warrant		245,810		75		63
Rocket Lawyer Incorporated (2)(12)		Internet and Media	Preferred Stock Warrant		261,721		92		352		Internet and Media	Preferred Stock Warrant		261,721		92		360
Skillshare, Inc. (2)(12)		Internet and Media	Preferred Stock Warrant		139,074		162		1,231		Internet and Media	Preferred Stock Warrant		139,074		162		1,211
Liqid, Inc. (2)(12)		Networking	Preferred Stock Warrant		344,102		364		237		Networking	Preferred Stock Warrant		344,102		364		247
Halio, Inc. (2)(12)		Power Management	Preferred Stock Warrant		5,002,574		1,585		2,808		Power Management	Preferred Stock Warrant		5,002,574		1,585		2,898
Avalanche Technology, Inc. (2)(12)		Semiconductors	Preferred and Common Stock Warrants		6,081		57		—		Semiconductors	Preferred and Common Stock Warrant		6,081		57		—
BriteCore Holdings, Inc. (2)(12)		Software	Preferred Stock Warrant		77,828		21		67		Software	Preferred Stock Warrant		77,828		21		70
Decisyon, Inc. (12)		Software	Common Stock Warrant		82,967		46		—
Dropoff, Inc. (2)(12)		Software	Common Stock Warrant		516,732		455		196		Software	Common Stock Warrant		516,732		455		169
E La Carte, Inc. (2)(5)(12)		Software	Common Stock Warrant		147,361		60		—		Software	Common Stock Warrant		147,361		60		121
Groundspeed Analytics, Inc. (2)(12)		Software	Preferred Stock Warrant		86,300		7		1
Everstream Holdings, LLC (2)(12)											Software	Preferred Stock Warrant		350,000		70		70
Kodiak Robotics, Inc. (2)(12)		Software	Preferred Stock Warrant		639,918		275		287		Software	Preferred Stock Warrant		639,918		273		299
Lemongrass Holdings, Inc. (2)(12)		Software	Preferred Stock Warrant		101,308		35		40		Software	Preferred Stock Warrant		101,308		34		41
Lotame Solutions, Inc. (2)(12)		Software	Preferred Stock Warrant		71,305		19		53		Software	Preferred Stock Warrant		71,305		21		57
Lytics, Inc. (2)(12)		Software	Preferred Stock Warrant		85,543		43		46		Software	Preferred Stock Warrant		85,543		46		18
Noodle Partners, Inc. (2)(12)		Software	Preferred Stock Warrant		84,037		116		116		Software	Preferred Stock Warrant		84,037		116		120
Reputation Institute, Inc. (2)(12)		Software	Preferred Stock Warrant		3,731		61		46		Software	Preferred Stock Warrant		3,731		56		50
Revinate Holdings, Inc. (2)(12)		Software	Preferred Stock Warrant		682,034		44		97		Software	Preferred Stock Warrant		682,034		44		101
Riv Data Corp. (2)(12)		Software	Preferred Stock Warrant		321,428		12		296
SIGNiX, Inc. (12)		Software	Preferred Stock Warrant		186,235		225		—		Software	Preferred Stock Warrant		186,235		225		—
Slingshot Aerospace, Inc. (2)(12)		Software	Preferred Stock Warrant		309,208		123		135		Software	Preferred Stock Warrant		309,208		123		135
Supply Network Visibility Holdings LLC (2)(12)		Software	Preferred Stock Warrant		682		64		140		Software	Preferred Stock Warrant		682		64		140
Topia Mobility, Inc. (2)(12)		Software	Preferred Stock Warrant		3,049,607		138		—		Software	Preferred Stock Warrant		3,049,607		138		—
Viken Detection Corporation (2)(12)											Software	Preferred Stock Warrant		345,443		120		120
xAd, Inc. (2)(12)		Software	Preferred Stock Warrant		4,343,348		177		11		Software	Preferred Stock Warrant		4,343,348		177		12
Total Non-Affiliate Warrants — Technology	Total Non-Affiliate Warrants — Technology						9,231		16,371	Total Non-Affiliate Warrants — Technology						9,401		16,392

						*Cost of*		*Fair*							*Cost of*		*Fair*
Portfolio Company (1)(3)		*Sector*	*Type of Investment (7)*	*Number of Shares*		*Investments (6)(9)*		*Value (9)*			*Sector*	*Type of Investment (7)*	*Number of Shares*		*Investments (6)(9)*		*Value (9)*
Non-Affiliate Warrants — Healthcare information and services — 0.6% (8)
Hound Labs, Inc (2) (12)		Diagnostics	Preferred Stock Warrant		159,893		47		53		Diagnostics	Preferred Stock Warrant		171,370		47		56
Kate Farms, Inc. (2)(12)		Other Healthcare	Preferred Stock Warrant		82,965		102		1,363		Other Healthcare	Preferred Stock Warrant		82,965		101		1,374
Secure Transfusion Services, Inc. (12)		Other Healthcare	Preferred Stock Warrant		77,690		48		—
BrightInsight, Inc. (2)(12)		Software	Preferred Stock Warrant		85,066		167		175		Software	Preferred Stock Warrant		85,066		167		181
Medsphere Systems Corporation (2)(12)		Software	Preferred Stock Warrant		7,097,792		60		354		Software	Preferred Stock Warrant		7,097,792		61		362
SafelyYou, Inc. (2)(12)											Software	Preferred Stock Warrant		150,353		163		163
Total Non-Affiliate Warrants — Healthcare information and services	Total Non-Affiliate Warrants — Healthcare information and services						424		1,945	Total Non-Affiliate Warrants — Healthcare information and services						539		2,136
*Total Non-Affiliate Warrants*	*Total Non-Affiliate Warrants*						14,735		25,658	*Total Non-Affiliate Warrants*						15,061		25,483
Non-Affiliate Other Investments — 0.4% (8)
Lumithera, Inc. (12)		Medical Device	Royalty Agreement				1,200		1,100		Medical Device	Royalty Agreement				1,200		1,100
ZetrOZ, Inc. (12)		Medical Device	Royalty Agreement				—		200		Medical Device	Royalty Agreement				—		200
*Total Non-Affiliate Other Investments*	*Total Non-Affiliate Other Investments*						1,200		1,300	*Total Non-Affiliate Other Investments*						1,200		1,300
Non-Affiliate Equity — 0.9% (8)
Non-Affiliate Equity — 1.2% (8)
Castle Creek Biosciences, Inc. (12)		Biotechnology	Common Stock		1,162		250		250		Biotechnology	Common Stock		1,162		250		250
Emalex Biosciences, Inc. (12)		Biotechnology	Common Stock		32,831		356		356		Biotechnology	Common Stock		32,831		356		356
Getaround, Inc. (2)(5)		Consumer-related Technologies	Common Stock		87,082		253		25		Consumer-related Technologies	Common Stock		87,082		253		30
NextCar Holding Company, Inc. (2)(12)											Technology	Preferred Stock		2,688,971		89		89
SnagAJob.com, Inc. (12)		Consumer-related Technologies	Common Stock		82,974		9		83		Consumer-related Technologies	Common Stock		82,974		9		83
Lumithera, Inc. (12)		Medical Device	Common Stock		392,651		2,000		1,700		Medical Device	Common Stock		392,651		2,000		1,700
Tigo Energy, Inc. (12)		Other Sustainability	Preferred Stock		22,313		8		27
Tigo Energy, Inc. (5)(12)											Other Sustainability	Common Stock		5,205		111		97
Branded Online, Inc. (2)(5)		Software	Common Stock		5,398		1,075		14		Software	Common Stock		5,398		1,079		8
Decisyon, Inc. (12)		Software	Preferred and Common Stock		72,638,663		229		—		Software	Preferred Stock		280,000		2,800		1,281
Lotame, Inc. (12)		Software	Preferred Stock		66,127		5		193		Software	Preferred Stock		66,127		2		193
Axiom Space, Inc. (12)		Technology	Preferred Stock		1,810		261		306		Technology	Preferred Stock		1,810		261		306
*Total Non-Affiliate Equity*	*Total Non-Affiliate Equity*						4,446		2,954	*Total Non-Affiliate Equity*						7,210		4,393
*Total Non-Affiliate Portfolio Investment Assets*	*Total Non-Affiliate Portfolio Investment Assets*					$	724,162	$	714,466	*Total Non-Affiliate Portfolio Investment Assets*					$	723,633	$	714,485
Non-controlled Affiliate Investments — 0.3% (8)
Non-controlled Affiliate Equity — Life Science —0.3% (8)
Cadrenal Therapeutics, Inc. (5)		Biotechnology	Common Stock		600,000		—		846		Biotechnology	Common Stock		600,000		—		906
*Total Non-Controlled Affiliate Equity*	*Total Non-Controlled Affiliate Equity*					$	—		846	*Total Non-Controlled Affiliate Equity*					$	—		906
*Total Non-Controlled Affiliate Portfolio Investment Assets*	*Total Non-Controlled Affiliate Portfolio Investment Assets*					$	—		846	*Total Non-Controlled Affiliate Portfolio Investment Assets*					$	—		906
*Total Portfolio Investment Assets — 222.4% (8)*						$	724,162	$	715,312
*Total Portfolio Investment Assets — 201.4% (8)*										*Total Portfolio Investment Assets — 201.4% (8)*					$	723,633	$	715,391

Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*			*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*		*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*			*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Non-Affiliate Investments — 226.1% (8)
Non-Affiliate Debt Investments — 215.5% (8)
Non-Affiliate Debt Investments — Life Science — 99.7% (8)
Avalo Therapeutics, Inc. (2)(5)(12)	Biotechnology	Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025	$	2,885	$	2,853	$	2,777	Biotechnology	Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025	$	2,885	$	2,853	$	2,777
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025		2,885		2,823		2,750		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025		2,885		2,823		2,750
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025		1,442		1,411		1,374		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025		1,442		1,411		1,374
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	February 1, 2025		2,885		2,821		2,748		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	February 1, 2025		2,885		2,821		2,748
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	February 1, 2025		2,885		2,821		2,748		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	February 1, 2025		2,885		2,821		2,748
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	April 1, 2025		1,442		1,408		1,371		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	April 1, 2025		1,442		1,408		1,371
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	April 1, 2025		1,442		1,408		1,371		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	April 1, 2025		1,442		1,408		1,371
Castle Creek Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,891		4,891	Biotechnology	Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,891		4,891
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,963		4,963		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,963		4,963
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		3,000		2,978		2,978		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		3,000		2,978		2,978
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,963		4,963		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,963		4,963
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,963		4,963		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,963		4,963
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		3,000		2,978		2,978		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		3,000		2,978		2,978
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		12.07	%	Libor		7.90	%		9.75	%		-			5.00	%	June 1, 2024		1,979		1,962		1,962	Biotechnology	Term Loan		12.07	%	Libor		7.90	%		9.75	%		-			5.00	%	June 1, 2024		1,979		1,962		1,962
		Term Loan		12.07	%	Libor		7.90	%		9.75	%		-			5.00	%	June 1, 2024		1,979		1,963		1,963		Term Loan		12.07	%	Libor		7.90	%		9.75	%		-			5.00	%	June 1, 2024		1,979		1,963		1,963
		Term Loan		12.07	%	Libor		7.90	%		9.75	%		-			5.00	%	November 1, 2025		5,000		4,923		4,923		Term Loan		12.07	%	Libor		7.90	%		9.75	%		-			5.00	%	November 1, 2025		5,000		4,923		4,923
		Term Loan		12.07	%	Libor		7.90	%		9.75	%		-			5.00	%	May 1, 2026		5,000		4,912		4,912		Term Loan		12.07	%	Libor		7.90	%		9.75	%		-			5.00	%	May 1, 2026		5,000		4,912		4,912
Evelo Biosciences, Inc. (2)(5)(12)	Biotechnology	Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		10,000		9,872		9,872	Biotechnology	Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		10,000		9,872		9,872
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		15,000		14,808		14,808		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		15,000		14,808		14,808
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		6,000		5,923		5,923		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		6,000		5,923		5,923
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		6,000		5,923		5,923		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		6,000		5,923		5,923
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		4,000		3,949		3,949		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		4,000		3,949		3,949
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		4,000		3,949		3,949		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		4,000		3,949		3,949
F-Star Therapeutics, Inc. (2)(5)(12)	Biotechnology	Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	April 1, 2025		2,500		2,476		2,476	Biotechnology	Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	April 1, 2025		2,500		2,476		2,476
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	July 1, 2025		2,500		2,473		2,473		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	July 1, 2025		2,500		2,473		2,473
Greenlight Biosciences, Inc. (2)(5)(12)	Biotechnology	Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			3.00	%	July 1, 2025		5,000		4,857		4,857	Biotechnology	Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			3.00	%	July 1, 2025		5,000		4,857		4,857
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			3.00	%	July 1, 2025		2,500		2,430		2,430		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			3.00	%	July 1, 2025		2,500		2,430		2,430
IMV Inc. (2)(5)(12)	Biotechnology	Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			5.00	%	July 1, 2025		5,000		4,946		4,946
IMV Inc. (2)(5)(12)(14)																										Biotechnology	Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			5.00	%	July 1, 2025		5,000		4,946		4,946
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			5.00	%	July 1, 2025		2,500		2,473		2,473		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			5.00	%	July 1, 2025		2,500		2,473		2,473
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			5.00	%	January 1, 2026		5,000		4,947		4,947		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			5.00	%	January 1, 2026		5,000		4,947		4,947
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			5.00	%	January 1, 2026		5,000		4,947		4,947		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			5.00	%	January 1, 2026		5,000		4,947		4,947
KSQ Therapeutics, Inc. (2) (12)	Biotechnology	Term Loan		12.25	%	Prime		4.75	%		8.50	%		-			5.50	%	May 1, 2027		6,250		6,077		6,077	Biotechnology	Term Loan		12.25	%	Prime		4.75	%		8.50	%		-			5.50	%	May 1, 2027		6,250		6,077		6,077
		Term Loan		12.25	%	Prime		4.75	%		8.50	%		-			5.50	%	May 1, 2027		6,250		6,177		6,177		Term Loan		12.25	%	Prime		4.75	%		8.50	%		-			5.50	%	May 1, 2027		6,250		6,177		6,177
Native Microbials, Inc (2) (12)	Biotechnology	Term Loan		12.75	%	Prime		5.25	%		8.50	%		-			5.00	%	November 1, 2026		3,750		3,630		3,630	Biotechnology	Term Loan		12.75	%	Prime		5.25	%		8.50	%		-			5.00	%	November 1, 2026		3,750		3,630		3,630
		Term Loan		12.75	%	Prime		5.25	%		8.50	%		-			5.00	%	November 1, 2026		2,500		2,469		2,469		Term Loan		12.75	%	Prime		5.25	%		8.50	%		-			5.00	%	November 1, 2026		2,500		2,469		2,469
PDS Biotechnology Corporation (2)(5)(12)	Biotechnology	Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		10,000		9,701		9,701	Biotechnology	Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		10,000		9,701		9,701
		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		3,750		3,697		3,697		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		3,750		3,697		3,697
		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		3,750		3,697		3,697		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		3,750		3,697		3,697
Provivi, Inc. (2)(12)	Biotechnology	Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		4,667		4,597		4,597	Biotechnology	Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		4,667		4,597		4,597
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		4,667		4,597		4,597		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		4,667		4,597		4,597
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,280		2,280		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,280		2,280
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,280		2,280		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,280		2,280
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,274		2,274		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,274		2,274
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,274		2,274		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,274		2,274
Stealth Biotherapeutics Inc. (2)(12)	Biotechnology	Term Loan		13.00	%	Prime		5.50	%		8.75	%		-			6.00	%	October 1, 2025		5,000		4,914		4,914	Biotechnology	Term Loan		13.00	%	Prime		5.50	%		8.75	%		-			6.00	%	October 1, 2025		5,000		4,914		4,914
		Term Loan		13.00	%	Prime		5.50	%		8.75	%		-			6.00	%	October 1, 2025		2,500		2,457		2,457		Term Loan		13.00	%	Prime		5.50	%		8.75	%		-			6.00	%	October 1, 2025		2,500		2,457		2,457
Aerobiotix, LLC (2)(12)	Medical Device	Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			6.00	%	April 1, 2026		2,500		2,463		2,364	Medical Device	Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			6.00	%	April 1, 2026		2,500		2,463		2,364
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			6.00	%	April 1, 2026		2,500		2,463		2,364		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			6.00	%	April 1, 2026		2,500		2,463		2,364
Canary Medical Inc. (2)(12)	Medical Device	Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			7.00	%	November 1, 2024		2,500		2,475		2,475	Medical Device	Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			7.00	%	November 1, 2024		2,500		2,475		2,475
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			7.00	%	November 1, 2024		2,500		2,489		2,489		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			7.00	%	November 1, 2024		2,500		2,489		2,489
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			7.00	%	November 1, 2024		2,500		2,473		2,473		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			7.00	%	November 1, 2024		2,500		2,473		2,473
Ceribell, Inc. (2)(12)	Medical Device	Term Loan		10.50	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		5,000		4,973		4,973	Medical Device	Term Loan		10.50	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		5,000		4,973		4,973
		Term Loan		10.50	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		5,000		4,973		4,973		Term Loan		10.50	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		5,000		4,973		4,973
		Term Loan		10.50	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		2,500		2,478		2,478		Term Loan		10.50	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		2,500		2,478		2,478
		Term Loan		10.50	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		2,500		2,478		2,478		Term Loan		10.50	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		2,500		2,478		2,478
Cognoa, Inc. (2)(12)	Medical Device	Term Loan		13.00	%	Prime		5.50	%		8.75	%		-			6.00	%	August 1, 2026		2,500		2,466		2,466	Medical Device	Term Loan		13.00	%	Prime		5.50	%		8.75	%		-			6.00	%	August 1, 2026		2,500		2,466		2,466
		Term Loan		13.00	%	Prime		5.50	%		8.75	%		-			6.00	%	August 1, 2026		5,000		4,932		4,932		Term Loan		13.00	%	Prime		5.50	%		8.75	%		-			6.00	%	August 1, 2026		5,000		4,932		4,932
Conventus Orthopaedics, Inc. (2)(12)	Medical Device	Term Loan		12.17	%	Libor		8.00	%		9.25	%		-			10.36	%	July 1, 2025		3,960		3,898		3,898	Medical Device	Term Loan		12.17	%	Libor		8.00	%		9.25	%		-			10.36	%	July 1, 2025		3,960		3,898		3,898
		Term Loan		12.17	%	Libor		8.00	%		9.25	%		-			10.36	%	July 1, 2025		3,960		3,898		3,898		Term Loan		12.17	%	Libor		8.00	%		9.25	%		-			10.36	%	July 1, 2025		3,960		3,898		3,898

Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*		*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*		*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*		*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Corinth Medtech, Inc. (2)(12)	Medical Device	Term Loan		12.25	%	Prime		5.25	%		8.50	%		-		20.00	%	September 15, 2022		2,500		2,500		2,500	Medical Device	Term Loan		12.25	%	Prime		5.25	%		8.50	%		-		20.00	%	September 15, 2022		2,500		2,500		2,500
		Term Loan		12.25	%	Prime		5.25	%		8.50	%		-		20.00	%	September 15, 2022		2,500		2,500		2,500		Term Loan		12.25	%	Prime		5.25	%		8.50	%		-		20.00	%	September 15, 2022		2,500		2,500		2,500
CSA Medical, Inc. (2)(12)	Medical Device	Term Loan		12.37	%	Libor		8.20	%		10.00	%		-		5.00	%	January 1, 2024		1,625		1,610		1,610	Medical Device	Term Loan		12.37	%	Libor		8.20	%		10.00	%		-		5.00	%	January 1, 2024		1,625		1,610		1,610
		Term Loan		12.37	%	Libor		8.20	%		10.00	%		-		5.00	%	January 1, 2024		108		107		107		Term Loan		12.37	%	Libor		8.20	%		10.00	%		-		5.00	%	January 1, 2024		108		107		107
		Term Loan		12.37	%	Libor		8.20	%		10.00	%		-		5.00	%	March 1, 2024		2,000		1,983		1,983		Term Loan		12.37	%	Libor		8.20	%		10.00	%		-		5.00	%	March 1, 2024		2,000		1,983		1,983
Embody, Inc. (2)(12)	Medical Device	Term Loan		14.00	%	Prime		6.50	%		9.75	%		-		28.00	%	August 1, 2026		2,500		2,482		2,482	Medical Device	Term Loan		14.00	%	Prime		6.50	%		9.75	%		-		28.00	%	August 1, 2026		2,500		2,482		2,482
InfoBionic, Inc. (2)(12)	Medical Device	Term Loan		13.25	%	Prime		6.25	%		9.50	%		-		4.00	%	October 1, 2024		3,208		3,143		3,143	Medical Device	Term Loan		13.25	%	Prime		6.25	%		9.50	%		-		4.00	%	October 1, 2024		3,208		3,143		3,143
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-		4.00	%	June 1, 2025		1,000		974		974		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-		4.00	%	June 1, 2025		1,000		974		974
Magnolia Medical Technologies, Inc. (2)(12)	Medical Device	Term Loan		12.00	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,939		4,939	Medical Device	Term Loan		12.00	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,939		4,939
		Term Loan		12.00	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,939		4,939		Term Loan		12.00	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,939		4,939
		Term Loan		12.00	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,933		4,933		Term Loan		12.00	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,933		4,933
		Term Loan		12.00	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,933		4,933		Term Loan		12.00	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,933		4,933
		Term Loan		12.50	%	Prime		5.00	%		9.75	%		-		4.00	%	January 1, 2027		5,000		4,913		4,913		Term Loan		12.50	%	Prime		5.00	%		9.75	%		-		4.00	%	January 1, 2027		5,000		4,913		4,913
		Term Loan		12.50	%	Prime		5.00	%		9.75	%		-		4.00	%	January 1, 2027		5,000		4,913		4,913		Term Loan		12.50	%	Prime		5.00	%		9.75	%		-		4.00	%	January 1, 2027		5,000		4,913		4,913
Robin Healthcare, Inc. (2)(12)	Medical Device	Term Loan		13.00	%	Prime		5.50	%		10.25	%		-		4.00	%	November 1, 2026		3,500		3,360		3,360	Medical Device	Term Loan		13.00	%	Prime		5.50	%		10.25	%		-		4.00	%	November 1, 2026		3,500		3,360		3,360
		Term Loan		13.00	%	Prime		5.50	%		10.25	%		-		4.00	%	November 1, 2026		3,500		3,460		3,460		Term Loan		13.00	%	Prime		5.50	%		10.25	%		-		4.00	%	November 1, 2026		3,500		3,460		3,460
Scientia Vascular, Inc. (2)(12)	Medical Device	Term Loan		11.75	%	Prime		4.75	%		8.50	%		-		5.00	%	January 1, 2027		3,750		3,597		3,597	Medical Device	Term Loan		11.75	%	Prime		4.75	%		8.50	%		-		5.00	%	January 1, 2027		3,750		3,597		3,597
		Term Loan		11.75	%	Prime		4.75	%		8.50	%		-		5.00	%	January 1, 2027		3,750		3,706		3,706		Term Loan		11.75	%	Prime		4.75	%		8.50	%		-		5.00	%	January 1, 2027		3,750		3,706		3,706
Sonex Health, Inc. (2)(12)	Medical Device	Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,476		2,476	Medical Device	Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,476		2,476
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,476		2,476		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,476		2,476
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,476		2,476		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,476		2,476
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	April 1, 2026		2,500		2,453		2,453		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	April 1, 2026		2,500		2,453		2,453
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	May 1, 2026		2,500		2,455		2,455		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	May 1, 2026		2,500		2,455		2,455
Spineology, Inc. (2)(12)	Medical Device	Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		1.00	%	October 1, 2025		5,000		4,966		4,966	Medical Device	Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		1.00	%	October 1, 2025		5,000		4,966		4,966
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		1.00	%	April 1, 2026		2,500		2,481		2,481		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		1.00	%	April 1, 2026		2,500		2,481		2,481
Swift Health Systems Inc. (2)(12)	Medical Device	Term Loan		12.25	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,349		3,349	Medical Device	Term Loan		12.25	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,349		3,349
		Term Loan		12.25	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,454		3,454		Term Loan		12.25	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,454		3,454
Total Non-Affiliate Debt Investments — Life Science																						318,172		317,568																						318,172		317,568
Non-Affiliate Debt Investments — Sustainability — 26.3% (8)
Aerofarms, Inc. (2)(12)	Other Sustainability	Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		3.00	%	April 1, 2026		3,750		3,699		3,699	Other Sustainability	Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		3.00	%	April 1, 2026		3,750		3,699		3,699
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		3.00	%	April 1, 2026		3,750		3,699		3,699		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		3.00	%	April 1, 2026		3,750		3,699		3,699
Nexii Building Solutions, Inc. (2)(12)	Other Sustainability	Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,371		7,371
Nexii Building Solutions, Inc. (2)(12)(14)																									Other Sustainability	Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,371		7,371
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,371		7,371		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,371		7,371
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,371		7,371		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,371		7,371
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	July 1, 2026		5,000		4,903		4,903		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	July 1, 2026		5,000		4,903		4,903
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	July 1, 2026		5,000		4,903		4,903		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	July 1, 2026		5,000		4,903		4,903
Soli Organic, Inc. (2)(12)	Other Sustainability	Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.75	%	April 1, 2026		2,500		2,463		2,463	Other Sustainability	Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.75	%	April 1, 2026		2,500		2,463		2,463
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.75	%	April 1, 2026		5,000		4,927		4,927		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.75	%	April 1, 2026		5,000		4,927		4,927
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.75	%	May 1, 2026		5,000		4,924		4,924		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.75	%	May 1, 2026		5,000		4,924		4,924
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.75	%	May 1, 2026		2,500		2,462		2,462		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.75	%	May 1, 2026		2,500		2,462		2,462
		Term Loan		13.00	%	Prime		5.50	%		10.00	%		-		2.75	%	December 1, 2026		5,000		4,900		4,900		Term Loan		13.00	%	Prime		5.50	%		10.00	%		-		2.75	%	December 1, 2026		5,000		4,900		4,900
		Term Loan		13.00	%	Prime		5.50	%		10.00	%		-		2.75	%	December 1, 2026		2,500		2,450		2,450		Term Loan		13.00	%	Prime		5.50	%		10.00	%		-		2.75	%	December 1, 2026		2,500		2,450		2,450
Temperpack Technologies, Inc. (2)(12)	Other Sustainability	Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	June 1, 2025		3,750		3,697		3,697	Other Sustainability	Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	June 1, 2025		3,750		3,697		3,697
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	June 1, 2025		3,750		3,717		3,717		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	June 1, 2025		3,750		3,717		3,717
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		7,500		7,424		7,424		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		7,500		7,424		7,424
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		3,750		3,712		3,712		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		3,750		3,712		3,712
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		3,750		3,712		3,712		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		3,750		3,712		3,712
Total Non-Affiliate Debt Investments — Sustainability																						83,705		83,705																						83,705		83,705
Non-Affiliate Debt Investments — Technology — 81.4% (8)
Axiom Space, Inc. (2)(12)	Communications	Term Loan		13.00	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,455		7,455	Communications	Term Loan		13.00	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,455		7,455
		Term Loan		13.00	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,455		7,455		Term Loan		13.00	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,455		7,455
		Term Loan		13.00	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,455		7,455		Term Loan		13.00	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,455		7,455
		Convertible Note		3.00	%													July 1, 2023		250		250		306		Convertible Note		3.00	%													July 1, 2023		250		250		306
Alula Holdings, Inc. (2)(12)	Consumer-related Technologies	Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		5,000		4,966		4,966	Consumer-related Technologies	Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		5,000		4,966		4,966
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		5,000		4,966		4,966		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		5,000		4,966		4,966
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		3,000		2,979		2,979		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		3,000		2,979		2,979
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	December 1, 2025		1,000		976		976		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	December 1, 2025		1,000		976		976
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	February 1, 2026		1,000		977		977		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	February 1, 2026		1,000		977		977
Better Place Forests Co. (2)(12)(13)	Consumer-related Technologies	Term Loan		13.75	%	Prime		6.25	%		9.50	%		-		1.85	%	July 1, 2025		5,000		4,951		3,834	Consumer-related Technologies	Term Loan		13.75	%	Prime		6.25	%		9.50	%		-		1.85	%	July 1, 2025		5,000		4,951		3,834
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-		1.85	%	October 1, 2025		2,500		2,474		1,916		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-		1.85	%	October 1, 2025		2,500		2,474		1,916
CAMP NYC, Inc. (2)(12)	Consumer-related Technologies	Term Loan		14.75	%	Prime		7.25	%		10.50	%		-		3.00	%	May 1, 2026		3,500		3,461		3,461	Consumer-related Technologies	Term Loan		14.75	%	Prime		7.25	%		10.50	%		-		3.00	%	May 1, 2026		3,500		3,461		3,461
Clara Foods Co. (2)(12)	Consumer-related Technologies	Term Loan		12.75	%	Prime		5.75	%		9.00	%		-		5.50	%	August 1, 2025		2,500		2,482		2,482	Consumer-related Technologies	Term Loan		12.75	%	Prime		5.75	%		9.00	%		-		5.50	%	August 1, 2025		2,500		2,482		2,482
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-		5.50	%	August 1, 2025		2,500		2,482		2,482		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-		5.50	%	August 1, 2025		2,500		2,482		2,482

						*Cost of*		*Fair*							*Cost of*		*Fair*
Portfolio Company (1)(3)		*Sector*	*Type of Investment (7)*	*Number of Shares*		*Investments (6)(9)*		*Value (9)*			*Sector*	*Type of Investment (7)*	*Number of Shares*		*Investments (6)(9)*		*Value (9)*
Non-Affiliate Warrant Investments — 9.4% (8)
Non-Affiliate Warrants — Life Science — 3.1% (8)
Avalo Therapeutics, Inc. (2)(5)(12)		Biotechnology	Common Stock Warrant		26,442		311		—		Biotechnology	Common Stock Warrant		26,442		311		—
Castle Creek Biosciences, Inc. (2)(12)		Biotechnology	Preferred Stock Warrant		7,404		214		335		Biotechnology	Preferred Stock Warrant		7,404		214		335
Corvium, Inc. (2)(12)		Biotechnology	Preferred Stock Warrant		661,956		53		—		Biotechnology	Preferred Stock Warrant		661,956		53		—
Emalex Biosciences, Inc. (2)(12)		Biotechnology	Preferred Stock Warrant		110,402		176		263		Biotechnology	Preferred Stock Warrant		110,402		176		263
Evelo Biosciences, Inc. (2)(5)(12)		Biotechnology	Common Stock Warrant		463,915		126		125		Biotechnology	Common Stock Warrant		463,915		126		125
F-Star Therapeutics, Inc. (2)(5)(12)		Biotechnology	Common Stock Warrant		21,120		35		—		Biotechnology	Common Stock Warrant		21,120		35		—
Greenlight Biosciences, Inc. (2)(5)(12)		Biotechnology	Common Stock Warrant		47,452		366		—		Biotechnology	Common Stock Warrant		47,452		366		—
Imunon, Inc. (2)(5)(12)		Biotechnology	Common Stock Warrant		16,502		66		—		Biotechnology	Common Stock Warrant		16,502		66		—
IMV Inc. (2)(5)(12)		Biotechnology	Common Stock Warrant		39,774		67		—
IMV Inc. (2)(5)(12)(14)											Biotechnology	Common Stock Warrant		39,774		67		—
KSQ Therapeutics, Inc. (2) (12)		Biotechnology	Preferred Stock Warrant		48,077		51		60		Biotechnology	Preferred Stock Warrant		48,077		51		60
Mustang Bio, Inc. (2)(5)(12)		Biotechnology	Common Stock Warrant		252,161		146		—		Biotechnology	Common Stock Warrant		252,161		146		—
Native Microbials, Inc (2) (12)		Biotechnology	Preferred Stock Warrant		103,679		64		162		Biotechnology	Preferred Stock Warrant		103,679		64		162
PDS Biotechnology Corporation (2)(5)(12)		Biotechnology	Common Stock Warrant		299,848		160		3,024		Biotechnology	Common Stock Warrant		299,848		160		3,024
Provivi, Inc. (2)(12)		Biotechnology	Preferred Stock Warrant		203,017		399		648		Biotechnology	Preferred Stock Warrant		203,017		399		648
Rocket Pharmaceuticals Corporation (5)(12)		Biotechnology	Common Stock Warrant		7,051		17		14		Biotechnology	Common Stock Warrant		7,051		17		14
Stealth Biotherapeutics Inc. (2)(12)		Biotechnology	Common Stock Warrant		318,181		264		37		Biotechnology	Common Stock Warrant		318,181		264		37
vTv Therapeutics Inc. (2)(5)(12)		Biotechnology	Common Stock Warrant		95,293		44		—		Biotechnology	Common Stock Warrant		95,293		44		—
Xeris Pharmaceuticals, Inc. (2)(5)(12)		Biotechnology	Common Stock Warrant		126,000		72		3		Biotechnology	Common Stock Warrant		126,000		72		3
AccuVein Inc. (2)(12)		Medical Device	Common Stock Warrant		1,175		24		—		Medical Device	Common Stock Warrant		1,175		24		—
Aerin Medical, Inc. (2)(12)		Medical Device	Preferred Stock Warrant		1,818,183		64		1,200		Medical Device	Preferred Stock Warrant		1,818,183		64		1,200
Aerobiotix, LLC (2)(12)		Medical Device	Preferred Stock Warrant		27,330		48		31		Medical Device	Preferred Stock Warrant		27,330		48		31
Canary Medical Inc. (2)(12)		Medical Device	Preferred Stock Warrant		12,153		84		1,864		Medical Device	Preferred Stock Warrant		12,153		84		1,864
Ceribell, Inc. (2)(12)		Medical Device	Preferred Stock Warrant		145,483		69		209		Medical Device	Preferred Stock Warrant		145,483		69		209
Cognoa, Inc. (2)(12)		Medical Device	Preferred Stock Warrant		775,000		148		179		Medical Device	Preferred Stock Warrant		775,000		148		179
Conventus Orthopaedics, Inc. (2)(12)		Medical Device	Preferred Stock Warrant		7,972,222		221		226		Medical Device	Preferred Stock Warrant		7,972,222		221		226
CSA Medical, Inc. (2)(12)		Medical Device	Preferred Stock Warrant		1,375,727		153		150		Medical Device	Preferred Stock Warrant		1,375,727		153		150
CVRx, Inc. (2)(5)(12)		Medical Device	Common Stock Warrant		47,410		76		394		Medical Device	Common Stock Warrant		47,410		76		394
Infobionic, Inc. (2)(12)		Medical Device	Preferred Stock Warrant		317,647		124		113		Medical Device	Preferred Stock Warrant		317,647		124		113
Magnolia Medical Technologies, Inc. (2)(12)		Medical Device	Preferred Stock Warrant		809,931		194		385		Medical Device	Preferred Stock Warrant		809,931		194		385
Meditrina, Inc. (2)(12)		Medical Device	Preferred Stock Warrant		233,993		83		101		Medical Device	Preferred Stock Warrant		233,993		83		101
Robin Healthcare, Inc. (2)(12)		Medical Device	Preferred Stock Warrant		86,066		16		16		Medical Device	Preferred Stock Warrant		86,066		16		16
Scientia Vascular, Inc (2)(12)		Medical Device	Preferred Stock Warrant		19,662		40		46		Medical Device	Preferred Stock Warrant		19,662		40		46
Sonex Health, Inc. (2)(12)		Medical Device	Preferred Stock Warrant		605,313		98		123		Medical Device	Preferred Stock Warrant		605,313		98		123
VERO Biotech LLC (2)(12)		Medical Device	Preferred Stock Warrant		408		53		1		Medical Device	Preferred Stock Warrant		408		53		1
Swift Health Systems Inc. (2)(12)		Medical Device	Preferred Stock Warrant		135,484		71		83		Medical Device	Preferred Stock Warrant		135,484		71		83
Total Non-Affiliate Warrants — Life Science	Total Non-Affiliate Warrants — Life Science						4,197		9,792	Total Non-Affiliate Warrants — Life Science						4,197		9,792
Non-Affiliate Warrants — Sustainability — 0.6% (8)
Aerofarms, Inc. (2)(12)		Other Sustainability	Preferred Stock Warrant		201,537		61		74		Other Sustainability	Preferred Stock Warrant		201,537		61		74
LiquiGlide, Inc. (2)(12)		Other Sustainability	Common Stock Warrant		61,539		39		55		Other Sustainability	Common Stock Warrant		61,539		39		55
Nexii Building Solutions, Inc. (2)(12)		Other Sustainability	Common Stock Warrant		204,832		488		1,061
Nexii Building Solutions, Inc. (2)(12)(14)											Other Sustainability	Common Stock Warrant		204,832		488		1,061
Soli Organic, Inc. (2)(12)		Other Sustainability	Preferred Stock Warrant		681		214		361		Other Sustainability	Preferred Stock Warrant		681		214		361
Temperpack Technologies, Inc. (2)(12)		Other Sustainability	Preferred Stock Warrant		35,906		126		268		Other Sustainability	Preferred Stock Warrant		35,906		126		268
Total Non-Affiliate Warrants — Sustainability	Total Non-Affiliate Warrants — Sustainability						928		1,819	Total Non-Affiliate Warrants — Sustainability						928		1,819

Horizon Technology Finance Corporation (the “Company”) was organized as a Delaware corporation on March 16, 2010 and is an externally managed, non-diversified, closed-end investment company. The Company has elected to be regulated as a business development company (“BDC”) under the 1940 Act. In addition, for tax purposes, the Company has elected to be treated as a regulated investment company (“RIC”) as defined under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”). As a RIC, the Company generally is not subject to corporate-level federal income tax on the portion of its taxable income (including net capital gains) the Company distributes to its stockholders. The Company primarily makes secured debt investments to development-stage companies in the technology, life science, healthcare information and services and sustainability industries. All of the Company’s debt investments consist of loans secured by all of, or a portion of, the applicable debtor company’s tangible and intangible assets.

On October 28, 2010, the Company completed an initial public offering (“IPO”) and its common stock trades on the Nasdaq Global Select Market under the symbol “HRZN”.

Horizon Credit II LLC (“Credit II”) was formed as a Delaware limited liability company on June 28, 2011, with the Company as its sole equity member. Credit II is a special purpose bankruptcy-remote entity and is a separate legal entity from the Company. Any assets conveyed to Credit II are not available to creditors of the Company or any other entity other than Credit II’s lenders.

The Company formed Horizon Funding 2019‑1 LLC (“2019‑1 LLC”) as a Delaware limited liability company on May 2, 2019 and Horizon Funding Trust 2019‑1 on May 15, 2019 (“2019‑1 Trust” and, together with the 2019‑1 LLC, the “2019‑1 Entities”). The 2019‑1 Entities are special purpose bankruptcy remote entities and are separate legal entities from the Company. The Company formed the 2019‑1 Entities for purposes of securitizing the 2019 Asset-Backed Notes.

Horizon Funding I, LLC (“HFI”) was formed as a Delaware limited liability company on May 9, 2018, with Horizon Secured Loan Fund I LLC, a Delaware limited liability company (“HSLFI”) as its sole member. HFI is a special purpose bankruptcy-remote entity and is a separate legal entity from HSLFI. Any assets conveyed to HFI are not available to creditors of HSLFI or any other entity other than HFI’s lenders. As of April 21, 2020, HSLFI and its subsidiary, HFI, are consolidated by the Company.

The Company formed Horizon Funding 2022‑1 LLC (“2022‑1 LLC”) as a Delaware limited liability company on September 30, 2022 and Horizon Funding Trust 2022‑1 on October 18, 2022 (“2022‑1 Trust” and, together with the 2022‑1 LLC, the “2022‑1 Entities”). The 2022‑1 Entities are special purpose bankruptcy remote entities and are separate legal entities from the Company. The Company formed the 2022‑1 Entities for purposes of securitizing the 2022 Asset-Backed Notes.

The Company has ~~also~~ established ~~an additional~~ wholly owned ~~subsidiary,~~subsidiaries, which isare structured as a Delaware limited liability ~~company,~~companies, either to hold ~~the~~ assets of a portfolio ~~company~~companies acquired in connection with a foreclosure or bankruptcy or to hold equity in portfolio companies which ~~is a~~the Company may control. Such wholly-owned subsidiaries are separate legal ~~entity~~entities from the Company.

The Company’s investment strategy is to maximize the investment portfolio’s return by generating current income from the debt investments the Company makes and capital appreciation from the warrants the Company receives when making such debt investments. The Company has entered into an investment management agreement (the “Investment Management Agreement”) with Horizon Technology Finance Management LLC (the “Advisor”) under which the Advisor manages the day-to-day operations of, and provides investment advisory services to, the Company.

The consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and pursuant to the requirements for reporting on Form 10‑Q and Articles 6 and 10 of Regulation S-X (“Regulation S-X”) under the Securities Act of 1933, as amended (the “Securities Act”). In the opinion of management, the consolidated financial statements reflect all adjustments and reclassifications, consisting solely of normal recurring accruals, that are necessary for the fair presentation of financial results as of and for the periods presented. All intercompany balances and transactions have been eliminated. The current period’s results of operations are not necessarily indicative of results that ultimately may be achieved for the year. Therefore, the unaudited financial statements and notes should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2022.

As required under GAAP and Regulation S-X, the Company will generally consolidate its investment in a company that is an investment company subsidiary or a controlled operating company whose business consists of providing services to the Company. Accordingly, the Company consolidated the results of the Company’s wholly-owned subsidiaries in its consolidated financial statements.

Assets related to transactions that do not meet Accounting Standards Codification (“ASC”) Topic 860, Transfers and Servicing requirements for accounting sale treatment are reflected in the Company’s Consolidated Statements of Assets and Liabilities as investments. Those assets are owned by special purpose entities, including 2019‑1 Entities and 2022-1 Entities, that are consolidated in the Company’s consolidated financial statements. The creditors of the special purpose entities have received security interests in such assets, and such assets are not intended to be available to the creditors of the Company (or any affiliate of the Company).

In preparing the consolidated financial statements in accordance with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities, as of the date of the balance sheet and income and expenses for the period. Actual results could differ from those estimates. Material estimates that are particularly susceptible to significant change in the near term relate to the valuation of investments.

The Company records all of its investments at fair value in accordance with relevant GAAP, which establishes a framework used to measure fair value and requires disclosures for fair value measurements. The Company has categorized its investments carried at fair value, based on the priority of the valuation technique, into a three-level fair value hierarchy as more fully described in Note 6. Fair value is a market-based measure considered from the perspective of the market participant who holds the financial instrument rather than an entity specific measure. Therefore, when market assumptions are not readily available, the Company’s own assumptions are set to reflect those that management believes market participants would use in pricing the financial instrument at the measurement date.

The availability of observable inputs can vary depending on the financial instrument and is affected by a wide variety of factors, including, for example, the type of product, whether the product is new, whether the product is traded on an active exchange or in the secondary market and the current market conditions. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for financial instruments classified as Level 3.

The Company has determined that it has a single reporting segment and operating unit structure. The Company lends to and invests in portfolio companies in various technology, life science, healthcare information and services and sustainability industries. The Company separately evaluates the performance of each of its lending and investment relationships. However, because each of these debt investments and investment relationships has similar business and economic characteristics, they have been aggregated into a single lending and investment segment.

Investments are recorded at fair value. Pursuant to the amended SEC Rule 2a-5 of the 1940 Act, on July 29, 2022, the Company's board of directors (the “Board”) designated the Advisor as the Company’s “valuation designee.” The valuation designee determines the fair value of the Company’s portfolio investments and the Board oversees the valuation designee. The Company has the intent to hold its debt investments for the foreseeable future or until maturity or payoff.

Interest on debt investments is accrued and included in income based on contractual rates applied to principal amounts outstanding. Interest income is determined using a method that results in a level rate of return on principal amounts outstanding. Generally, when a debt investment becomes 90 days or more past due, or if the Company otherwise does not expect to receive interest and principal repayments, the debt investment is placed on non-accrual status and the recognition of interest income may be discontinued. Interest payments received on non-accrual debt investments may be recognized as income, on a cash basis, or applied to principal depending upon management’s judgment at the time the debt investment is placed on non-accrual status. As of ~~March 31,~~June 30, 2023, there were ~~three~~two investments on nonaccrual status with a cost of ~~$20.3~~$25.6 million and a fair value of ~~$5.3~~$15.3 million. As of December 31, 2022, there were three investments on non-accrual status with a cost of $20.9 million and a fair value of $8.3 million. For the three and sixmonths ended ~~March 31,~~June 30, 2023and 2022, the Company did not recognize any interest income received from debt investments on non-accrual status.

The Company has a limited number of debt investments in its portfolio that contain a PIK provision. Contractual PIK interest, which represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on an accrual basis to the extent such amounts are expected to be collected. The Company will generally cease accruing PIK interest if there is insufficient value to support the accrual or management does not expect the portfolio company to be able to pay all principal and interest due. The Company recorded $1.0 million and $2.2 million in PIK interest income during the three and six months ended June 30, 2023, respectively. The Company recorded no PIK interest income during the three and six months ended June 30, 2022.

The Company receives a variety of fees from borrowers in the ordinary course of conducting its business, including advisory fees, commitment fees, amendment fees, non-utilization fees, success fees and prepayment fees. In a limited number of cases, the Company may also receive a non-refundable deposit earned upon the termination of a transaction. Debt investment origination fees, net of certain direct origination costs, are deferred and, along with unearned income, are amortized as a level-yield adjustment over the respective term of the debt investment. All other income is recognized when earned. Fees for counterparty debt investment commitments with multiple debt investments are allocated to each debt investment based upon each debt investment’s relative fair value. When a debt investment is placed on non-accrual status, the amortization of the related fees and unearned income is discontinued until the debt investment is returned to accrual status.

Certain debt investment agreements also require the borrower to make an ETP, that is accrued into interest receivable and taken into income over the life of the debt investment to the extent such amounts are expected to be collected. The Company will generally cease accruing the income if there is insufficient value to support the accrual or the Company does not expect the borrower to be able to pay the ETP when due. The proportion of the Company’s total investment income that resulted from the portion of ETPs not received in cash for the three months ended ~~March 31,~~June 30, 2023 and 2022 was ~~6.3%~~3.1% and ~~9.5%~~6.8%, respectively. The proportion of the Company’s total investment income that resulted from the portion of ETPs not received in cash for the six months ended June 30, 2023 and 2022 was 4.7% and 8.0%, respectively.

In connection with substantially all lending arrangements, the Company receives warrants to purchase shares of stock from the borrower. The warrants are recorded as assets at estimated fair value on the grant date using the Black-Scholes valuation model. The warrants are considered loan fees and are recorded as unearned income on the grant date. The unearned income is recognized as interest income over the contractual life of the related debt investment in accordance with the Company’s income recognition policy. Subsequent to debt investment origination, the fair value of the warrants is determined using the Black-Scholes valuation model. Any adjustment to fair value is recorded through earnings as net unrealized appreciation or depreciation on investments. Gains and losses from the disposition of the warrants or stock acquired from the exercise of warrants are recognized as realized gains and losses on investments.

Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not recoverable, are calculated using the specific identification method. The Company measures realized gains or losses by calculating the difference between the net proceeds from the repayment or sale and the amortized cost basis of the investment. Net change in unrealized appreciation or depreciation reflects the change in the fair values of the Company’s portfolio investments during the reporting period, including any reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized.

Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing from its lenders and issuing debt securities. The unamortized balance of debt issuance costs as of ~~March 31,~~June 30, 2023 and December 31, 2022 was ~~$6.6~~$6.9 million and $7.1 million, respectively. These amounts are amortized and included in interest expense in the consolidated statements of operations over the life of the borrowings. The accumulated amortization balances as of ~~March 31,~~June 30, 2023 and December 31, 2022 were ~~$5.3~~$5.8 million and $4.8 million, respectively. The amortization expense for the three months ended ~~March 31,~~June 30, 2023 and 2022 was $0.5 million and ~~$0.3~~$0.4 million, respectively. The amortization expense for the six months ended June 30, 2023 and 2022 was $0.9 million and $0.7 million, respectively.

As a BDC, the Company has elected to be treated as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC and to avoid the imposition of corporate-level income tax on the portion of its taxable income distributed to stockholders, among other things, the Company is required to meet certain source of income and asset diversification requirements and to timely distribute dividends out of assets legally available for distribution to its stockholders of an amount generally at least equal to 90% of its investment company taxable income, as defined by the Code and determined without regard to any deduction for dividends paid, for each tax year. The Company, among other things, has made and intends to continue to make the requisite distributions to its stockholders, which generally relieves the Company from corporate-level U.S. federal income taxes. Accordingly, no provision for federal income tax has been recorded in the financial statements. Differences between taxable income and net increase in net assets resulting from operations either can be temporary, meaning they will reverse in the future, or permanent. In accordance with ASC Topic 946, Financial Services—Investment Companies, as amended, of the Financial Accounting Standards Board (“FASB”), permanent tax differences, such as non-deductible excise taxes paid, are reclassified from distributions in excess of net investment income and net realized loss on investments to paid-in-capital at the end of each fiscal year. These permanent book-to-tax differences are reclassified on the consolidated statements of changes in net assets to reflect their tax character but have no impact on total net assets.

Depending on the level of taxable income earned in a tax year, the Company may choose to carry forward taxable income in excess of current year distributions into the next tax year and incur a 4% U.S. federal excise tax on such income, as required. To the extent that the Company determines that its estimated current year annual taxable income will be in excess of estimated current year distributions, the Company accrues excise tax, if any, on estimated excess taxable income as taxable income is earned. For the three months ended ~~March 31,~~June 30, 2023 and 2022,, $0.2 million and $0.1 million, respectively, was accrued for U.S. federal excise tax. For the six months ended June 30, 2023 and 2022, $0.4 million and $0.2 million, respectively, was accrued for U.S. federal excise tax.

The Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than-not” to be sustained by the applicable tax authority in accordance with ASC Topic 740, Income Taxes, as modified by ASC Topic 946. Tax benefits of positions not deemed to meet the more-likely-than-not threshold, or uncertain tax positions, would be recorded as a tax expense in the current year. It is the Company’s policy to recognize accrued interest and penalties related to uncertain tax benefits in income tax expense. The Company had no material uncertain tax positions at ~~March 31,~~June 30, 2023 and December 31, 2022. The Company’s income tax returns for the 2021, 2020 and 2019 tax years remain subject to examination by U.S. federal and state tax authorities.

Distributions to common stockholders are recorded on the declaration date. The amount to be paid out as distributions is determined by the Board. Net realized capital gains, if any, may be distributed, although the Company may decide to retain such net realized gains for investment.

The Company has adopted a dividend reinvestment plan that provides for reinvestment of cash distributions on behalf of its stockholders, unless a stockholder elects to receive cash. As a result, if the Board declares a cash distribution, then stockholders who have not “opted out” of the dividend reinvestment plan will have their cash distributions automatically reinvested in additional shares of the Company’s common stock, rather than receiving the cash distribution. The Company may issue new shares or purchase shares in the open market to fulfill its obligations under the plan.

On August 2, 2021, the Company entered into an At-The-Market (“ATM”) sales agreement (the “2021 Equity Distribution Agreement”), with Goldman Sachs & Co. LLC and B. Riley FBR, Inc. (each a “Sales Agent” and, collectively, the “Sales Agents”). The 2021 Equity Distribution Agreement provides that the Company may offer and sell its shares from time to time through the Sales Agents up to $100.0 million worth of its common stock, in amounts and at times to be determined by the Company. Sales of the Company’s common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at-the-market,” as defined in Rule 415 under the Securities Act, including sales made directly on the Nasdaq or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices.

During the three months ended ~~March 31,~~June 30, 2023, the Company sold ~~605,848~~448,175 shares of common stock under the 2021 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately ~~$7.2~~$5.1 million, including ~~$0.2~~$0.1 million of offering expenses, from these sales.

During the three months ended ~~March 31,~~June 30, 2022, the Company sold ~~250,171~~868,230 shares of common stock under the 2021 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately ~~$3.9~~$10.3 million, including ~~$0.1~~$0.2 million of offering expenses, from these sales.

During the six months ended June 30, 2023, the Company sold 1,054,023 shares of common stock under the 2021 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $12.3 million, including $0.3 million of offering expenses, from these sales.

During the six months ended June 30,2022, the Company sold 1,118,401 shares of common stock under the 2021 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $14.2 million, including $0.2 million of offering expenses, from these sales.

The Company generally uses net proceeds from these offerings to make investments, to pay down liabilities and for general corporate purposes. As of June 30, 2023, shares representing approximately $18.9 million of its common stock remain available for issuance and sale under the 2021 Equity Distribution Agreement.

On March 14, 2022, the Company completed a follow-on public offering of 2,500,000 shares of its common stock at a public offering price of $14.35 per share, for total net proceeds to the Company of $34.3 million, after deducting underwriting commission and discounts and other offering expenses.

On June 2, 2023, the Company completed a follow-on public offering of 3,250,000 shares of its common stock at a public offering price of $12.50 per share, for total net proceeds to the Company of $38.9 million, after deducting underwriting commission and discounts and other offering expenses.

~~The Company generally uses net proceeds from these offerings to make investments, to pay down liabilities and for general corporate purposes. As of~~ ~~March 31, 2023~~~~, shares representing approximately $24.1 million of its common stock remain available for issuance and sale under the~~ ~~2021~~ ~~Equity Distribution Agreement.~~

On April 28, 2023, the Board extended a previously authorized stock repurchase program which allows the Company to repurchase up to $5.0 million of its common stock at prices below the Company’s net asset value per share as reported in its most recent consolidated financial statements. Under the repurchase program, the Company may, but is not obligated to, repurchase shares of its outstanding common stock in the open market or in privately negotiated transactions from time to time. Any repurchases by the Company will comply with the requirements of Rule 10b‑18 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any applicable requirements of the 1940 Act. Unless extended by the Board, the repurchase program will terminate on the earlier of June 30, 2024 or the repurchase of $5.0 million of the Company’s common stock. During the three and sixmonths ended ~~March 31,~~June 30, 2023 and 2022, the Company did not make any repurchases of its common stock. From the inception of the stock repurchase program through ~~March 31,~~June 30, 2023, the Company repurchased 167,465 shares of its common stock at an average price of $11.22 on the open market at a total cost of $1.9 million.

Assets related to transactions that do not meet the requirements under ASC Topic 860, Transfers and Servicing for sale treatment under GAAP are reflected in the Company’s consolidated statements of assets and liabilities as investments. Those assets are owned by special purpose entities that are consolidated in the Company’s financial statements. The creditors of the special purpose entities have received security interests in such assets and such assets are not intended to be available to the creditors of the Company (or any other affiliate of the Company).

Transfers of financial assets are accounted for as sales when control over the assets has been surrendered. Control over transferred assets is deemed to be surrendered when (1) the assets have been isolated from the Company — put presumptively beyond the reach of the transferor and its creditors, even in bankruptcy or other receivership, (2) the transferee obtains the right (free of conditions that constrain it from taking advantage of that right) to pledge or exchange the transferred assets and (3) the transferor does not maintain effective control over the transferred assets through either (a) an agreement that both entitles and obligates the transferor to repurchase or redeem the assets before maturity or (b) the ability to unilaterally cause the holder to return specific assets, other than through a cleanup call.

In June 2022, the FASB issued Accounting Standards Update No. 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 clarifies the guidance when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of the security. The amendments in ASU 2022-03 are effective for public companies for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently assessing the impact of ASU 2022-03 on its consolidated financial statements.

~~At a special meeting of the stockholders on~~ ~~October~~ ~~30,~~~~2018,~~ ~~the stockholders approved a new Investment Management Agreement which became effective on~~ ~~March~~ 7,~~2019.~~ ~~The new Investment Management Agreement replaced the previously effective Amended and Restated Investment Management Agreement dated as of~~ ~~October~~ ~~28,~~~~2010~~ ~~and amended effective~~ ~~July~~ 1,~~2014.~~On October 28, 2022, the Board unanimously approved the renewal of the Investment Management Agreement dated as of March 7, 2019 (the “2019 Investment Management Agreement”). At a meeting of the stockholders convened on May 25, 2023 and reconvened on June 28, 2023, the stockholders approved a new Investment Management Agreement which became effective on June 30, 2023 (the “New Investment Management Agreement” and collectively with the 2019 Investment Management Agreement, the “Investment Management Agreement”) upon the closing of the acquisition of the Advisor by MCH Holdco LLC, an affiliate of Monroe Capital LLC. The new Investment Management Agreement replaced the previously effective 2019 Investment Management Agreement. The 2019 Investment Management and the New Investment Management Agreement contain the same economic terms. Under the terms of the Investment Management Agreement, the Advisor determines the composition of the Company’s investment portfolio, the nature and timing of the changes to the investment portfolio and the manner of implementing such changes; identifies, evaluates and negotiates the structure of the investments the Company makes (including performing due diligence on the Company’s prospective portfolio companies); and closes, monitors and administers the investments the Company makes, including the exercise of any voting or consent rights.

On ~~February 23, 2023,~~ ~~the Company announced that an affiliate of Monroe Capital LLC (“Monroe Capital”) has entered into a definitive purchase agreement to acquire~~ ~~one hundred~~ percent (100%) of the membership interests of the Advisor and that the Company’s Board has unanimously approved a new investment management agreement with the Advisor, subject to stockholder approval at the annual meeting of stockholders to be held on ~~May 25, 2023~~ ~~and the closing of the purchase transaction. The Company is~~ ~~not~~ a party to the definitive purchase agreement. Additional information on the approval of the new investment management agreement can be found in the Company’s proxy statement mailed to stockholders on or around ~~April 6, 2023,~~ ~~and is available on the SEC’s website at~~ ~~http://www.sec.gov, or on the Company’s website at http://www.horizontechfinance.com.~~

The Advisor’s services under the Investment Management Agreement are not exclusive to the Company, and the Advisor is free to furnish similar services to other entities so long as its services to the Company are not impaired. The Advisor is a registered investment adviser with the SEC. The Advisor receives fees for providing services to the Company under the Investment Management Agreement, consisting of two components, a base management fee and an incentive fee.

The base management ~~fee was and will be~~is calculated at an annual rate of 2.00% of the Company’s gross assets (less cash and cash equivalents) including any assets acquired with the proceeds of leverage; provided, that, to the extent the Company’s gross assets (less cash and cash equivalents) exceed $250 million, the base management fee on the amount of such excess over $250 million will be calculated at an annual rate of 1.60% of the Company’s gross assets (less cash and cash equivalents) including any assets acquired with the proceeds of leverage. The base management fee is payable monthly in arrears and is prorated for any partial month.

The base management fee payable at ~~March 31,~~June 30, 2023 and December 31, 2022 was $1.1 million. The base management fee expense was $3.2 million and ~~$2.2~~$2.5 million for the three months ended ~~March 31,~~June 30, 2023 and 2022, respectively. The base management fee expense was $6.4 million and $4.8 million for the six months ended June 30, 2023 and 2022, respectively.

The first part, which is subject to the Incentive Fee Cap and Deferral Mechanism, as defined below, is calculated and payable quarterly in arrears based on the Company’s Pre-Incentive Fee Net Investment Income for the immediately preceding calendar quarter. For this purpose, “Pre-Incentive Fee Net Investment Income” means interest income, dividend income and any other income (including any other fees (other than fees for providing managerial assistance), such as commitment, origination, structuring, diligence and consulting fees or other fees received from portfolio companies) accrued during the calendar quarter, minus expenses for the quarter (including the base management fee, expenses payable under the Administration Agreement (as defined below), and any interest expense and any dividends paid on any issued and outstanding preferred stock, but excluding the incentive fee). Pre-Incentive Fee Net Investment Income includes, in the case of investments with a deferred interest feature (such as original issue discount, debt instruments with PIK interest and zero coupon securities), accrued income the Company has not yet received in cash. The incentive fee with respect to the Pre-Incentive Fee Net Investment Income is 20.00% of the amount, if any, by which the Pre-Incentive Fee Net Investment Income for the immediately preceding calendar quarter exceeds a hurdle rate of 1.75% (which is 7.00% annualized) of the Company’s net assets at the end of the immediately preceding calendar quarter, adjusted for any share issuances or repurchases during the relevant quarter, subject to a “catch-up” provision measured as of the end of each calendar quarter. Under this provision, in any calendar quarter, the Advisor receives no incentive fee until the Pre-Incentive Fee Net Investment Income equals the hurdle rate of 1.75%, but then receives, as a “catch-up,” 100.00% of the Pre-Incentive Fee Net Investment Income with respect to that portion of such Pre-Incentive Fee Net Investment Income, if any, that exceeds the hurdle rate but is less than 2.1875% quarterly (which is 8.75% annualized). The effect of this “catch-up” provision is that, if Pre-Incentive Fee Net Investment Income exceeds 2.1875% in any calendar quarter, the Advisor will receive 20.00% of the Pre-Incentive Fee Net Investment Income as if the hurdle rate did not apply.

Pre-Incentive Fee Net Investment Income does not include any realized capital gains, realized capital losses or unrealized capital appreciation or depreciation. Because of the structure of the incentive fee, it is possible that the Company may pay an incentive fee in a quarter in which the Company incurs a loss. For example, if the Company receives Pre-Incentive Fee Net Investment Income in excess of the quarterly minimum hurdle rate, the Company will pay the applicable incentive fee up to the Incentive Fee Cap, defined below, even if the Company has incurred a loss in that quarter due to realized and unrealized capital losses. The Company’s net investment income used to calculate this part of the incentive fee is also included in the amount of the Company’s gross assets used to calculate the 2.00% base management fee. These calculations are appropriately prorated for any period of less than three months and adjusted for any share issuances or repurchases during the current quarter.

The incentive fee on Pre-Incentive Fee Net Investment Income is subject to a fee cap and deferral mechanism which is determined based upon a look-back period of up to three years and is expensed when incurred. For this purpose, the look-back period for the incentive fee based on Pre-Incentive Fee Net Investment Income (the “Incentive Fee Look-back Period”) includes the relevant calendar quarter and the 11 preceding full calendar quarters. Each quarterly incentive fee payable on Pre-Incentive Fee Net Investment Income is subject to a cap (the “Incentive Fee Cap”) and a deferral mechanism through which the Advisor may recoup a portion of such deferred incentive fees (collectively, the “Incentive Fee Cap and Deferral Mechanism”). The Incentive Fee Cap is equal to (a) 20.00% of Cumulative Pre-Incentive Fee Net Return (as defined below) during the Incentive Fee Look-back Period less (b) cumulative incentive fees of any kind paid to the Advisor during the Incentive Fee Look-back Period. To the extent the Incentive Fee Cap is zero or a negative value in any calendar quarter, the Company will not pay an incentive fee on Pre-Incentive Fee Net Investment Income to the Advisor in that quarter. To the extent that the payment of incentive fees on Pre-Incentive Fee Net Investment Income is limited by the Incentive Fee Cap, the payment of such fees will be deferred and paid in subsequent calendar quarters up to three years after their date of deferment, subject to certain limitations, which are set forth in the Investment Management Agreement. The Company only pays incentive fees on Pre-Incentive Fee Net Investment Income to the extent allowed by the Incentive Fee Cap and Deferral Mechanism. “Cumulative Pre-Incentive Fee Net Return” during any Incentive Fee Look-back Period means the sum of (a) Pre-Incentive Fee Net Investment Income and the base management fee for each calendar quarter during the Incentive Fee Look-back Period and (b) the sum of cumulative realized capital gains and losses, cumulative unrealized capital appreciation and cumulative unrealized capital depreciation during the applicable Incentive Fee Look-back Period.

The second part of the incentive fee is determined and payable in arrears as of the end of each calendar year (or, upon termination of the Investment Management Agreement, as of the termination date), and equals 20.00% of the Company’s realized capital gains, if any, on a cumulative basis from the date of the election to be a BDC through the end of each calendar year, computed net of all realized capital losses and unrealized capital depreciation on a cumulative basis through the end of such year, less all previous amounts paid in respect of the capital gain incentive fee. However, in accordance with GAAP, the Company is required to include the aggregate unrealized capital appreciation on investments in the calculation and accrue a capital gain incentive fee on a quarterly basis, as if such unrealized capital appreciation were realized, even though such unrealized capital appreciation is not permitted to be considered in calculating the fee actually payable under the Investment Management Agreement.

The performance based incentive fee expense was ~~$3.0~~$0.1 million and ~~$1.4~~$2.1 million for the three months ended ~~March 31,~~June 30, 2023 and 2022, respectively. The performance based incentive fee expense was $3.1 million and $3.6 million for the six months ended June 30, 2023 and 2022, respectively. The incentive fee on Pre-Incentive Fee Net Investment Income was subject to the Incentive Fee Cap and Deferral Mechanism for the three and sixmonths ended ~~March 31,~~June 30, 2023, which resulted in ~~$0.2~~$3.1 million and $3.3 million of reduced expense and additional net investment ~~income.~~income, respectively. This deferral represents a contingent future liability and is not accrued until the amount can be reasonably estimated and payment is probable. The deferred amount may be paid up to three years after the date of deferment. The total contingent future liability as of ~~March 31,~~June 30, 2023 was ~~$1.3 million.~~$4.4 million, of which $1.1 million expires on December 31, 2025, $0.2 million expires on March 31, 2026 and $3.1 million expires on June 30, 2026, respectively. The incentive fee on Pre-Incentive Fee Net Investment Income was not subject to the Incentive Fee Cap and Deferral Mechanism for the three and sixmonths ended ~~March 31,~~June 30, 2022. The performance based incentive fee payable as of ~~March 31,~~June 30, 2023 and December 31, 2022 was ~~$3.0~~$0.1 million and $1.4 million, respectively. The entire incentive fee payable as of ~~March 31,~~June 30, 2023 and December 31, 2022 represented part one of the incentive fee.

The Company entered into an administration agreement (the “Administration Agreement”) with the Advisor to provide administrative services to the Company. For providing these services, facilities and personnel, the Company reimburses the Advisor for the Company’s allocable portion of overhead and other expenses incurred by the Advisor in performing its obligations under the Administration Agreement, including rent, the fees and expenses associated with performing compliance functions and the Company’s allocable portion of the costs of compensation and related expenses of the Company’s Chief Financial Officer and Chief Compliance Officer and their respective staffs. The administrative fee expense was $0.4 million for the three months ended ~~March 31,~~June 30, 2023 and 2022. The administrative fee expense was $0.8 million and $0.7 million for the six months ended June 30, 2023 and 2022, respectively.

The following table shows the Company’s investments as of ~~March 31,~~June 30, 2023 and December 31, 2022:

	*March 31, 2023*				*December 31, 2022*				*June 30, 2023*				*December 31, 2022*
	*Cost*		*Fair Value*		*Cost*		*Fair Value*		*Cost*		*Fair Value*		*Cost*		*Fair Value*
	(In thousands)								(In thousands)
Investments
Debt	$	703,781	$	684,554	$	701,074	$	686,458	$	700,162	$	683,309	$	701,074	$	686,458
Warrants		14,735		25,658		14,790		29,712		15,061		25,483		14,790		29,712
Other		1,200		1,300		1,200		1,300		1,200		1,300		1,200		1,300
Equity		4,446		3,800		4,184		2,556		7,210		5,299		4,184		2,556
Total investments	$	724,162	$	715,312	$	721,248	$	720,026	$	723,633	$	715,391	$	721,248	$	720,026

The following table shows the Company’s investments by industry sector as of ~~March 31,~~June 30, 2023 and December 31, 2022:

	*March 31, 2023*				*December 31, 2022*				*June 30, 2023*				*December 31, 2022*
	*Cost*		*Fair Value*		*Cost*		*Fair Value*		*Cost*		*Fair Value*		*Cost*		*Fair Value*
	(In thousands)								(In thousands)
Life Science
Biotechnology	$	187,970	$	186,981	$	193,372	$	195,006	$	182,489	$	174,598	$	193,372	$	195,006
Medical Device		129,102		131,823		132,803		135,960		128,203		130,634		132,803		135,960
Technology
Communications		22,913		26,168		22,892		26,176		22,922		26,170		22,892		26,176
Consumer-Related		107,802		99,140		121,961		114,050		113,903		108,275		121,961		114,050
Data Storage		476		1,302		476		1,316		417		1,060		476		1,316
Internet and Media		329		1,583		329		1,159		329		1,634		329		1,159
Networking		10,111		9,984		11,831		11,710		8,391		8,274		11,831		11,710
Power Management		1,585		2,808		1,585		2,610		1,585		2,898		1,585		2,610
Semiconductors		57		—		56		—		57		—		56		—
Software		145,706		143,680		120,157		118,716		142,853		139,934		120,157		118,716
Sustainability
Energy Efficiency		8		27		8		27		111		97		8		27
Other Sustainability		84,753		83,734		84,633		85,524		86,095		83,942		84,633		85,524
Healthcare Information and Services
Diagnostics		9,862		9,868		9,851		9,858		9,960		9,969		9,851		9,858
Other		6,990		1,414		7,559		3,870		101		1,374		7,559		3,870
Software		16,498		16,800		13,735		14,044		26,217		26,532		13,735		14,044
Total investments	$	724,162	$	715,312	$	721,248	$	720,026	$	723,633	$	715,391	$	721,248	$	720,026

A non-controlled affiliated company is generally a portfolio company in which the Company owns 5% or more of such portfolio company’s voting securities but not more than 25% of such portfolio company’s voting securities.

Transactions related to investments in non-controlled affiliated companies for the three months ended ~~March 31,~~June 30, 2023 were as follows:

																							Three months ended June 30, 2023
					Three months ended March 31, 2023
	*Fair value at*						*Transfers*				*Net*				*Fair value at*				*Fair value at*						*Transfers*				*Net*				*Fair value at*
Portfolio	*December 31,*				*Principal*		*in/(out) at*		*Discount*		*unrealized*		*Net realized*		*March 31,*		*Interest*		*March 31,*						*in/(out) at*		*Dividends*		*unrealized*		*Net realized*		*June 30,*
Company	*2022*		*Purchases*		*Payments*		*fair value*		*accretion*		*gain/(loss)*		*gain/(loss)*		*2023*		*income*		*2023*		*Purchases*		*Sales*		*fair value*		*declared*		*gain/(loss)*		*gain/(loss)*		*2023*
	(In thousands)																		(In thousands)
Cadrenal Therapeutics, Inc.	$	—	$	—	$	—	$	—	$	—	$	846	$	—	$	846	$	—		846		—		—		—		—		60		—		906
Total non-controlled affiliates	$	—	$	—	$	—	$	—	$	—	$	846	$	—	$	846	$	—	$	846	$	—	$	—	$	—	$	—	$	60	$	—	$	906

Transactions related to investments in non-controlled affiliated companies for the six months ended June 30, 2023 were as follows:

For the three and sixmonths ended ~~March 31,~~June 30, 2022, there were no transactions related to investments in non-controlled affiliated companies.

A controlled affiliated company is generally a portfolio company in which the Company owns more than 25% of such portfolio company’s voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement).

For the three and sixmonths ended ~~March 31,~~June 30, 2023, there were no transactions related to investments in controlled affiliated companies.

Transactions related to investments in controlled affiliated companies for the three months ended ~~March 31,~~June 30, 2022 were as follows:

					*Three months ended March 31, 2022*																			Three months ended June 30, 2022

	*Fair value at*							*Transfers*				*Net*				*Fair value at*				*Fair value at*							*Transfers*				*Net*					*Fair value at*
Portfolio	*December 31,*							*in/(out) at*		*Dividends*		*unrealized*		*Net realized*		*March 31,*		*Dividend*		*March 31,*							*in/(out) at*		*Dividends*		*unrealized*		*Net realized*			*June 30,*
Company	*2021*		*Purchases*		*Sales*			*fair value*		*declared*		*gain/(loss)*		*gain/(loss)*		*2022*		*income*		*2022*		*Purchases*		*Sales*			*fair value*		*declared*		*gain/(loss)*		*gain/(loss)*			*2022*
	(In thousands)																			(In thousands)
HESP LLC		—		—		(50	)		—		—		50		—		—		—		—		—		(200	)		—		—		1,400		(1,200	)		—
Total controlled affiliates	$	—	$	—	$	(50	)	$	—	$	—	$	50	$	—	$	—	$	—	$	—	$	—	$	(200	)	$	—	$	—	$	1,400	$	(1,200	)	$	—

Transactions related to investments in controlled affiliated companies for the six months ended June 30, 2022 were as follows:

Prior to July 30, 2022, the Board determined the fair value of the Company’s investments. Pursuant to the amended SEC Rule 2a-5 of the 1940 Act, on July 29, 2022, the Board designated the Advisor as the Company’s “valuation designee.” The Board is responsible for oversight of the valuation designee. The valuation designee has established a Valuation Committee to determine in good faith the fair value of the Company’s investments, based on input from the Advisor’s management and personnel and independent valuation firms which are engaged at the direction of the Valuation Committee to assist in the valuation of certain portfolio investments lacking a readily available market quotation at least once during a trailing twelve-month period. The Valuation Committee determines fair values pursuant to a valuation policy approved by the Board and pursuant to a consistently applied valuation process. This valuation process is conducted at the end of each fiscal quarter, with at least 25% (based on fair value) of the Company’s valuation of portfolio companies lacking readily available market quotations subject to review by an independent valuation firm.

The Company uses fair value measurements made by the valuation designee to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is best determined based upon quoted market prices. However, in certain instances, there are no quoted market prices for certain assets or liabilities. In cases where quoted market prices are not available, fair values are based on estimates using present value or other valuation techniques. Those techniques are significantly affected by the assumptions used, including the discount rate and estimates of future cash flows. Accordingly, the fair value estimates may not be realized in an immediate settlement of the asset or liability.

Fair value measurements focus on exit prices in an orderly transaction (that is, not a forced liquidation or distressed sale) between market participants at the measurement date under current market conditions. If there has been a significant decrease in the volume and level of activity for the asset or liability, a change in valuation technique or the use of multiple valuation techniques may be appropriate. In such instances, determining the price at which willing market participants would transact at the measurement date under current market conditions depends on the facts and circumstances and requires the use of significant judgment.

The Company’s fair value measurements are classified into a fair value hierarchy in accordance with ASC Topic 820, Fair Value Measurement, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. The three categories within the hierarchy are as follows:

Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Company’s investments may fluctuate from period to period. Additionally, the fair value of the Company’s investments may differ significantly from the values that would have been used had a ready market existed for such investments and may differ materially from the values that the Company may ultimately realize. Further, such investments are generally subject to legal and other restrictions on resale or otherwise are less liquid than publicly traded securities. If the Company was required to liquidate a portfolio investment in a forced or liquidation sale, the Company could realize significantly less than the value at which the Company has recorded such portfolio investment.

Cash and interest receivable: The carrying amount is a reasonable estimate of fair value. These financial instruments are not recorded at fair value on a recurring basis and are categorized as Level 1 within the fair value hierarchy described above.

Money market funds: The carrying amounts are valued at their net asset value as of the close of business on the day of valuation. These financial instruments are recorded at fair value on a recurring basis and are categorized as Level 2 within the fair value hierarchy described above as these funds can be redeemed daily.

Debt investments: The fair value of debt investments is estimated by discounting the expected future cash flows using the period end rates at which similar debt investments would be made to borrowers with similar credit ratings and for the same remaining maturities. Significant increases (decreases) in this unobservable input would result in a significantly lower (higher) fair value measurement. These assets are recorded at fair value on a recurring basis and are categorized as Level 3 within the fair value hierarchy described above.

Under certain circumstances, the Company may use an alternative technique to value debt investments that better reflects its fair value such as the use of multiple probability weighted cash flow models when the expected future cash flows contain elements of variability.

Warrant investments: The Company values its warrants using the Black-Scholes valuation model incorporating the following material assumptions:

Under certain circumstances the Company may use an alternative technique to value warrants that better reflects the warrants’ fair value, such as an expected settlement of a warrant in the near term or a model that incorporates a put feature associated with the warrant. The fair value may be determined based on the expected proceeds to be received from such settlement or based on the net present value of the expected proceeds from the put option.

The fair value of the Company’s warrants held in publicly traded companies is determined based on inputs that are readily available in public markets or can be derived from information available in public markets. Therefore, the Company has categorized these warrants as Level 2 within the fair value hierarchy described above. The fair value of the Company’s warrants held in private companies is determined using both observable and unobservable inputs and represents management’s best estimate of what market participants would use in pricing the warrants at the measurement date. Therefore, the Company has categorized these warrants as Level 3 within the fair value hierarchy described above. These assets are recorded at fair value on a recurring basis.

Equity investments: The fair value of an equity investment in a privately held company is initially the face value of the amount invested. The Company adjusts the fair value of equity investments in private companies upon the completion of a new third-party round of equity financing. The Company may make adjustments to fair value, absent a new equity financing event, based upon positive or negative changes in a portfolio company’s financial or operational performance. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement. The Company has categorized these equity investments as Level 3 within the fair value hierarchy described above. The fair value of an equity investment in a publicly traded company is based upon the closing public share price on the date of measurement. Therefore, the Company has categorized these equity investments as Level 1 within the fair value hierarchy described above. These assets are recorded at fair value on a recurring basis.

Other investments: Other investments are valued based on the facts and circumstances of the underlying contractual agreement. The Company currently values these contractual agreements using a multiple probability weighted cash flow model as the contractual future cash flows contain elements of variability. Significant changes in the estimated cash flows and probability weightings would result in a significantly higher or lower fair value measurement. The Company has categorized these other investments as Level 3 within the fair value hierarchy described above. These other investments are recorded at fair value on a recurring basis.

The following tables detail the investments that are carried at fair value and measured at fair value on a recurring basis as of ~~March 31,~~June 30, 2023 and December 31, 2022 and indicate the fair value hierarchy of the valuation techniques utilized by the Company to determine the fair value:

	*March 31, 2023*								*June 30, 2023*
	*Level 1*		*Level 2*		*Level 3*		*Total*		*Level 1*		*Level 2*		*Level 3*		*Total*
	(In thousands)								(In thousands)
Debt investments	$	—	$	—	$	684,554	$	684,554	$	—	$	—	$	683,309	$	683,309
Warrant investments		—		1,020		24,638		25,658		—		1,107		24,376		25,483
Other investments		—		—		1,300		1,300		—		—		1,300		1,300
Equity investments		885		—		2,915		3,800		1,040		—		4,259		5,299
Total investments	$	885	$	1,020	$	713,407	$	715,312	$	1,040	$	1,107	$	713,244	$	715,391

The following tables provide a summary of quantitative information about the Company’s Level 3 fair value measurements of the Company’s investments as of ~~March 31,~~June 30, 2023 and December 31, 2022. In addition to the techniques and inputs noted in the table below, according to the Company’s valuation policy, the Company may also use other valuation techniques and methodologies when determining its fair value measurements.

The following table is not intended to be all-inclusive, but rather provides information on the significant Level 3 inputs as they relate to the Company’s fair value measurements as of ~~March 31,~~June 30, 2023:

*March 31, 2023*
*June 30, 2023*									*June 30, 2023*
	*Fair*		*Valuation Techniques/*	*Unobservable*		*Weighted*				*Fair*		*Valuation Techniques/*	*Unobservable*		*Weighted*
Investment Type	*Value*		*Methodologies*	*Input*	*Range*	*Average(1)*				*Value*		*Methodologies*	*Input*	*Range*	*Average(1)*
			(Dollars in thousands, except per share data)									(Dollars in thousands, except per share data)
Debt investments	$	644,854	Discounted Expected Future Cash Flows	Hypothetical Market Yield	11% – 20%		14	%		$	611,524	Discounted Expected Future Cash Flows	Hypothetical Market Yield	11% – 24%		14	%

		39,700	Multiple Probability Weighted Cash Flow Model	Probability Weighting	10% - 100%		43	%			71,785	Multiple Probability Weighted Cash Flow Model	Probability Weighting	5% - 100%		50	%

Warrant investments		24,638	Black-Scholes Valuation Model	Price Per Share	0.100 –1,89999	$	62.82				24,314	Black-Scholes Valuation Model	Price Per Share	0.000 –1,89999	$	59.21
				Average Industry Volatility	28%		28	%					Average Industry Volatility	28%		28	%
				Marketability Discount	20%		20	%					Marketability Discount	20%		20	%
				Estimated Time to Exit (in years)	1 to 5		3						Estimated Time to Exit (in years)	1 to 5		3
											62	Expected Proceeds	Price Per Share	$0.25	$	0.25

Other investments		1,300	Multiple Probability Weighted Cash Flow Model	Discount Rate	25%		25	%			1,300	Multiple Probability Weighted Cash Flow Model	Discount Rate	25%		25	%
				Probability Weighting	100%		100	%					Probability Weighting	100%		100	%

Equity investments		2,915	Last Equity Financing	Price Per Share	$1.00– $215.03	$	40.27				4,259	Last Equity Financing	Price Per Share	$0.03– $215.03	$	27.56

Total Level 3 investments	$	713,407								$	713,244

Borrowings: The Key Facility and the NYL Facility approximate fair value due to the variable interest rate of the facilities and are categorized as Level 2 within the fair value hierarchy described above. Additionally, the Company considers its creditworthiness in determining the fair value of such borrowings. The fair value of the fixed-rate 2026 Notes (as defined in Note 7) is based on the closing public share price on the date of measurement. On ~~March 31,~~June 30, 2023, the closing price of the 2026 Notes on the New York Stock Exchange was ~~$23.39~~$23.35 per note and had an aggregate fair value of ~~$53.8~~$53.7 million. Therefore, the Company has categorized this borrowing as Level 1 within the fair value hierarchy described above. The fair value of the fixed-rate 2027 Notes (as defined in Note 7) is based on the closing public share price on the date of measurement. On ~~March 31,~~June 30, 2023, the closing price of the 2027 Notes on the New York Stock Exchange was ~~$24.00~~$24.14 per note and had an aggregate fair value of ~~$55.2~~$55.5 million. Therefore, the Company has categorized this borrowing as Level 1 within the fair value hierarchy described above. Based on market quotations on ~~March 31,~~June 30, 2023, the 2019 Asset-Backed Notes were trading at par value, or ~~$37.8~~$30.8 million, and are categorized as Level 3 within the fair value hierarchy described above. Based on market quotations on ~~March 31,~~June 30, 2023, the 2022 Asset-Backed Notes were trading at par value, or $100.0 million, and are categorized as Level 3 within the fair value hierarchy described above. These borrowings are not recorded at fair value on a recurring basis.

Off-balance-sheet instruments: Fair values for off-balance-sheet lending commitments are based on fees currently charged to enter into similar agreements, taking into account the remaining terms of the agreements and the counterparties’ credit standings. Therefore, the Company has categorized these instruments as Level 3 within the fair value hierarchy described above.

The following table shows a reconciliation of the beginning and ending balances for Level 3 assets measured at fair value on a recurring basis for the three months ended ~~March 31,~~June 30, 2023:

	*Three months ended March 31, 2023*													*Three months ended June 30, 2023*
	*Debt*			*Warrant*			*Equity*		*Other*					*Debt*			*Warrant*			*Equity*			*Other*
	*Investments*			*Investments*			*Investments*		*Investments*		*Total*			*Investments*			*Investments*			*Investments*			*Investments*		*Total*
	(In thousands)													(In thousands)
Level 3 assets, beginning of period	$	686,458		$	26,145		$	2,416	$	1,300	$	716,319		$	684,554		$	24,638		$	2,915		$	1,300	$	713,407
Purchase of investments		46,998			—			10		—		47,008			40,545			—			—			—		40,545
Warrants received and classified as Level 3		—			141			—		—		141
Warrants and equity received and classified as Level 3															—			515			89			—		604
Principal payments received on investments		(39,756	)		—			—		—		(39,756	)		(24,740	)		—			—			—		(24,740	)
Payment-in-kind interest on investments		1,204			—			—		—		1,204			950			—			—			—		950
Proceeds from sale of investments		(6,508	)		(12	)		—		—		(6,520	)		(528	)		(1,458	)		—			—		(1,986	)
Net realized gain (loss) on investments		7			(141	)		—		—		(134	)
Unrealized (depreciation) appreciation included in earnings		(4,566	)		(1,490	)		189		—		(5,867	)
Net realized (loss) gain on investments															(17,672	)		1,287			(127	)		—		(16,512	)
Unrealized appreciation (depreciation) included in earnings															2,118			(606	)		(1,307	)		—		205
Transfer out of Level 3															—			—			(111	)		—		(111	)
Transfer out of debt investments		(295	)		(5	)		300		—		—			(2,800	)		—			2,800			—		—
Other		1,012			—			—		—		1,012			882			—			—			—		882
Level 3 assets, end of period	$	684,554		$	24,638		$	2,915	$	1,300	$	713,407		$	683,309		$	24,376		$	4,259		$	1,300	$	713,244

During the three months ended ~~March 31,~~June 30, 2023, there ~~were no transfers in or~~was one transfer out of Level 3.

The ~~change~~one transfer out of Level 3 related to equity held in ~~unrealized depreciation included in the consolidated statement~~one portfolio company with an aggregate fair value of ~~operations attributable~~$0.1 million that was transferred to Level 31 ~~investments still held at~~ ~~March 31, 2023~~ includes $4.6 million in unrealized depreciation on debt and other investments, $1.4 million in unrealized depreciation on warrant investments and $0.2 million in unrealized appreciation on equity investments.upon the portfolio company becoming a public company.

	*Three months ended March 31, 2022*														*Three months ended June 30, 2022*
	*Debt*			*Warrant*			*Equity*		*Other*						*Debt*			*Warrant*			*Equity*		*Other*
	*Investments*			*Investments*			*Investments*		*Investments*			*Total*			*Investments*			*Investments*			*Investments*		*Investments*			*Total*
	(In thousands)														(In thousands)
Level 3 assets, beginning of period	$	437,317		$	19,837		$	203	$	200		$	457,557		$	492,194		$	21,645		$	203	$	200		$	514,242
Purchase of investments		94,485			—			—		—			94,485			158,985			—			250		—			159,235
Warrants received and classified as Level 3		—			808			—		—			808			—			669			—		—			669
Principal payments received on investments		(14,095	)		—			—		(50	)		(14,145	)		(73,096	)		—			—		(232	)		(73,328	)
Proceeds from sale of investments		(21,250	)		(30	)		—		—			(21,280	)		(21,750	)		(396	)		—		—			(22,146	)
Net realized gain on investments		—			30			—		—			30
Net realized gain (loss) on investments																—			239			—		(1,168	)		(929	)
Unrealized (depreciation) appreciation included in earnings		(3,170	)		1,000			—		50			(2,120	)		(3,797	)		3,010			—		1,400			613
Other		(1,093	)		—			—		—			(1,093	)		(976	)		—			—		—			(976	)
Level 3 assets, end of period	$	492,194		$	21,645		$	203	$	200		$	514,242		$	551,560		$	25,167		$	453	$	200		$	577,380

During the three months ended ~~March 31,~~June 30, 2022, there were no transfers in or out of Level 3.

The following table shows a reconciliation of the beginning and ending balances for Level 3 assets measured at fair value on a recurring basis for the six months ended June 30, 2023:

During the six months ended June 30, 2023, there was one transfer out of Level 3. The one transfer out of Level 3 related to equity held in one portfolio company with an aggregate fair value of $0.1 million that was transferred to Level 1 upon the portfolio company becoming a public company.

The change in unrealized depreciation included in the consolidated statement of operations attributable to Level 3 investments still held at June 30, 2023 includes $13.1 million in unrealized depreciation on debt investments, $1.9 million in unrealized depreciation on warrant investments and $1.3 million in unrealized depreciation on equity investments.

The following table shows a reconciliation of the beginning and ending balances for Level 3 assets measured at fair value on a recurring basis for the six months ended June 30, 2022:

During the six months ended June 30, 2022, there were no transfers in or out of Level 3.

The change in unrealized depreciation included in the consolidated statement of operations attributable to Level 3 investments still held at ~~March 31,~~June 30, 2022 includes ~~$3.3~~$7.0 million in unrealized depreciation on debt ~~and other~~ investments and ~~$1.0~~$4.7 million in unrealized appreciation on warrant investments.

The Company discloses fair value information about financial instruments, whether or not recognized in the consolidated statement of assets and liabilities, for which it is practicable to estimate that value. Certain financial instruments are excluded from the disclosure requirements. Accordingly, the aggregate fair value amounts presented do not represent the underlying value of the Company.

The fair value amounts have been measured as of the reporting date and have not been reevaluated or updated for purposes of these financial statements subsequent to that date. As such, the fair values of these financial instruments subsequent to the reporting date may be different than amounts reported.

As of ~~March 31,~~June 30, 2023 and December 31, 2022, all of the balances of all the Company’s financial instruments were recorded at fair value, except for the Company’s borrowings, as previously described.

The Company assumes interest rate risk (the risk that general interest rate levels will change) as a result of its normal operations. As a result, the fair values of the Company’s financial instruments will change when interest rate levels change, and that change may be either favorable or unfavorable to the Company. Management attempts to match maturities of assets and liabilities to the extent believed necessary to minimize interest rate risk. Management monitors rates and maturities of assets and liabilities and attempts to minimize interest rate risk by adjusting terms of new debt investments and by investing in securities with terms that mitigate the Company’s overall interest rate risk.

The following table shows the Company’s borrowings as of ~~March 31,~~June 30, 2023 and December 31, 2022:

	*March 31, 2023*							*December 31, 2022*							*June 30, 2023*							*December 31, 2022*
	*Total*		*Balance*			*Unused*		*Total*		*Balance*			*Unused*		*Total*		*Balance*			*Unused*		*Total*		*Balance*			*Unused*
	*Commitment*		*Outstanding*			*Commitment*		*Commitment*		*Outstanding*			*Commitment*		*Commitment*		*Outstanding*			*Commitment*		*Commitment*		*Outstanding*			*Commitment*
	(In thousands)														(In thousands)
Key Facility	$	125,000	$	15,000		$	110,000	$	125,000	$	5,000		$	120,000	$	150,000	$	—		$	150,000	$	125,000	$	5,000		$	120,000
NYL Facility		200,000		176,750			23,250		200,000		176,750			23,250		250,000		176,750			73,250		200,000		176,750			23,250
2019 Asset-Backed Notes		37,791		37,791			—		42,573		42,573			—		30,807		30,807			—		42,573		42,573			—
2022 Asset-Backed Notes		100,000		100,000			—		100,000		100,000			—		100,000		100,000			—		100,000		100,000			—
2027 Notes		57,500		57,500			—		57,500		57,500			—		57,500		57,500			—		57,500		57,500			—
2026 Notes		57,500		57,500			—		57,500		57,500			—		57,500		57,500			—		57,500		57,500			—
Total before debt issuance costs		577,791		444,541			133,250		582,573		439,323			143,250		645,807		422,557			223,250		582,573		439,323			143,250
Unamortized debt issuance costs attributable to term borrowings		—		(4,896	)		—		—		(5,245	)		—		—		(4,541	)		—		—		(5,245	)		—
Total borrowings outstanding, net	$	577,791	$	439,645		$	133,250	$	582,573	$	434,078		$	143,250	$	645,807	$	418,016		$	223,250	$	582,573	$	434,078		$	143,250

As of ~~March 31,~~June 30, 2023, with certain limited exceptions, the Company, as a BDC, is only allowed to borrow amounts such that the Company’s asset coverage, as defined in the 1940 Act, is at least 150% after such borrowings. As of ~~March 31,~~June 30, 2023, the asset coverage for borrowed amounts was ~~172%~~184%.

The Company entered into the Key Facility with Key effective November 4, 2013. On June ~~22, 2021,~~29, 2023, the Company amended the Key Facility, among other things, to ~~amend~~increase the ~~interest rate applied~~commitment amount to ~~the outstanding principal balance~~$150 million and to ~~extend~~increase the ~~period during which~~amount of the ~~Company~~ ~~may~~ ~~request advances under the Key Facility to~~ ~~June 22, 2024.~~ ~~The Key Facility has an~~ accordion feature which now allows for anthe potential increase in the total ~~loan~~ commitment amount to ~~$150 million from the $125 million commitment.~~$300 million. The Key Facility is collateralized by all debt investments and warrants held by Credit II and permits an advance rate of up to 60% of eligible debt investments held by Credit II. The Key Facility contains covenants that, among other things, require the Company to maintain a minimum net worth and to restrict the debt investments securing the Key Facility to certain criteria for qualified debt investments and includes portfolio company concentration limits as defined in the related loan agreement. The Company may request advances under the Key Facility through June 22, 2024 and the Key Facility is scheduled to mature on June 22, 2026. The interest rate on the Key Facility is based on the rate of interest published in The Wall Street Journal as the prime rate in the United States plus 0.25%, with a prime rate floor of 4.25%. The prime rate was ~~8.00%~~8.25% and 7.50% on ~~March 31,~~June 30, 2023 and December 31, 2022, respectively. The average interest rate on the Key Facility for the three months ended ~~March 31,~~June 30, 2023 and 2022 was ~~7.94%~~8.41% and 4.25%, respectively. The average interest rate on the Key Facility for the six months ended June 30, 2023 and 2022 was 8.17% and 4.25%, respectively. The Key Facility requires the payment of an unused line fee in an amount up to 0.50% on an annualized basis of any unborrowed amount available under the facility. As of ~~March 31,~~June 30, 2023 and December 31, 2022, the Company had borrowing capacity under the Key Facility of ~~$110.0~~$150.0 million and $120.0 million, respectively. At ~~March 31,~~June 30, 2023 and December 31, 2022, ~~$47.7~~$61.4 million and $40.2 million, respectively, was available for borrowing, subject to existing terms and advance rates.

On April 21, 2020, the Company purchased all of the limited liability company interests ~~of Arena~~ in ~~HSLFI, which is a party to the NYL Facility.~~HSLFI. HFI entered into the NYL Facility with the NYL Noteholders for an aggregate purchase price of up to $100.0 million, with an accordion feature of up to $200.0 million at the mutual discretion and agreement of HSLFI and the NYL Noteholders. On June 1, 2018, HSLFI sold or contributed to HFI certain secured loans made to certain portfolio companies pursuant to the Sale and Servicing Agreement. Any notes issued by HFI are collateralized by all investments held by HFI and permit an advance rate of up to 67% of the aggregate principal amount of eligible debt investments. The notes were issued pursuant to the Indenture. The interest rate on the notes issued under the NYL Facility was based on the three year USD mid-market swap rate plus a margin of between 3.55% and 5.15% with an interest rate floor, depending on the rating of such notes at the time of issuance.

On February 25, 2022, the Company amended its NYL Facility ~~increasing~~to, among other things, reduce the applicable margin used to calculate the credit facility’s interest rate on the Company’s borrowings above $100.0 million. Such borrowings were priced at the three-year USD mid-market swap rate plus 3.00%.

On May 24, 2023, the Company amended its NYL Facility to, among other things, increase the commitment by ~~$100.0~~$50.0 million to enable its wholly-owned subsidiary to issue up to ~~$200.0~~$250.0 million of secured notes. The amendment to the NYL Facility extends the investment period to June ~~2023~~2024 and the maturity date of all advances to June ~~2028.~~2029. In addition, the amendment ~~among other things, reduces~~amended the ~~applicable margin used to calculate the credit facility’s~~ interest rate onfor advances made after May 24, 2023, fixing the ~~Company’s borrowings above~~ ~~$100.0~~ ~~million. Such borrowings will be priced~~interest rate at the ~~three~~~~-year USD mid-market swap~~greater of (i) 4.60% and (ii) the Three Year I Curve plus 3.50%, with the interest rate ~~plus 3.00%.~~to be reset on any advance date.

There were $176.8 million in advances made by the NYL Noteholders as of ~~March 31,~~June 30, 2023 and December 31, 2022. The interest rate as of ~~March 31,~~June 30, 2023 and December 31, 2022 was 5.62% and 5.57%., respectively. As of ~~March 31,~~June 30, 2023 and December 31, 2022, the Company had borrowing capacity under the NYL Facility of $73.2 million and $23.2 ~~million.~~million, respectively. At ~~March 31,~~June 30, 2023 and December 31, 2022, ~~$21.1~~$3.0 million and $23.2 million, respectively, was available for borrowing, subject to existing terms and advance rates.

Under the terms of the NYL Facility, the Company is required to maintain a reserve cash balance, which may be used to pay monthly interest and principal payments on the NYL Facility. The Company has segregated these funds and classified them as restricted investments in money market funds. At ~~March 31,~~June 30, 2023 and December 31, 2022, there were approximately $1.3 million and $1.0 million, respectively, of restricted investments.

On August 13, 2019, the Company completed a term debt securitization in connection with which an affiliate of the Company made an offering of the 2019 Asset-Backed Notes. The 2019 Asset-Backed Notes were rated A+(sf) by Morningstar Credit Ratings, LLC. There has been no change in the rating since August 13, 2019.

The 2019 Asset-Backed Notes were issued by the 2019‑1 Trust pursuant to a note purchase agreement, dated as of August 13, 2019, by and among the Company and Keybanc Capital Markets Inc. as Initial Purchaser, and are backed by a pool of loans made to certain portfolio companies of the Company and secured by certain assets of those portfolio companies and are to be serviced by the Company. Interest on the 2019 Asset-Backed Notes will be paid, to the extent of funds available, at a fixed rate of 4.21% per annum. The reinvestment period of the 2019 Asset-Backed Notes ended July 15, 2021 and the maturity date is September 15, 2027.

As of ~~March 31,~~June 30, 2023 and December 31, 2022, the 2019 Asset-Backed Notes had an outstanding principal balance of ~~$37.8~~$30.8 million and $42.6 million, respectively.

Under the terms of the 2019 Asset-Backed Notes, the Company is required to maintain a reserve cash balance, funded through proceeds from the sale of the 2019 Asset-Backed Notes, which may be used to pay monthly interest and principal payments on the 2019 Asset-Backed Notes. The Company has segregated these funds and classified them as restricted investments in money market funds. At ~~March 31,~~June 30, 2023 and December 31, 2022, there were approximately $0.5 million and $0.6 million of restricted investments, respectively.

On November 9, 2022, the Company completed a term debt securitization in connection with which an affiliate of the Company made an offering of the 2022 Asset-Backed Notes. The 2022 Asset-Backed Notes were rated A by ~~DRBS,~~DBRS, Inc. There has been no change in the rating since November 9, 2022.

The 2022 Asset-Backed Notes were issued by the 2022‑1 Trust pursuant to a note purchase agreement, dated as of November 9, 2022, by and among the Company and Keybanc Capital Markets Inc. as Initial Purchaser, and are backed by a pool of loans made to certain portfolio companies of the Company and secured by certain assets of those portfolio companies and are to be serviced by the Company. Interest on the 2022 Asset-Backed Notes will be paid, to the extent of funds available, at a fixed rate of 7.56% per annum. The reinvestment period of the 2022 Asset-Backed Notes ends November 15, 2024 and the maturity date is November 15, 2030.

As of ~~March 31,~~June 30, 2023 and December 31, 2022, the 2022 Asset-Backed Notes had an outstanding principal balance of ~~$100.0~~$100.0 million.

Under the terms of the 2022 Asset-Backed Notes, the Company is required to maintain a reserve cash balance, funded through proceeds from the sale of the 2022 Asset-Backed Notes, which may be used to pay monthly interest and principal payments on the 2022 Asset-Backed Notes. The Company has segregated these funds and classified them as restricted investments in money market funds. At ~~March 31,~~June 30, 2023 and December 31, 2022, there were approximately $1.1 million and ~~$1.0~~$1.2 million of restricted investments, respectively.

On March 30, 2021, the Company issued and sold an aggregate principal amount of $57.5 million of 4.875% notes due in 2026 (the “2026 Notes”). The amount of 2026 Notes issued and sold included the full exercise by the underwriters of their option to purchase $7.5 million in aggregate principal of additional notes. The 2026 Notes have a stated maturity of March 30, 2026 and may be redeemed in whole or in part at the Company’s option at any time or from time to time on or after March 30, 2023 at a redemption price of $25 per security plus accrued and unpaid interest. The 2026 Notes bear interest at a rate of 4.875% per year, payable quarterly on March 30, June 30, September 30 and December 30 of each year. The 2026 Notes are the Company’s direct unsecured obligations and (i) rank equally in right of payment with the Company’s current and future unsecured indebtedness; (ii) are senior in right of payment to any of the Company’s future indebtedness that expressly provides it is subordinated to the 2026 Notes; (iii) are effectively subordinated to all of the Company’s existing and future secured indebtedness (including indebtedness that is initially unsecured to which the Company subsequently grants security), to the extent of the value of the assets securing such indebtedness, and (iv) are structurally subordinated to all existing and future indebtedness and other obligations of any of the Company’s subsidiaries. As of ~~March 31,~~June 30, 2023, the Company was in material compliance with the terms of the 2026 Notes. The 2026 Notes are listed on the New York Stock Exchange under the symbol “HTFB”.

On June 15, 2022, the Company issued and sold an aggregate principal amount of $50.0 million of 6.25% notes due in 2027 and on July 11, 2022, pursuant to the underwriters’ 30 day option to purchase additional notes, the Company sold an additional $7.5 million of such notes (collectively, the “2027 Notes”). The 2027 Notes have a stated maturity of June 15, 2027 and may be redeemed in whole or in part at the Company’s option at any time or from time to time on or after June 15, 2024 at a redemption price of $25 per security plus accrued and unpaid interest. The 2027 Notes bear interest at a rate of 6.25% per year, payable quarterly on March 30, June 30, September 30 and December 30 of each year, commencing on September 30, 2022. The 2027 Notes are the Company’s direct unsecured obligations and (i) rank equally in right of payment with the Company’s current and future unsecured indebtedness; (ii) are senior in right of payment to any of the Company’s future indebtedness that expressly provides it is subordinated to the 2027 Notes; (iii) are effectively subordinated to all of the Company’s existing and future secured indebtedness (including indebtedness that is initially unsecured to which the Company subsequently grants security), to the extent of the value of the assets securing such indebtedness, and (iv) are structurally subordinated to all existing and future indebtedness and other obligations of any of the Company’s subsidiaries. As of ~~March 31,~~June 30, 2023, the Company was in material compliance with the terms of the 2027 Notes. The 2027 Notes are listed on the New York Stock Exchange under the symbol “HTFC”.

In the normal course of business, the Company is party to financial instruments with off-balance-sheet risk to meet the financing needs of its borrowers. These financial instruments include commitments to extend credit and involve, to varying degrees, elements of credit risk in excess of the amount recognized in the consolidated statement of assets and liabilities. The Company attempts to limit its credit risk by conducting extensive due diligence and obtaining collateral where appropriate.

The balance of unfunded commitments to extend credit was ~~$166.2~~$143.4 million and $190.0 million as of ~~March 31,~~June 30, 2023 and December 31, 2022, respectively. Commitments to extend credit consist principally of the unused portions of commitments that obligate the Company to extend credit, often subject to financial or non-financial milestones and other conditions to borrow that must be achieved before the commitment can be drawn. In addition, the commitments generally have fixed expiration dates or other termination clauses. Since commitments may expire without being drawn upon, the total commitment amounts do not necessarily represent future cash requirements.

The following table provides the Company’s unfunded commitments by portfolio company as of ~~March 31,~~June 30, 2023:

	March 31, 2023				December 31, 2022				*June 30, 2023*				*December 31, 2022*
			Fair Value of				Fair Value of				*Fair Value of*				*Fair Value of*
			Unfunded				Unfunded				*Unfunded*				*Unfunded*
	*Principal*		*Commitment*		*Principal*		*Commitment*		*Principal*		*Commitment*		*Principal*		*Commitment*
	*Balance*		*Liability*		*Balance*		*Liability*		*Balance*		*Liability*		*Balance*		*Liability*
	(In thousands)				(In thousands)				(In thousands)				(In thousands)
BrightInsight, Inc.	$	18,250	$	241	$	21,000	$	278	$	18,250	$	241	$	21,000	$	278
Britecore Holdings, Inc.		—		—		5,000		66		—		—		5,000		66
Castle Creek Biosciences		4,000		72		4,000		72		4,000		72		4,000		72
Corinth Medtech, Inc.		200		—		—		—
Divergent Technologies, Inc.		18,750		197		22,500		236		11,250		118		22,500		236
Engage3, LLC		8,000		40		8,000		40		—		—		8,000		40
Groundspeed Analytics, Inc.		15,500		150		15,000		150		—		—		15,000		150
Hound Labs, Inc.		7,500		88		7,500		88		—		—		7,500		88
KSQ Therapeutics, Inc.		10,000		100		10,000		100		—		—		10,000		100
Lytics, Inc.		4,000		52		5,000		65		4,000		52		5,000		65
Native Microbials, Inc.		—		—		7,500		72		—		—		7,500		72
Nexii Building Solutions, Inc.										1,488		—		—		—
Noodle Partners, Inc.		10,000		123		—		—		10,000		123		—		—
Optoro, Inc.		15,000		38		15,000		38		11,250		—		15,000		38
PDS Biotechnology Corporation		10,000		158		10,000		158		10,000		158		10,000		158
Robin Healthcare, Inc.		5,000		50		10,000		100		5,000		50		10,000		100
SafelyYou, Inc.										20,000		270		—		—
Scientia Vascular, Inc.		10,000		110		10,000		110		5,000		55		10,000		110
STS (ABC), LLC										140		—		—		—
Slingshot Aerospace, Inc.		5,000		63		5,000		64		5,000		64		5,000		64
Supply Network Visibility Holdings, LLC										10,000		35		—		—
Swift Health Systems Inc.		18,500		—		25,500		105		11,500		—		25,500		105
Temperpack Technologies, Inc.		6,500		14		9,000		19		6,500		14		9,000		19
Viken Detection Corporation										10,000		160		—		—
Total	$	166,200	$	1,496	$	190,000	$	1,761	$	143,378	$	1,412	$	190,000	$	1,761

The table above also provides the fair value of the Company’s unfunded commitment liability as of ~~March 31,~~June 30, 2023 and December 31, 2022, which totaled ~~$1.5~~$1.4 million and $1.8 million, respectively. The fair value at inception of the delay draw credit agreements is equal to the fees and/or warrants received to enter into these agreements, taking into account the remaining terms of the agreements and the counterparties’ credit profile. The unfunded commitment liability reflects the fair value of these future funding commitments and is included in the Company’s consolidated statement of assets and liabilities.

The Company’s debt investments consist primarily of loans to development-stage companies at various stages of development in the technology, life science, healthcare information and services and sustainability industries. Many of these companies may have relatively limited operating histories and also may experience variation in operating results. Many of these companies conduct business in regulated industries and could be affected by changes in government regulations. Most of the Company’s borrowers will need additional capital to satisfy their continuing working capital needs and other requirements, and in many instances, to service the interest and principal payments on the loans.

The Company’s largest debt investments may vary from period to period as new debt investments are recorded and existing debt investments are repaid. The Company’s five largest debt investments, at cost and fair value, represented 25% and 23% of total debt investments outstanding as of ~~March 31,~~June 30, 2023 and December 31, 2022. No single debt investment represented more than 10% of the total debt investments at cost or fair value as of ~~March 31,~~June 30, 2023 and December 31, 2022. Investment income, consisting of interest and fees, can fluctuate significantly upon repayment of large debt investments. Interest income from the five largest debt investments at cost ~~and fair value~~ accounted for ~~22%~~23% and ~~26%~~22% of total interest and fee income on investments for the three months ended ~~March 31,~~June 30, 2023 and 2022, respectively. Interest income from the five largest debt investments at fair value accounted for 23% of total interest and fee income on investments for the three months ended June 30, 2023 and 2022. Interest income from the five largest debt investments at cost accounted for 23% and 22% of total interest and fee income on investments for the six months ended June 30, 2023 and 2022, respectively. Interest income from the five largest debt investments at fair value accounted for 23% and 22% of total interest and fee income on investments for the six months ended June 30, 2023 and 2022, respectively.

The Company’s distributions are recorded on the declaration date. The following table summarizes the Company’s distribution activity for the ~~three~~six months ended ~~March 31,~~June 30, 2023 and for the year ended December 31, 2022:

							*DRIP*		*DRIP*								*DRIP*		*DRIP*
Date			*Amount*		*Cash*		*Shares*		*Share*				*Amount*		*Cash*		*Shares*		*Share*
Declared	*Record Date*	*Payment Date*	*Per Share*		*Distribution*		*Issued*		*Value*		*Record Date*	*Payment Date*	*Per Share*		*Distribution*		*Issued*		*Value*
			(In thousands, except share and per share data)										(In thousands, except share and per share data)
Three Months Ended March 31, 2023
Six Months Ended June 30, 2023
4/28/2023											8/17/23	9/15/23	$	0.11	$	—		—	$	—
4/28/2023											7/18/23	8/15/23		0.11		—		—		—
4/28/2023											6/16/23	7/14/23		0.11		3,434		7,424		96
2/23/2023	5/18/23	6/14/23	$	0.11	$	—		—	$	—	5/18/23	6/14/23		0.11		3,087		7,128		86
2/23/2023	4/18/23	5/16/23		0.11		—		—		—	4/18/23	5/16/23		0.11		3,068		6,705		84
2/23/2023	3/17/23	4/14/23		0.11		3,035		6,894		81	3/17/23	4/14/23		0.11		3,035		6,894		81
			$	0.33	$	3,035		6,894	$	81			$	0.66	$	12,624		28,151	$	347
Year Ended December 31, 2022
10/28/2022	2/17/23	3/15/23	$	0.11	$	3,040		6,764	$	75	2/17/23	3/15/23	$	0.11	$	3,040		6,764	$	75
10/28/2022	1/18/23	2/15/23		0.11		3,021		5,754		74	1/18/23	2/15/23		0.11		3,021		5,754		74
10/28/2022	12/19/22	1/13/23		0.11		2,978		5,618		69	12/19/22	1/13/23		0.11		2,978		5,618		69
10/28/2022	11/17/22	12/15/22		0.05		1,319		2,171		27	11/17/22	12/15/22		0.05		1,319		2,171		27
7/29/2022	11/17/22	12/15/22		0.10		2,638		4,341		57	11/17/22	12/15/22		0.10		2,638		4,341		57
7/29/2022	10/18/22	11/15/22		0.10		2,580		4,621		60	10/18/22	11/15/22		0.10		2,580		4,621		60
7/29/2022	9/19/22	10/14/22		0.10		2,558		7,703		81	9/19/22	10/14/22		0.10		2,558		7,703		81
4/29/2022	8/18/22	9/15/22		0.10		2,528		4,925		60	8/18/22	9/15/22		0.10		2,528		4,925		60
4/29/2022	7/19/22	8/16/22		0.10		2,484		3,939		55	7/19/22	8/16/22		0.10		2,484		3,939		55
4/29/2022	6/17/22	7/15/22		0.10		2,434		4,286		51	6/17/22	7/15/22		0.10		2,434		4,286		51
2/25/2022	5/18/22	6/15/22		0.10		2,378		4,428		50	5/18/22	6/15/22		0.10		2,378		4,428		50
2/25/2022	4/19/22	5/16/22		0.10		2,349		4,088		49	4/19/22	5/16/22		0.10		2,349		4,088		49
2/25/2022	3/18/22	4/14/22		0.10		2,352		3,221		46	3/18/22	4/14/22		0.10		2,352		3,221		46
			$	1.28	$	32,659		61,859	$	754			$	1.28	$	32,659		61,859	$	754

On ~~April~~July 28, 2023, the Board declared monthly distributions per share, payable as set forth in the following table:

After paying distributions of $0.33 per share and earning net investment income of ~~$0.46~~$0.54 per share for the quarter, the Company’s undistributed spillover income as of ~~March 31,~~June 30, 2023 was ~~$0.81~~$1.02 per share. Spillover income includes any ordinary income and net capital gains from the preceding tax years that were not distributed during such tax years.

	*Three months ended March 31,*								*Six months ended June 30,*
	*2023*				*2022*				*2023*				*2022*
	(In thousands, except share and per share data)								(In thousands, except share and per share data)
Per share data:
Net asset value at beginning of period	$	11.47			$	11.56			$	11.47			$	11.56
Net investment income		0.46				0.26				1.00				0.62
Realized loss		(0.01	)			—				(0.58	)			(0.04	)
Unrealized depreciation on investments		(0.26	)			(0.10	)			(0.23	)			(0.10	)
Net increase in net assets resulting from operations		0.19				0.16				0.19				0.48
Distributions declared ⁽¹⁾		(0.33	)			(0.30	)			(0.66	)			(0.60	)
From net investment income		(0.33	)			(0.30	)			(0.66	)			(0.60	)
From net realized gain on investments		—				—				—				—
Return of capital		—				—				—				—
Other ⁽²⁾		0.01				0.26				0.07				0.25
Net asset value at end of period	$	11.34			$	11.68			$	11.07			$	11.69
Per share market value, beginning of period	$	11.60			$	15.92			$	11.60			$	15.92
Per share market value, end of period	$	11.28			$	13.90			$	12.08			$	11.54
Total return based on a market value ⁽³⁾		0.1	%			(10.8	)%			9.8	%			(23.7	)%
Shares outstanding at end of period		28,377,357				23,977,137				32,096,259				24,857,104
Ratios to average net assets:
Expenses without incentive value ⁽⁴⁾		14.8	%			10.6	%			14.2	%			10.8	%
Incentive fees ⁽⁴⁾		3.7	%			2.2	%			1.9	%			2.6	%
Net expenses ⁽⁴⁾		18.5	%			12.8	%			16.1	%			13.4	%
Net investment income with incentive fees ⁽⁴⁾		16.3	%			8.7	%			17.5	%			10.5	%
Net assets at the end of the period	$	321,683			$	279,989			$	355,419			$	290,605
Average net asset value	$	320,066			$	262,662			$	331,850			$	271,976
Average debt per share	$	15.61			$	12.21			$	15.11			$	12.81
Portfolio turnover ratio		4.2	%	(5)		2.6	%	(5)		7.6	%	(5)		11.3	%	(5)

InOn ~~April~~July 6, 2023, the Company ~~sold 272,303~~funded a $0.3 million debt investment to an existing portfolio company, Nexii Building Solutions, Inc. ("Nexii"). On July 25, 2023, the Company funded an additional $0.3 million debt investment to Nexii. On July 27, 2023, the Company funded an additional $0.2 million debt investment to Nexii.

On July 12, 2023, Evelo Biosciences, Inc. (“Evelo”) paid down $5.0 million of the principal amount of its loans outstanding under that certain Venture Loan and Security Agreement by and among the Company, the other lender parties therein and Evelo, dated as of December 15, 2022, as amended (the “Loan Agreement”), and the Company and Evelo converted $5.0 million of the principal amount of the loans outstanding under the Loan Agreement into 2,164,502 unregistered shares of ~~common stock under the~~ ~~2021~~ ~~Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds~~Common Stock of ~~approximately $3.1 million, including $0.1 million of offering expenses, from these sales.~~Evelo.

~~IMV Inc.~~On July 13, 2023, the Company funded a $0.8 million equity investment to an existing portfolio company, Better Place Forests Co. (“~~IMV”~~Better Place”) ~~(NASDAQ: IMV; TSX: IMV)~~, ~~announced on~~ ~~May 1, 2023~~ ~~that the Nova Scotia Supreme Court has issued an initial order (the “Initial Order”) granting IMV and its subsidiaries protection under the Companies’ Creditors Arrangement Act (R.S.C.,~~ ~~1985,~~ ~~c. C-~~36~~) and IMV will seek the recognition~~converted $0.5 million of the ~~Initial Order~~principal amount of its outstanding debt investments in ~~the United States by filing a petition commencing proceedings under the Chapter~~ 15Better Place into preferred stock of Better Place and converted $2.7 million of the ~~United States Bankruptcy Code.~~principal amount of its outstanding debt investments in Better Place into common stock of Better Place.

On July 18, 2023, the Company funded a $0.2 million debt investment to an existing portfolio company, Aerobiotix, LLC.

On July 31, 2023, the Company funded a $5.0 million debt investment to a new portfolio company, Tallac Therapeutics, Inc.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

In this quarterly report on Form 10‑Q, except where the context suggests otherwise, the terms “we,” “us,” “our” and “Horizon Technology Finance” refer to Horizon Technology Finance Corporation and its consolidated subsidiaries. The information contained in this section should be read in conjunction with our consolidated financial statements and related notes thereto appearing elsewhere in this quarterly report on Form 10‑Q.

This quarterly report on Form 10‑Q, including the Management’s Discussion and Analysis of Financial Condition and Results of Operations, contains statements that constitute forward-looking statements, which relate to future events or our future performance or financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our industry, our beliefs and our assumptions. The forward-looking statements contained in this quarterly report on Form 10‑Q involve risks and uncertainties, including statements as to:

We use words such as “anticipates,” “believes,” “expects,” “intends,” “seeks” and similar expressions to identify forward-looking statements. Undue influence should not be placed on the forward looking statements as our actual results could differ materially from those projected in the forward-looking statements for any reason, including the factors in “Risk Factors” and elsewhere in our annual report on Form 10‑K for the year ended December 31, 2022, and elsewhere in this quarterly report on Form 10‑Q.

We have based the forward-looking statements included in this quarterly report on Form 10-Q on information available to us on the date of this quarterly report on Form 10-Q, and we assume no obligation to update any such forward-looking statements. Although we undertake no obligation to revise or update any forward-looking statements in this quarterly report on Form 10‑Q, whether as a result of new information, future events or otherwise, you are advised to consult any additional disclosures that we may make directly to you or through reports that we in the future may file with the U.S. Securities and Exchange Commission, or the SEC, including periodic reports on Form 10‑Q and Form 10‑K and current reports on Form 8‑K.

We are a specialty finance company that lends to and invests in development-stage companies in the technology, life science, healthcare information and services and sustainability industries, which we refer to as our “Target Industries.” Our investment objective is to maximize our investment portfolio’s total return by generating current income from the debt investments we make and capital appreciation from the warrants we receive when making such debt investments. We are focused on making secured debt investments, which we refer to collectively as “Venture Loans,” to venture capital and private equity backed companies and publicly traded companies in our Target Industries, which we refer to as “Venture Lending.” Our debt investments are typically secured by first liens or first liens behind a secured revolving line of credit, or collectively “Senior Term Loans.” Some of our debt investments may also be subordinated to term debt provided by third parties. As of ~~March 31,~~June 30, 2023, ~~86.7%~~86.9%, or $593.6 million, of our debt investment portfolio at fair value consisted of Senior Term Loans. Venture Lending is typically characterized by (1) the making of a secured debt investment after a venture capital or equity investment in the portfolio company has been made, which investment provides a source of cash to fund the portfolio company’s debt service obligations under the Venture Loan, (2) the senior priority of the Venture Loan which requires repayment of the Venture Loan prior to the equity investors realizing a return on their capital, (3) the amortization of the Venture Loan and (4) the lender’s receipt of warrants or other success fees with the making of the Venture Loan.

We are an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a BDC under the Investment Company Act of 1940, as amended, or the 1940 Act. In addition, for U.S. federal income tax purposes, we have elected to be treated as a RIC under Subchapter M of the Code. As a BDC, we are required to comply with regulatory requirements, including limitations on our use of debt. We are permitted to, and expect to, finance our investments through borrowings subject to a 150% asset coverage test. As defined in the 1940 Act, asset coverage of 150% means that for every $100 of net assets a BDC holds, it may raise up to $200 from borrowing and issuing senior securities. The amount of leverage that we may employ will depend on our assessment of market conditions and other factors at the time of any proposed borrowing. As a RIC, we generally are not subject to corporate-level income taxes on our investment company taxable income, determined without regard to any deductions for dividends paid, and our net capital gain that we distribute as dividends for U.S. federal income tax purposes to our stockholders as long as we meet certain source-of-income, distribution, asset diversification and other requirements.

Our investment activities, and our day-to-day operations, are managed by our Advisor and supervised by our Board, of which a majority of the members are independent of us. Under the Investment Management Agreement, we have agreed to pay our Advisor a base management fee and an incentive fee for its advisory services to us. We have also entered into the Administration Agreement with our Advisor under which we have agreed to reimburse our Advisor for our allocable portion of overhead and other expenses incurred by our Advisor in performing its obligations under the Administration Agreement.

The following table shows our portfolio by type of investment as of ~~March 31,~~June 30, 2023 and December 31, 2022:

	March 31, 2023						December 31, 2022						June 30, 2023						December 31, 2022
				Percentage of						Percentage of						Percentage of						Percentage of
	Number of	Fair		Total			Number of	Fair		Total			Number of	Fair		Total			Number of	Fair		Total
	Investments	Value		Portfolio			Investments	Value		Portfolio			Investments	Value		Portfolio			Investments	Value		Portfolio
	(Dollars in thousands)												(Dollars in thousands)
Debt investments	57	$	684,554		95.7	%	60	$	686,458		95.3	%	54	$	683,309		95.5	%	60	$	686,458		95.3	%
Warrants	88		25,658		3.6		90		29,712		4.1		85		25,483		3.6		90		29,712		4.1
Other investments	2		1,300		0.2		2		1,300		0.2		2		1,300		0.2		2		1,300		0.2
Equity	11		3,800		0.5		8		2,556		0.4		12		5,299		0.7		8		2,556		0.4
Total		$	715,312		100.0	%		$	720,026		100.0	%		$	715,391		100.0	%		$	720,026		100.0	%

The following table shows total portfolio investment activity as of and for the three and six months ended ~~March 31,~~June 30, 2023 and 2022:

	For the three months ended						For the three months ended						For the six months ended
	March 31,						June 30,						June 30,
	2023			2022			2023			2022			2023			2022
							(In thousands)
Beginning portfolio	$	720,026		$	458,075		$	715,312		$	515,009		$	720,026		$	458,075
New debt investments		47,008			94,485			50,545			159,235			97,553			253,720
Less refinanced debt balances								(10,000	)		(25,000	)		(10,000	)		(25,000	)
Net new debt investments								40,545			134,235			87,553			228,720
Principal payments received on investments		(6,815	)		(2,095	)		(6,075	)		(4,861	)		(12,890	)		(6,956	)
Payment-in-kind interest on investments		1,204			—			950			—			2,154			—
Early pay-offs and principal paydowns		(32,941	)		(12,050	)		(18,665	)		(43,467	)		(51,606	)		(55,517	)
Accretion of debt investment fees		1,448			1,006			1,645			1,547			3,093			2,553
New debt investment fees		(300	)		(925	)		(502	)		(1,860	)		(802	)		(2,785	)
Equity received in settlement of fee income								89			—			89			—
Proceeds from sale of investments		(6,520	)		(21,280	)		(1,986	)		(22,146	)		(8,506	)		(43,426	)
Net (loss) gain on investments		(168	)		30
Net unrealized depreciation on investments		(7,537	)		(2,237	)
Net loss on investments								(16,529	)		(929	)		(16,697	)		(899	)
Net unrealized appreciation (depreciation) on investments								608			(36	)		(6,929	)		(2,273	)
Other		(93	)		—			(1	)		—			(94	)		—
Ending portfolio	$	715,312		$	515,009		$	715,391		$	577,492		$	715,391		$	577,492

We receive payments on our debt investments based on scheduled amortization of the outstanding balances. In addition, we receive repayments of some of our debt investments prior to their scheduled maturity date. The frequency or volume of these repayments may fluctuate significantly from period to period.

The following table shows our debt investments by industry sector as of ~~March 31,~~June 30, 2023 and December 31, 2022:

	March 31, 2023					December 31, 2022						June 30, 2023					December 31, 2022
	Debt		Percentage of			Debt		Percentage of			��	Debt		Percentage of			Debt		Percentage of
	Investments at		Total			Investments at		Total				Investments at		Total			Investments at		Total
	Fair Value		Portfolio			Fair Value		Portfolio				Fair Value		Portfolio			Fair Value		Portfolio
	(Dollars in thousands)											(Dollars in thousands)
Life Science
Biotechnology	$	183,625		26.8	%	$	189,729		27.6	%		$	171,256		25.1	%	$	189,729		27.6	%
Medical Device		124,124		18.1			127,839		18.6				123,196		18.0			127,839		18.6
Technology
Communications		22,377		3.3			22,671		3.3				22,386		3.3			22,671		3.3
Consumer-Related		93,607		13.7			108,226		15.8				102,521		15.0			108,226		15.8
Networking		9,747		1.4			11,467		1.7				8,027		1.2			11,467		1.7
Software		141,942		20.7			117,002		17.0				136,929		20.0			117,002		17.0
Sustainability
Other Sustainability		82,995		12.1			83,705		12.2				83,255		12.2			83,705		12.2
Healthcare Information and Services
Diagnostics		9,815		1.4			9,804		1.4				9,913		1.4			9,804		1.4
Other Healthcare		51		0.1			2,500		0.4				—		—			2,500		0.4
Software		16,271		2.4			13,515		2.0				25,826		3.8			13,515		2.0
Total	$	684,554		100.0	%	$	686,458		100.0	%		$	683,309		100.0	%	$	686,458		100.0	%

The largest debt investments in our portfolio may vary from period to period as new debt investments are originated and existing debt investments are repaid. Our five largest debt investments at cost and fair value represented 25% and 23% of total debt investments outstanding as of ~~March 31,~~June 30, 2023 and December 31, ~~2022.~~2022 respectively. No single debt investment at cost or fair value represented more than 10% of our total debt investments as of ~~March 31,~~June 30, 2023 and December 31, 2022.

We use an internal credit rating system which rates each debt investment on a scale of 4 to 1, with 4 being the highest credit quality rating and 3 being the rating for a standard level of risk. A rating of 2 represents an increased level of risk and, while no loss is currently anticipated for a 2‑rated debt investment, there is potential for future loss of principal. A rating of 1 represents a deteriorating credit quality and a high degree of risk of loss of principal. Our internal credit rating system is not a national credit rating system. As of ~~March 31,~~June 30, 2023 and December 31, 2022, our debt investments had a weighted average credit rating of ~~3.0 and 3.1, respectively.~~3.1. The following table shows the classification of our debt investment portfolio by credit rating as of ~~March 31,~~June 30, 2023 and December 31, 2022:

	March 31, 2023							December 31, 2022							June 30, 2023							December 31, 2022
			Debt		Percentage					Debt		Percentage					Debt		Percentage					Debt		Percentage
	Number of		Investments at		of Debt			Number of		Investments at		of Debt			Number of		Investments at		of Debt			Number of		Investments at		of Debt
	Investments		Fair Value		Investments			Investments		Fair Value		Investments			Investments		Fair Value		Investments			Investments		Fair Value		Investments
	(Dollars in thousands)														(Dollars in thousands)
Credit Rating
4		9	$	108,482		15.8	%		8	$	93,832		13.7	%		11	$	151,399		22.2	%		8	$	93,832		13.7	%
3		38		483,615		70.6			47		557,554		81.2			38		460,125		67.3			47		557,554		81.2
2		7		87,206		12.7			2		26,822		3.9			4		61,985		9.1			2		26,822		3.9
1		3		5,251		0.9			3		8,250		1.2			1		9,800		1.4			3		8,250		1.2
Total		57	$	684,554		100.0	%		60	$	686,458		100.0	%		54	$	683,309		100.0	%		60	$	686,458		100.0	%

As of ~~March 31,~~June 30, 2023, there ~~were three~~was one debt ~~investments~~investment with an internal credit rating of 1, with an aggregate cost of ~~$20.3~~$17.4 million and an aggregate fair value of ~~$5.3~~$9.8 million. As of December 31, 2022, there were three debt investments with an internal credit rating of 1, with an aggregate cost of $20.9 million and an aggregate fair value of $8.3 million.

As a BDC and a RIC, we are subject to certain constraints on our operations, including limitations imposed by the 1940 Act and the Code. The consolidated results of operations described below may not be indicative of the results we report in future periods.

The following table shows consolidated results of operations for the three months ended ~~March 31,~~June 30, 2023 and 2022:

	For the three months ended						For the three months ended
	March 31,						June 30,
	2023			2022			2023			2022
	(In thousands)						(In thousands)
Total investment income	$	28,037		$	14,204		$	28,117		$	18,588
Total expenses		14,842			8,375			11,865			9,900
Net investment income before excise tax		13,195			5,829			16,252			8,688
Provision for excise tax		184			100			179			106
Net investment income		13,011			5,729			16,073			8,582
Net realized (loss) gain		(168	)		30
Net unrealized depreciation on investments		(7,537	)		(2,237	)
Net realized loss								(16,529	)		(929	)
Net unrealized appreciation (depreciation) on investments								608			(36	)
Net increase in net assets resulting from operations	$	5,306		$	3,522		$	152		$	7,617
Average debt investments, at fair value	$	687,602		$	459,386		$	687,529		$	522,521
Average gross assets less cash	$	737,826		$	498,363		$	739,141		$	568,079
Average borrowings outstanding	$	440,695		$	267,376		$	435,402		$	324,392

Net increase in net assets resulting from operations can vary substantially from period to period for various reasons, including, without limitation, the recognition of realized gains and losses and unrealized appreciation and depreciation on investments. As a result, quarterly comparisons of net increase in net assets resulting from operations may not be meaningful.

Total investment income increased by ~~$13.8~~$9.5 million, or ~~97.4%~~51.3%, to ~~$28.0~~$28.1 million for the three months ended ~~March 31,~~June 30, 2023 as compared to the three months ended ~~March 31,~~June 30, 2022. For the three months ended ~~March 31,~~June 30, 2023, total investment income consisted primarily of ~~$27.4~~$26.6 million in interest income from investments, which included ~~$4.3~~$3.1 million in income from the accretion of origination fees and end of term payments, or ETPs, and ~~$0.6~~$1.5 million in fee income. Interest income on debt investments increased by ~~$13.5~~$8.9 million, or ~~97.8%~~50.2%, to ~~$27.4~~$26.6 million, for the three months ended ~~March 31,~~June 30, 2023 compared to the three months ended ~~March 31,~~June 30, 2022. Interest income on debt investments for the three months ended ~~March 31,~~June 30, 2023 as compared to the three months ended ~~March 31,~~June 30, 2022 increased primarily due to an increase of ~~$228.2~~$165.0 million, or ~~49.7%~~31.6%, in the average size of our debt investment portfolio and an increase in the prime rate which is the base rate for most of our variable rate debt investments. Fee income, which includes success fee, other fee and prepayment fee income on debt investments, increased by ~~$0.3~~$0.6 million, or ~~81.8%~~72.0%, to ~~$0.6~~$1.5 million for the three months ended ~~March 31,~~June 30, 2023 compared to the three months ended ~~March 31,~~June 30, 2022 primarily due to a higher ~~aggregate amount of principal~~fee income earned on prepayments for the three months ended ~~March 31, 2023.~~June 30, 2023 compared to the three months ended June 30, 2022.

The following table shows our dollar-weighted annualized yield for the three months ended ~~March 31,~~June 30, 2023 and 2022:

Investment income, consisting of interest income and fees on debt investments, can fluctuate significantly upon repayment of large debt investments. Interest income from the five largest debt investments at cost in the aggregate accounted for 23% and 22% of investment income for the three months ended June 30, 2023 and 2022, respectively. Interest income from the five largest debt investments at fair value in the aggregate accounted for 23% of investment income for the three months ended June 30, 2023 and 2022.

Total expenses increased by $2.0 million, or 19.8%, to $11.9 million for the three months ended June 30, 2023 as compared to the three months ended June 30, 2022. Total expenses for each period consisted of interest expense, base management fee, incentive and administrative fees, professional fees and general and administrative expenses.

Interest expense increased by $3.0 million, or 69.9%, to $7.2 million for the three months ended June 30, 2023 as compared to the three months ended June 30, 2022. Interest expense, which includes the amortization of debt issuance costs, increased primarily due to an increase in average borrowings of $111.0 million, or 34.2%, for the three months ended June 30, 2023 as compared to the three months ended June 30, 2022 and an increase in our effective cost of debt for the three months ended June 30, 2023 as compared to the three months ended June 30, 2022.

Base management fee expense increased by $0.7 million, or 27.1%, to $3.2 million for the three months ended June 30, 2023 as compared to the three months ended June 30, 2022. Base management fee increased primarily due to an increase of $165.0 million, or 31.6%, in average debt investments for the three months ended June 30, 2023 as compared to the three months ended June 30, 2022.

Performance based incentive fee expense decreased by $2.0 million, or 94.5%, to $0.1 million for the three months ended June 30, 2023 as compared to the three months ended June 30, 2022. This decrease was due to an Incentive Fee Cap calculated based on the Incentive Fee Cap and Deferral Mechanism in our Investment Management Agreement of $3.1 million for the three months ended June 30, 2023 compared to the three months ended June 30, 2022. The Incentive Fee Cap and Deferral Mechanism resulted in $3.1 million of reduced incentive fee expense and increased net investment income for the three months ended June 30, 2023. The incentive fee on Pre-Incentive Fee Net Investment Income was subject to the Incentive Fee Cap for the three months ended June 30, 2023 due to the cumulative incentive fees paid exceeding 20% of cumulative pre-incentive fee net return during the applicable quarter and the 11 preceding full calendar quarters.

Administrative fee expense, professional fees and general and administrative expenses were $1.4 million and $1.0 million for the three months ended June 30, 2023 and 2022, respectively.

Net realized gains and losses and net unrealized appreciation and depreciation

Realized gains or losses on investments are measured by the difference between the net proceeds from the repayment or sale and the cost basis of our investments without regard to unrealized appreciation or depreciation previously recognized. Realized gains or losses on investments include investments charged off during the period, net of recoveries. The net change in unrealized appreciation or depreciation on investments primarily reflects the change in portfolio investment fair values during the reporting period, including the reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized.

During the three months ended June 30, 2023, we realized net losses on investments totaling $16.5 million primarily due to the settlement of three of our debt investments. Such net realized losses were primarily the result of portfolio companies ceasing operations due to their inability to raise additional capital and the sale of their assets for less than the cost of their debt investments. During the three months ended June 30, 2022, we realized net losses on investments totaling $0.9 million primarily due to the settlement of one of our other investments.

During the three months ended June 30, 2023, net unrealized appreciation on investments totaled $0.6 million which was primarily due to the reversal of previously recorded unrealized depreciation from the settlement of two of our debt investments offset by (1) the unrealized depreciation on three of our debt investments and (2) the unrealized depreciation on one of our equity investments. During the three months ended June 30, 2022, net unrealized depreciation on investments totaled $0.04 million which was primarily due (1) the unrealized appreciation on our warrant investments and (2) the reversal of previously recorded unrealized depreciation from the settlement of one of our other investments partially offset by the unrealized depreciation on three of our debt investments.

The following table shows consolidated results of operations for the six months ended June 30, 2023 and 2022:

Total investment income increased by $23.4 million, or 71.2%, to $56.2 million for the six months ended June 30, 2023 as compared to the six months ended June 30, 2022. For the six months ended June 30, 2023, total investment income consisted primarily of $54.0 million in interest income from investments, which included $7.4 million in income from the accretion of origination fees and end of term payments, or ETPs, and $2.1 million in fee income. Interest income on debt investments increased by $22.5 million, or 71.1%, to $54.0 million, for the six months ended June 30, 2023 compared to the six months ended June 30, 2022. Interest income on debt investments for the six months ended June 30, 2023 as compared to the six months ended June 30, 2022 increased primarily due to an increase of $197.2 million, or 40.2%, in the average size of our debt investment portfolio and an increase in the prime rate which is the base rate for most of our variable rate debt investments. Fee income, which includes success fee, other fee and prepayment fee income on debt investments, increased by $0.9 million, or 74.8%, to $2.1 million for the six months ended June 30, 2023 compared to the six months ended June 30, 2022 primarily due to higher fee income earned on prepayments for the six months ended June 30, 2023 compared to the six months ended June 30, 2022.

The following table shows our dollar-weighted annualized yield for the six months ended June 30, 2023 and 2022:

Investment income, consisting of interest income and fees on debt investments, can fluctuate significantly upon repayment of large debt investments. Interest income from the five largest debt investments at cost and fair value in the aggregate accounted for ~~22%~~23% and ~~26%~~22% of investment income for the ~~three~~six months ended ~~March 31,~~June 30, 2023 and 2022, respectively.

Total expenses increased by ~~$6.5~~$8.4 million, or ~~77.2%~~46.1%, to ~~$14.8~~$26.7 million for the ~~three~~six months ended ~~March 31,~~June 30, 2023 as compared to the ~~three~~six months ended ~~March 31,~~June 30, 2022. Total expenses for each period consisted of interest expense, base management fee, incentive and administrative fees, professional fees and general and administrative expenses.

Interest expense increased by ~~$3.7~~$6.7 million, or ~~107.9%~~86.9%, to ~~$7.1~~$14.3 million for the ~~three~~six months ended ~~March 31,~~June 30, 2023 as compared to the ~~three~~six months ended ~~March 31,~~June 30, 2022. Interest expense, which includes the amortization of debt issuance costs, increased primarily due to an increase in average borrowings of ~~$173.3~~$141.9 million, or ~~64.8%~~47.9%, for the ~~three~~six months ended ~~March 31,~~June 30, 2023 as compared to the ~~three~~six months ended ~~March 31,~~June 30, 2022 and an increase in our effective cost of debt for the ~~three~~six months ended ~~March 31,~~June 30, 2023 as compared to the ~~three~~six months ended ~~March 31,~~June 30, 2022.

Base management fee expense increased by ~~$1.0~~$1.6 million, or ~~42.6%~~34.4%, to ~~$3.2~~$6.4 million for the ~~three~~six months ended ~~March 31,~~June 30, 2023 as compared to the ~~three~~six months ended ~~March 31,~~June 30, 2022. Base management fee increased primarily due to an increase of ~~$228.2~~$197.2 million, or ~~49.7%~~40.2%, in average debt investments for the ~~three~~six months ended ~~March 31,~~June 30, 2023 as compared to the ~~three~~six months ended ~~March 31,~~June 30, 2022.

Performance based incentive fee expense ~~increased~~decreased by ~~$1.6~~$0.5 million, or ~~109.1%~~13.3%, to ~~$3.0~~$3.1 million for the ~~three~~six months ended ~~March 31,~~June 30, 2023 as compared to the ~~three~~six months ended ~~March 31,~~June 30, 2022. This ~~increase~~decrease was due to ~~an increase of $8.8 million, or 123.5%, in Pre-Incentive Fee Net Investment Income for the three months ended March 31, 2023 compared to the three months ended March 31, 2022 offset by~~ an Incentive Fee Cap calculated based on the Incentive Fee Cap and Deferral Mechanism in our Investment Management Agreement of ~~$0.2~~$3.3 million for the ~~three~~six months ended ~~March 31,~~June 30, 2023 compared to the ~~three~~six months ended ~~March 31,~~June 30, 2022. The Incentive Fee Cap and Deferral Mechanism resulted in ~~$0.2~~$3.3 million of reduced incentive fee expense and increased net investment income for the ~~three~~six months ended ~~March 31,~~June 30, 2023. The incentive fee on Pre-Incentive Fee Net Investment Income was subject to the Incentive Fee Cap for the ~~three~~six months ended ~~March 31,~~June 30, 2023 due to the cumulative incentive fees paid exceeding 20% of cumulative pre-incentive fee net return during the applicable quarter and the 11 preceding full calendar quarters.

Administrative fee expense, professional fees and general and administrative expenses were ~~$1.5~~$2.9 million and ~~$1.3~~$2.3 million for the ~~three~~six months ended ~~March 31,~~June 30, 2023 and 2022, respectively.

Net realized gains and losses and net unrealized appreciation and depreciation

During the ~~three~~six months ended ~~March 31,~~June 30, 2023, we realized net losses on investments totaling ~~$0.2~~$16.7 million primarily due to the ~~write off~~settlement of ~~warrants in~~ three of our debt investments. Such net realized losses were primarily the result of portfolio ~~companies.~~companies ceasing operations due to their inability to raise additional capital and the sale of their assets for less than the cost of their debt investments. During the ~~three~~six months ended ~~March 31,~~June 30, 2022, we realized net ~~gains~~losses on investments totaling ~~$0.03~~$0.9 million primarily due to the ~~realized gain from the consideration we received from the exercise and sale~~settlement of ~~two~~one of our ~~warrant~~other investments.

During the ~~three~~six months ended ~~March 31,~~June 30, 2023, net unrealized depreciation on investments totaled ~~$7.5~~$6.9 million which was primarily due to (1) the unrealized depreciation on ~~five~~three of our debt investments and (2) the unrealized depreciation on one of our ~~warrant~~equity investments offset by the reversal of previously recorded unrealized depreciation from the settlement of two of our debt investments. During the ~~three~~six months ended ~~March 31,~~June 30, 2022, net unrealized depreciation on investments totaled ~~$2.2~~$2.3 million which was primarily due to the unrealized depreciation on three of our debt investments partially offset by (1) the unrealized appreciation on our warrant investments and (2) the reversal of previously recorded unrealized depreciation from the settlement of one of our other investments.

As of ~~March 31,~~June 30, 2023 and December 31, 2022, we had cash and investments in money market funds of ~~$43.5~~$50.3 million and $27.7 million, respectively. Cash and investments in money market funds are available to fund new investments, reduce borrowings, pay expenses, repurchase common stock and pay distributions. In addition, as of ~~March 31,~~June 30, 2023 and December 31, 2022, we had ~~$3.0~~$2.9 million and $2.8 million, respectively, of restricted investments in money market funds. Restricted investments in money market funds may be used to make monthly interest and principal payments on our 2019 Asset-Backed Notes, 2022 Asset-Backed Notes, or our NYL Facility. Our primary sources of capital have been from our public and private equity offerings, use of our revolving credit facility (the “Key Facility”) with KeyBank National Association (“Key”) and the Note Funding Agreement (the “NYL Facility”, together with the Key Facility, the “Credit Facilities”) with several entities owned or affiliated with New York Life Insurance Company, and issuance of our public debt ~~offerings.~~securities. In the current economic environment, such avenues for liquidity may not be available, ~~in the future,~~ or may be available on less attractive terms.

On August 2, 2021, we entered into an At-The-Market (“ATM”) sales agreement (the “2021 Equity Distribution Agreement”) with Goldman Sachs & Co. LLC and B. Riley FBR, Inc., (each a “Sales Agent” and, collectively, the “Sales Agents”). The 2021 Equity Distribution Agreement provides that we may offer and sell our shares from time to time through the Sales Agents up to $100.0 million worth of our common stock, in amounts and at times to be determined by us. Sales of our common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at-the-market,” as defined in Rule 415 under the Securities Act, including sales made directly on the NASDAQ or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices.

During the three months ended ~~March 31,~~June 30, 2023, we sold ~~605,848~~448,175 shares of common stock under the 2021 Equity Distribution Agreement. For the same period, we received total accumulated net proceeds of approximately ~~$7.2~~$5.1 million, including ~~$0.2~~$0.1 million of offering expenses, from these sales.

During the three months ended ~~March 31,~~June 30, 2022, we sold ~~250,171~~868,230 shares of common stock under the 2021 Equity Distribution Agreement. For the same period, we received total accumulated net proceeds of approximately ~~$3.9~~$10.3 million, including ~~$0.1~~$0.2 million of offering expenses, from these sales.

During the six months ended June 30, 2023, we sold 1,054,023 shares of common stock under the 2021 Equity Distribution Agreement. For the same period, we received total accumulated net proceeds of approximately $12.3 million, including $0.3 million of offering expenses, from these sales.

During the six months ended June 30, 2022, we sold 1,118,401 shares of common stock under the 2021 Equity Distribution Agreement. For the same period, we received total accumulated net proceeds of approximately $14.2 million, including $0.2 million of offering expenses, from these sales.

On March 14, 2022, we completed a follow-on public offering of 2,500,000 shares of our common stock at a public offering price of $14.35 per share, for total net proceeds to us of $34.3 million, after deducting underwriting commission and discounts and other offering expenses.

On June 2, 2023, we completed a follow-on public offering of 3,250,000 shares of our common stock at a public offering price of $12.50 per share, for total net proceeds to us of $38.9 million, after deducting underwriting commission and discounts and other offering expenses.

On April 28, 2023, our Board extended a previously authorized stock repurchase program which allows us to repurchase up to $5.0 million of our common stock at prices below our net asset value (“NAV”) per share as reported in our most recent consolidated financial statements. Under the repurchase program, we may, but are not obligated to, repurchase shares of our outstanding common stock in the open market or in privately negotiated transactions from time to time. Any repurchases by us will comply with the requirements of Rule 10b‑18 under the Exchange Act and any applicable requirements of the 1940 Act. Unless extended by our Board, the repurchase program will terminate on the earlier of June 30, 2024 or the repurchase of $5.0 million of our common stock. During the three and six months ended ~~March 31,~~June 30, 2023 and 2022, we did not make any repurchases of our common stock. From the inception of the stock repurchase program through ~~March 31,~~June 30, 2023, we repurchased 167,465 shares of our common stock at an average price of $11.22 on the open market at a total cost of $1.9 million.

At ~~March 31,~~June 30, 2023, ~~and~~there was no outstanding principal balance under our Key Facility. At December 31, 2022, the outstanding principal balance under our Key Facility was ~~$15.0 million and~~ $5.0 ~~million, respectively.~~million. As of ~~March 31,~~June 30, 2023 and December 31, 2022, we had borrowing capacity under the Key Facility of ~~$110.0~~$150.0 million and $120.0 million, respectively. At ~~March 31,~~June 30, 2023 and December 31, 2022, ~~$47.7~~$61.4 million and $40.2 million, respectively, was available, subject to existing terms and advance rates.

At ~~March 31,~~June 30, 2023 and December 31, 2022, the outstanding principal balance under the NYL Facility was $176.8 million. As of ~~March 31,~~June 30, 2023 and December 31, 2022, we had borrowing capacity under the NYL Facility of $73.2 million and $23.2 ~~million.~~million, respectively. At ~~March 31,~~June 30, 2023 and December 31, 2022, ~~$21.1~~$3.0 million and $23.2 million, respectively, was available, subject to existing terms and advance rates.

Our operating activities provided cash of ~~$12.7~~$7.2 million for the ~~three~~six months ended ~~March 31,~~June 30, 2023, and our financing activities provided cash of ~~$3.3~~$15.5 million for the same period. Our operating activities provided cash from principal payments received on our debt investments partially offset by cash used to purchase investments in portfolio companies. Our financing activities provided cash primarily from ~~advances on our Credit Facilities~~the completion of a follow-on public offering of 3.25 million shares of common stock for net proceeds of $38.9 million, after deducting underwriting commission and discounts and other offering expenses and the sale of shares through our ATM for net proceeds of ~~$7.2~~$12.3 million, partially offset by cash used to repay our 2019 Asset-Backed Notes, to repay the outstanding principal balance under our Key Facility and to pay distributions to our stockholders.

Our operating activities used cash of ~~$55.4~~$110.7 million for the ~~three~~six months ended ~~March 31,~~June 30, 2022, and our financing activities provided cash of ~~$24.1~~$141.4 million for the same period. Our operating activities used cash to purchase investments in portfolio companies partially offset by principal payments received on our debt investments. Our financing activities provided cash primarily from the issuance of the 2027 Notes (as defined below), the completion of a follow-on public offering of 2.5 million shares of common stock for net proceeds of $34.3 million, after deducting underwriting commission and discounts and other offering expenses and advances on our Credit Facilities, partially offset by cash used to repay a portion of the outstanding principal under our Key Facility, to repay our 2019 Asset-Backed Notes and to pay distributions to our stockholders.

Our primary use of available funds is to make debt investments in portfolio companies and for general corporate purposes. We expect to raise additional equity and debt capital opportunistically as needed and, subject to market conditions, to support our future growth to the extent permitted by the 1940 Act.

In order to remain subject to taxation as a RIC, we intend to distribute to our stockholders all or substantially all of our investment company taxable income. In addition, as a BDC, we are required to maintain asset coverage of at least 150%. This requirement limits the amount that we may borrow.

We believe that our current cash, cash generated from operations, and funds available from our Credit Facilities will be sufficient to meet our working capital and capital expenditure commitments for at least the next 12 months.

The following table shows our borrowings as of ~~March 31,~~June 30, 2023 and December 31, 2022:

	March 31, 2023							December 31, 2022							June 30, 2023							December 31, 2022
	Total		Balance			Unused		Total		Balance			Unused		Total		Balance			Unused		Total		Balance			Unused
	Commitment		Outstanding			Commitment		Commitment		Outstanding			Commitment		Commitment		Outstanding			Commitment		Commitment		Outstanding			Commitment
	(In thousands)														(In thousands)
Key Facility	$	125,000	$	15,000		$	110,000	$	125,000	$	5,000		$	120,000	$	150,000	$	—		$	150,000	$	125,000	$	5,000		$	120,000
NYL Facility		200,000		176,750			23,250		200,000		176,750			23,250		250,000		176,750			73,250		200,000		176,750			23,250
2019 Asset-Backed Notes		37,791		37,791			—		42,573		42,573			—		30,807		30,807			—		42,573		42,573			—
2022 Asset-Backed Notes		100,000		100,000			—		100,000		100,000			—		100,000		100,000			—		100,000		100,000			—
2027 Notes		57,500		57,500			—		57,500		57,500			—		57,500		57,500			—		57,500		57,500			—
2026 Notes		57,500		57,500			—		57,500		57,500			—		57,500		57,500			—		57,500		57,500			—
Total before debt issuance costs		577,791		444,541			133,250		582,573		439,323			143,250		645,807		422,557			223,250		582,573		439,323			143,250
Unamortized debt issuance costs attributable to term borrowings		—		(4,896	)		—		—		(5,245	)		—		—		(4,541	)		—		—		(5,245	)		—
Total borrowings outstanding, net	$	577,791	$	439,645		$	133,250	$	582,573	$	434,078		$	143,250	$	645,807	$	418,016		$	223,250	$	582,573	$	434,078		$	143,250

We entered into the Key Facility effective November 4, 2013. ~~Through June 21, 2021, the interest rate on the Key Facility was based upon the one-month LIBOR plus a spread of 3.25%, with a LIBOR floor of 1.00%. From and after June 30, 2021, the~~The interest rate on the Key Facility is based on the rate of interest published in The Wall Street Journal as the prime rate in the United States plus 0.25%, with a prime rate floor of 4.25%. The prime rate was ~~8.00%~~8.25% and 7.50% as of ~~March 31,~~June 30, 2023 and December 31, 2022, respectively. The interest rates in effect were ~~8.25%~~8.50% and 7.75% as of ~~March 31,~~June 30, 2023 and December 31, 2022, respectively. The Key Facility requires the payment of an unused line fee in an amount equal to 0.50% of any unborrowed amount available under the facility annually.

~~The Key Facility has an accordion feature which allows for an increase in the total loan commitment to $150 million.~~ On June ~~22, 2021,~~29, 2023, we amended the Key Facility to, among other things, increase the commitment amount to ~~amend the interest rate applied to the outstanding principal balance~~$150 million and to ~~extend~~increase the ~~period during~~amount of the accordion feature which ~~we may request advances under~~now allows the ~~Key Facility (or~~potential increase in the ~~“Revolving Period”),~~total commitment amount to ~~June 22, 2024.~~$300 million. The Key Facility is collateralized by debt investments held by Credit II and permits an advance rate of up to sixty percent (60%) of eligible debt investments held by Credit II. The Key Facility contains covenants that, among other things, require us to maintain a minimum net worth, to restrict the debt investments securing the Key Facility to certain criteria for qualified debt investments and to comply with portfolio company concentration limits as defined in the related loan agreement. After the ~~Revolving Period,~~period during which we may request advances under the Key Facility (or the “Revolving Period”), we may not request new advances, and we must repay the outstanding advances under the Key Facility as of such date, at such times and in such amounts as are necessary to maintain compliance with the terms and conditions of the Key Facility, particularly the condition that the principal balance of the Key Facility not exceed sixty percent (60%) of the aggregate principal balance of our eligible debt investments to our portfolio companies. The Revolving Period ends on June 22, 2024 and the maturity date of the Key Facility, the date on which all outstanding advances under the Key Facility are due and payable, is June 22, 2026.

On April 21, 2020, we purchased all of the limited liability company interests ~~of Arena~~ in HSLFI. HFI is a wholly-owned subsidiary of HSLFI. HFI entered into the NYL Facility with the NYL Noteholders for an aggregate purchase price of up to $100.0 million, with an accordion feature of up to $200.0 million at the mutual discretion and agreement of HSLFI and the NYL Noteholders. On June 1, 2018, HSLFI sold or contributed to HFI certain secured loans made to certain portfolio companies pursuant to the Sale and Servicing Agreement. Any notes issued by HFI are collateralized by all investments held by HFI and permit an advance rate of up to 67% of the aggregate principal amount of eligible debt investments.

On February 25, 2022, we amended the NYL Facility ~~increasing the commitment by $100 million~~ to, enable our wholly-owned subsidiary to issue up to $200 million of secured notes. The amendment to the NYL Facility extends the investment period to June 2023 and the maturity date to June 2028. In addition, the amendment, among other things, ~~reduces~~reduce the applicable margin used to calculate the NYL Facility’s interest rate on our borrowings above $100 million. Such borrowings ~~will be~~were priced at the three-year USD mid-market swap rate plus 3.00%.

On May 24, 2023, we amended the NYL Facility to, among other things, increase the commitment by $50.0 million to enable our wholly-owned subsidiary to issue up to $250.0 million of secured notes. The amendment to the NYL Facility extends the investment period to June 2024 and the maturity date of all advances to June 2029. In addition, the amendment amended the interest rate for advances made after May 24, 2023, fixing the interest rate at the greater of (i) 4.60% and (ii) the Three Year I-Curve plus 3.50% with the interest rate to be reset on any advance date.

Under the terms of the NYL Facility, we are required to maintain a reserve cash balance, which may be used to pay monthly interest and principal payments on the NYL Facility. We have segregated these funds and classified them as restricted investments in money market funds. At ~~March 31,~~June 30, 2023, and December 31, 2022, there were approximately $1.3 million and $1.0 million, respectively, of restricted investments.

There were $176.8 million in notes issued to the NYL Noteholders as of ~~March 31,~~June 30, 2023 and December 31, 2022 at an interest rate of 5.62% and 5.57%., respectively. As of ~~March 31,~~June 30, 2023 and December 31, 2022, we had borrowing capacity under the NYL Facility of ~~$23.2 million.~~$73.2 million and $23.3 million, respectively. At ~~March 31,~~June 30, 2023 and December 31, 2022, ~~$21.1~~$3.0 million and $23.2 million, respectively, was available for borrowing, subject to existing terms and advance rates.

On August 13, 2019, the 2019 Asset-Backed Notes were issued by the 2019‑1 Trust pursuant to a note purchase agreement, dated as of August 13, 2019, by and among us and Keybanc Capital Markets Inc. as Initial Purchaser, and are backed by a pool of loans made to certain portfolio companies of ours and secured by certain assets of those portfolio companies and are to be serviced by us. Interest on the 2019 Asset-Backed Notes will be paid, to the extent of funds available, at a fixed rate of 4.21% per annum. The 2019 Asset-Backed Notes had a two-year reinvestment period and a stated maturity of September 15, 2027. The 2019 Asset-Backed Notes were rated A+(sf) by Morningstar Credit Ratings, LLC on August 13, 2019. There has been no change in the rating since August 13, 2019.

At ~~March 31,~~June 30, 2023, and December 31, 2022, the 2019 Asset-Backed Notes had an outstanding principal balance of ~~$37.8~~$30.8 million and $42.6 million, respectively.

Under the terms of the 2019 Asset-Backed Notes, we are required to maintain a reserve cash balance, funded through proceeds from the sale of the 2019 Asset-Backed Notes, which may be used to pay monthly interest and principal payments on the 2019 Asset-Backed Notes. We have segregated these funds and classified them as restricted investments in money market funds. At ~~March 31,~~June 30, 2023, and December 31, 2022, there were approximately $0.5 million and $0.6 million, respectively, of restricted investments.

On November 9, 2022, the 2022 Asset-Backed Notes were issued by the 2022‑1 Trust pursuant to a note purchase agreement, dated as of November 9, 2022, by and among us and Keybanc Capital Markets Inc. as Initial Purchaser, and are backed by a pool of loans made to certain portfolio companies of ours and secured by certain assets of those portfolio companies and are to be serviced by us. Interest on the 2022 Asset-Backed Notes will be paid, to the extent of funds available, at a fixed rate of 7.56% per annum. The 2022 Asset-Backed Notes have a two-year reinvestment period and a stated maturity of November 15, 2030. The 2022 Asset-Backed Notes were rated A by Morningstar Credit Ratings, LLC on November 9, 2022. There has been no change in the rating since November 9, 2022.

As of ~~March 31,~~June 30, 2023 and December 31, 2022, the 2022 Asset-Backed Notes had an outstanding principal balance of $100.0 million.

Under the terms of the 2022 Asset-Backed Notes, we are required to maintain a reserve cash balance, funded through proceeds from the sale of the 2022 Asset-Backed Notes, which may be used to pay monthly interest and principal payments on the 2022 Asset-Backed Notes. We have segregated these funds and classified them as restricted investments in money market funds. At ~~March 31,~~June 30, 2023, and December 31, 2022, there were approximately $1.1 million and $1.2 million, respectively, of restricted investments.

On March 30, 2021, we issued and sold an aggregate principal amount of $57.5 million of 4.875% notes due in 2026, or the 2026 Notes. The amount of 2026 Notes issued and sold included the full exercise by the underwriters of their option to purchase $7.5 million in aggregate principal of additional notes. The 2026 Notes have a stated maturity of March 30, 2026 and may be redeemed in whole or in part at our option at any time or from time to time on or after March 30, 2023 at a redemption price of $25 per security plus accrued and unpaid interest. The 2026 Notes bear interest at a rate of 4.875% per year, payable quarterly on March 30, June 30, September 30 and December 30 of each year. The 2026 Notes are our direct unsecured obligations and (i) rank equally in right of payment with our current and future unsecured indebtedness; (ii) are senior in right of payment to any of our future indebtedness that expressly provides it is subordinated to the 2026 Notes; (iii) are effectively subordinated to all of our existing and future secured indebtedness (including indebtedness that is initially unsecured to which we subsequently grant security), to the extent of the value of the assets securing such indebtedness, and (iv) are structurally subordinated to all existing and future indebtedness and other obligations of any of our subsidiaries. As of ~~March 31,~~June 30, 2023, we were in material compliance with the terms of the 2026 Notes. The 2026 Notes are listed on the New York Stock Exchange under the symbol “HTFB”.

On June 15, 2022, we issued and sold an aggregate principal amount of $50.0 million of 6.25% notes due in 2027 and on July 11, 2022, pursuant to the underwriters’ 30 day option to purchase additional notes, we sold an additional $7.5 million of such notes ~~or collectively,~~(collectively, the ~~2027 Notes.~~“2027 Notes”). The 2027 Notes have a stated maturity of June 15, 2027 and may be redeemed in whole or in part at our option at any time or from time to time on or after June 15, 2024 at a redemption price of $25 per security plus accrued and unpaid interest. The 2027 Notes bear interest at a rate of 6.25% per year, payable quarterly on March 30, June 30, September 30 and December 30 of each year, commencing on September 30, 2022. The 2027 Notes are our direct unsecured obligations and (i) rank equally in right of payment with our current and future unsecured indebtedness; (ii) are senior in right of payment to any of our future indebtedness that expressly provides it is subordinated to the 2027 Notes; (iii) are effectively subordinated to all of our existing and future secured indebtedness (including indebtedness that is initially unsecured to which we subsequently grant security), to the extent of the value of the assets securing such indebtedness, and (iv) are structurally subordinated to all existing and future indebtedness and other obligations of any of our subsidiaries. As of ~~March 31,~~June 30, 2023, we were in material compliance with the terms of the 2027 Notes. The 2027 Notes are listed on the New York Stock Exchange under the symbol “HTFC”.

As of ~~March 31,~~June 30, 2023 and December 31, 2022, other assets were ~~$2.6~~$4.0 million and $2.8 million, respectively, which iswas primarily comprised of debt issuance costs and prepaid expenses.

The following table shows our significant contractual payment obligations and off-balance sheet arrangements as of ~~March 31,~~June 30, 2023:

	Payments due by period										Payments due by period
			Less than		1 – 3		3 – 5		After 5				Less than		1 – 3		3 – 5		After 5
	Total		1 year		Years		Years		years		Total		1 year		Years		Years		years
	(In thousands)										(In thousands)
Borrowings	$	444,541	$	35,217	$	284,192	$	125,132	$	—	$	422,557	$	42,934	$	272,457	$	107,166	$	—
Unfunded commitments		166,200		143,700		22,500		—		—		143,380		118,380		25,000		—		—
Incentive fee deferral		1,255		—		1,255		—		—		4,376		—		4,376		—		—
Total	$	611,996	$	178,917	$	307,947	$	125,132	$	—	$	570,313	$	161,314	$	301,833	$	107,166	$	—

In the normal course of business, we are party to financial instruments with off-balance sheet risk. These consist primarily of unfunded commitments to extend credit, in the form of loans, to our portfolio companies. Unfunded commitments to provide funds to portfolio companies are not reflected on our balance sheet. Our unfunded commitments may be significant from time to time. As of ~~March 31,~~June 30, 2023, we had unfunded commitments of ~~$166.2~~$143.4 million. This includes no undrawn revolver commitments. These commitments are subject to the same underwriting and ongoing portfolio maintenance requirements as are the financial instruments that we hold on our balance sheet. In addition, these commitments are often subject to financial or non-financial milestones and other conditions to borrowing that must be achieved before the commitment can be drawn. Since these commitments may expire without being drawn upon, the total commitment amount does not necessarily represent future cash requirements. We regularly monitor our unfunded commitments and anticipated refinancings, maturities and capital raising, to ensure that we have sufficient liquidity to fund unfunded commitments. As of ~~March 31,~~June 30, 2023, we reasonably believed that our assets would provide adequate financial resources to satisfy all of our unfunded commitments.

In addition to the Credit Facilities, we have certain commitments pursuant to our Investment Management Agreement entered into with our Advisor. We have agreed to pay a fee for investment advisory and management services consisting of two components (1) a base management fee equal to a percentage of the value of our gross assets less cash or cash equivalents, and (2) a two-part incentive fee. We have also entered into a contract with our Advisor to serve as our administrator. Payments under the Administration Agreement are equal to an amount based upon our allocable portion of our Advisor’s overhead in performing its obligations under the agreement, including rent, fees and other expenses inclusive of our allocable portion of the compensation of our Chief Financial Officer and Chief Compliance Officer and their respective staffs. See Note 3 to our consolidated financial statements for additional information regarding our Investment Management Agreement and our Administration Agreement.

The incentive fee on Pre-Incentive Fee Net Investment Income is subject to a fee cap and deferral mechanism which is determined based upon a look-back period of up to three years and is expensed when incurred. For this purpose, the Incentive Fee Look-back Period includes the relevant calendar quarter and the 11 preceding full calendar quarters. Each quarterly incentive fee payable on Pre-Incentive Fee Net Investment Income is subject to the Incentive Fee Cap and Deferral Mechanism. The Incentive Fee Cap is equal to (a) 20.00% of Cumulative Pre-Incentive Fee Net Return during the Incentive Fee Look-back Period less (b) cumulative incentive fees of any kind paid to our Advisor during the Incentive Fee Look-back Period. To the extent the Incentive Fee Cap is zero or a negative value in any calendar quarter, we will not pay an incentive fee on Pre-Incentive Fee Net Investment Income to our Advisor in that quarter. To the extent that the payment of incentive fees on Pre-Incentive Fee Net Investment Income is limited by the Incentive Fee Cap, the payment of such fees will be deferred and paid in subsequent calendar quarters up to three years after their date of deferment, subject to certain limitations, which are set forth in the Investment Management Agreement. During the three and six months ended ~~March 31,~~June 30, 2023, the Incentive Fee Cap and Deferral Mechanism resulted in deferral of ~~$0.2~~$3.1 million and $3.3 million, respectively, of incentive fee which may become subject to payment up to three years after the date of deferment. As of ~~March 31,~~June 30, 2023, the total amount subject to recoupment was ~~$1.3~~$4.4 million.

In order to qualify and be subject to tax as a RIC, we must meet certain source-of-income, asset diversification and annual distribution requirements. Generally, in order to qualify as a RIC, we must derive at least 90% of our gross income for each tax year from dividends, interest, payments with respect to certain securities, loans, gains from the sale or other disposition of stock, securities or foreign currencies, income derived from certain publicly traded partnerships, or other income derived with respect to our business of investing in stock or other securities. We must also meet certain asset diversification requirements at the end of each quarter of each tax year. Failure to meet these diversification requirements on the last day of a quarter may result in us having to dispose of certain investments quickly in order to prevent the loss of RIC status. Any such dispositions could be made at disadvantageous prices or times, and may cause us to incur substantial losses.

In addition, in order to be subject to tax as a RIC and to avoid the imposition of corporate-level tax on the income and gains we distribute to our stockholders in respect of any tax year, we are required under the Code to distribute as dividends to our stockholders out of assets legally available for distribution each tax year an amount generally at least equal to 90% of the sum of our net ordinary income and net short-term capital gains in excess of net long-term capital losses, if any. Additionally, in order to avoid the imposition of a U.S. federal excise tax, we are required to distribute, in respect of each calendar year, dividends to our stockholders of an amount at least equal to the sum of 98% of our calendar year net ordinary income (taking into account certain deferrals and elections); 98.2% of our capital gain net income (adjusted for certain ordinary losses) for the one year period ending on October 31 of such calendar year; and any net ordinary income and capital gain net income for preceding calendar years that were not distributed during such calendar years and on which we previously did not incur any U.S. federal income tax. If we fail to qualify as a RIC for any reason and become subject to corporate tax, the resulting corporate taxes could substantially reduce our net assets, the amount of income available for distribution and the amount of our distributions. Such a failure would have a material adverse effect on us and our stockholders. In addition, we could be required to recognize unrealized gains, incur substantial taxes and interest and make substantial distributions in order to re-qualify as a RIC. We cannot assure stockholders that they will receive any distributions.

To the extent our taxable earnings in a tax year fall below the total amount of our distributions made to stockholders in respect of such tax year, a portion of those distributions may be deemed a return of capital to our stockholders for U.S. federal income tax purposes. Thus, the source of a distribution to our stockholders may be the original capital invested by the stockholder rather than our income or gains. Stockholders should review any written disclosure accompanying a distribution payment carefully and should not assume that the source of any distribution is our ordinary income or gains.

We have adopted an “opt out” dividend reinvestment plan, or DRIP, for our common stockholders. As a result, if we declare a distribution, then stockholders’ cash distributions will be automatically reinvested in additional shares of our common stock unless a stockholder specifically “opts out” of our DRIP. If a stockholder opts out, that stockholder will receive cash distributions. Although distributions paid in the form of additional shares of our common stock will generally be subject to U.S. federal, state and local taxes, stockholders participating in our DRIP will not receive any corresponding cash distributions with which to pay any such applicable taxes. If our common stock is trading above NAV, a stockholder receiving distributions in the form of additional shares of our common stock will be treated as receiving a distribution of an amount equal to the fair market value of such shares of our common stock. We may use newly issued shares to implement the DRIP, or we may purchase shares in the open market in connection with our obligations under the DRIP.

We have entered into the Investment Management Agreement with our Advisor. Our Advisor is registered as an investment adviser under the Investment Advisers Act of 1940, as amended. Our investment activities are managed by our Advisor and supervised by our Board, the majority of whom are independent directors. Under the Investment Management Agreement, we have agreed to pay our Advisor a base management fee as well as an incentive fee. During the three months ended ~~March 31,~~June 30, 2023 and 2022, our Advisor earned ~~$6.2~~$3.3 million and ~~$3.7~~$4.7 million, respectively, pursuant to the Investment Management Agreement. During the six months ended June 30, 2023 and 2022, our Advisor earned $9.5 million and $8.3 million, respectively, pursuant to the Investment Management Agreement.

On February 22, 2023, our Advisor, Horizon Technology Finance Principals LLC f/k/a Horizon Technology Finance, LLC (“HTF Principals”), owns more than seventy percent (70%) of our Advisor. Our Chief Executive Officer, Robert D. Pomeroy Jr. and our President, Gerald A. Michaud own one hundred percent (100%) of HTF Principals. By virtue of their ownership interest in HTF Principals, Mr. Pomeroy and Mr. Michaud control our Advisor.

~~On February 22, 2023, our Advisor, HTF Principals~~ and Horizon Technology Finance Employees LLC (“HTF Employees”) entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) with MCH Holdco LLC (“MCH Holdco”), an affiliate of Monroe Capital LLC (“Monroe Capital”), and Monroe Capital Investment Holdings, L.P., an affiliate of Monroe Capital and the sole stockholder of MCH ~~Holdco,~~Holdco. On June 30, 2023, pursuant to ~~which~~the Purchase Agreement, HTF Principals and HTF Employees ~~will sell~~sold all of their membership interests in our Advisor (which constitute one hundred percent (100%) of the membership interests of our Advisor) to MCH Holdco and our Advisor ~~will become~~became a direct wholly owned subsidiary of MCH Holdco and an affiliate of Monroe ~~Capital (the “Transaction”). Subject~~Capital. Pursuant to ~~customary closing conditions,~~ the ~~Transaction is expected to close around the end of May 2023. A~~Purchase Agreement, a significant portion of the consideration payable by Monroe Capital to HTF Principals and HTF Employees ~~pursuant to the Purchase Agreement~~ is in the form of earnout payments contingent upon our performance in 2023, 2024, and 2025, aligning the incentives of our Advisor’s current officers with our stockholders.

We have also entered into the Administration Agreement with our Advisor. Under the Administration Agreement, we have agreed to reimburse our Advisor for our allocable portion of overhead and other expenses incurred by our Advisor in performing its obligations under the Administration Agreement, including rent and our allocable portion of the costs of compensation and related expenses of our Chief Financial Officer and Chief Compliance Officer and their respective staffs. In addition, pursuant to the terms of the Administration Agreement our Advisor provides us with the office facilities and administrative services necessary to conduct our day-to-day operations. During the three months ended ~~March 31,~~June 30, 2023 and 2022, our Advisor earned $0.4 million pursuant to the Administration Agreement. During the six months ended June 30, 2023 and 2022, our Advisor earned $0.8 million and $0.7 million, respectively, pursuant to the Administration Agreement.

In connection with the Purchase Agreement, HTF Principals ~~has granted us a~~sold MCH Holdco its trademark interest in “Horizon Technology Finance” subject to our non-exclusive, royalty-free license to use the name “Horizon Technology Finance.”

We believe that we derive substantial benefits from our relationship with our Advisor. Our Advisor may manage other investment vehicles, or Advisor Funds, with the same investment strategy as ~~us.~~us, which now may include investment vehicles managed by affiliates of Monroe Capital. Our Advisor may provide us an opportunity to co-invest with the Advisor Funds. Under the 1940 Act, absent receipt of exemptive relief from the SEC, we and our affiliates are precluded from co-investing in negotiated investments. On November 27, 2017, we were granted exemptive relief from the SEC which permits us to co-invest with the Advisor Funds, subject to certain conditions.

The discussion of our financial condition and results of operation is based upon our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Changes in the economic environment, financial markets and any other parameters used in determining such estimates could cause actual results to differ. In addition to the discussion below, we describe our significant accounting policies in the notes to our consolidated financial statements.

Investments are recorded at fair value. Prior to July 30, 2022, our Board determined the fair value of our investments. Pursuant to the amended SEC Rule 2a-5 of the 1940 Act, on July 29, 2022, our Board designated our Advisor as our “valuation designee.” Our Board is responsible for oversight of the valuation designee. The valuation designee has established a Valuation Committee to determine in good faith the fair value of our investments, based on input of our Advisor’s management and personnel and independent valuation firms which are engaged at the direction of the Valuation Committee to assist in the valuation of certain portfolio investments lacking a readily available market quotation at least once during a trailing twelve-month period. The Valuation Committee determines fair values pursuant to a valuation policy approved by our Board and pursuant to a consistently applied valuation process. This valuation process is conducted at the end of each fiscal quarter, with at least 25% (based on fair value) of our valuation of portfolio companies lacking readily available market quotations subject to review by an independent valuation firm. We apply fair value to substantially all of our investments in accordance with Topic 820, Fair Value Measurement, of the Financial Accounting Standards Board’s, or FASB’s, Accounting Standards Codification as amended, or ASC, which establishes a framework used to measure fair value and requires disclosures for fair value measurements. We have categorized our investments carried at fair value, based on the priority of the valuation technique, into a three-level fair value hierarchy. Fair value is a market-based measure considered from the perspective of the market participant who holds the financial instrument rather than an entity specific measure. Therefore, when market assumptions are not readily available, our own assumptions are set to reflect those that we believe market participants would use in pricing the financial instrument at the measurement date.

The availability of observable inputs can vary depending on the financial instrument and is affected by a wide variety of factors, including, for example, the type of product, whether the product is new, whether the product is traded on an active exchange or in the secondary market and the current market conditions. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. The three categories within the hierarchy are as follows:

Interest on debt investments is accrued and included in income based on contractual rates applied to principal amounts outstanding. Interest income is determined using a method that results in a level rate of return on principal amounts outstanding. Generally, when a debt investment becomes 90 days or more past due, or if we otherwise do not expect to receive interest and principal repayments, the debt investment is placed on non-accrual status and the recognition of interest income may be discontinued. Interest payments received on non-accrual debt investments may be recognized as income, on a cash basis, or applied to principal depending upon management’s judgment at the time the debt investment is placed on non-accrual status. For the three and six months ended ~~March 31,~~June 30, 2023 and 2022, we did not recognize any interest income from debt investments on non-accrual status.

We receive a variety of fees from borrowers in the ordinary course of conducting our business, including advisory fees, commitment fees, amendment fees, non-utilization fees, success fees and prepayment fees. In a limited number of cases, we may also receive a non-refundable deposit earned upon the termination of a transaction. Debt investment origination fees, net of certain direct origination costs, are deferred, and along with unearned income, are amortized as a level yield adjustment over the respective term of the debt investment. All other income is recorded into income when earned. Fees for counterparty debt investment commitments with multiple debt investments are allocated to each debt investment based upon each debt investment’s relative fair value. When a debt investment is placed on non-accrual status, the amortization of the related fees and unearned income is discontinued until the debt investment is returned to accrual status.

Certain debt investment agreements also require the borrower to make an ETP that is accrued into income over the life of the debt investment to the extent such amounts are expected to be collected. We will generally cease accruing the income if there is insufficient value to support the accrual or if we do not expect the borrower to be able to pay all principal and interest due.

In connection with substantially all lending arrangements, we receive warrants to purchase shares of stock from the borrower. We record the warrants as assets at estimated fair value on the grant date using the Black-Scholes valuation model. We consider the warrants as loan fees and record them as unearned income on the grant date. The unearned income is recognized as interest income over the contractual life of the related debt investment in accordance with our income recognition policy. Subsequent to origination, the warrants are also measured at fair value using the Black-Scholes valuation model. Any adjustment to fair value is recorded through earnings as net unrealized gain or loss on investments. Gains and losses from the disposition of the warrants or stock acquired from the exercise of warrants are recognized as realized gains and losses on investments.

Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not recoverable, are calculated using the specific identification method. We measure realized gains or losses by calculating the difference between the net proceeds from the repayment or sale and the amortized cost basis of the investment. Net change in unrealized appreciation or depreciation reflects the change in the fair values of our portfolio investments during the reporting period, including any reversal of previously recorded unrealized appreciation or depreciation, when gains or losses are realized.

We have elected to be treated as a RIC under Subchapter M of the Code and operate in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC and to avoid the imposition of corporate-level U.S. federal income tax on the amounts we distribute to our stockholders, among other things, we are required to meet certain source of income and asset diversification requirements, and we must timely distribute dividends to our stockholders out of assets legally available for distribution each tax year of an amount generally equal to at least 90% of our investment company taxable income, as defined by the Code and determined without regard to any deduction for dividends paid. We, among other things, have made and intend to continue to make the requisite distributions to our stockholders, which will generally relieve us from incurring any material liability for U.S. federal income taxes.

Depending on the level of taxable income earned in a tax year, we may choose to carry forward taxable income in excess of current year distributions into the next tax year and incur a 4% excise tax on such income, as required. To the extent that we determine that our estimated current year annual taxable income will be in excess of estimated current year distributions, we will accrue excise tax, if any, on estimated excess taxable income as taxable income is earned.

We evaluate tax positions taken in the course of preparing our tax returns to determine whether the tax positions are “more-likely-than-not” to be sustained by the applicable tax authority in accordance with ASC Topic 740, Income Taxes, as modified by ASC Topic 946, Financial Services — Investment Companies. Tax benefits of positions not deemed to meet the more-likely-than-not threshold, or uncertain tax positions, are recorded as a tax expense in the current year. It is our policy to recognize accrued interest and penalties related to uncertain tax benefits in income tax expense. We had no material uncertain tax positions at ~~March 31,~~June 30, 2023 and December 31, 2022.

~~In April~~On July 6, 2023,we ~~sold 272,303 shares of common stock under the 2021 Equity Distribution Agreement. For the same period,~~funded a $0.3 million debt investment to an existing portfolio company, Nexii Building Solutions, Inc. ("Nexii). On July 25, 2023, we ~~received total accumulated net proceeds of approximately $3.1~~funded an additional $0.3 million ~~including $0.1~~debt investment to Nexii. On July 27, 2023, we funded an additional $0.2 million ~~of offering expenses, from these sales.~~debt investment to Nexii

~~IMV~~On July 12, 2023, Evelo Biosciences, Inc. (“~~IMV”~~Evelo”) ~~(NASDAQ: IMV; TSX: IMV)~~paid down $5.0 million of the principal amount of its loans outstanding under that certain Venture Loan and Security Agreement by and among us, the other lender parties therein and Evelo, dated as of December 15, 2022, as amended (the “Loan Agreement”), ~~announced on May 1, 2023 that~~and we and Evelo converted $5.0 million of the ~~Nova Scotia Supreme Court has issued an initial order (the “Initial Order”) granting IMV and its subsidiaries protection~~principal amount of the loans outstanding under the ~~Companies’ Creditors Arrangement Act (R.S.C.~~Loan Agreement into 2,164,502 unregistered shares of Common Stock of Evelo.

On July 13, 2023, we funded a $0.8 million equity investment to an existing portfolio company, Better Place Forests Co. (“Better Place”), ~~1985, c. C-36) and IMV will seek the recognition~~converted $0.5 million of the ~~Initial Order~~principal amount of our outstanding debt investments in ~~the United States by filing a petition commencing proceedings under the Chapter 15~~Better Place into preferred stock of Better Place and converted $2.7 million of the ~~United States Bankruptcy Code.~~principal amount of our outstanding debt investments in Better Place into common stock of Better Place.

On July 18, 2023, we funded a $0.2 million debt investment to an existing portfolio company, Aerobiotix, LLC.

On July 31, 2023, we funded a $5.0 million debt investment to a new portfolio company, Tallac Therapeutics, Inc.

In June 2022, the FASB issued Accounting Standards Update No. 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, or ASU 2022-03. ASU 2022-03 clarifies the guidance when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of the security. The amendments in ASU 2022-03 are effective for public companies for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. We are currently assessing the impact of ASU 2022-03 on our consolidated financial statements.

We are subject to financial market risks, including changes in interest rates. During the periods covered by our financial statements, the interest rates on the debt investments within our portfolio were primarily at floating rates. We expect that our debt investments in the future will primarily have floating interest rates. As of ~~March 31,~~June 30, 2023 and December 31, 2022, ~~96%~~95% and 100%, respectively, of the outstanding principal amount of our debt investments bore interest at floating rates. New commitments to lend to our portfolio companies are typically based on the Prime Rate as published in The Wall Street Journal.

Based on our ~~March 31,~~June 30, 2023 consolidated statement of assets and liabilities (without adjustment for potential changes in the credit market, credit quality, size and composition of assets on the consolidated statement of assets and liabilities or other business developments that could affect net income) and the base index rates at ~~March 31,~~June 30, 2023, the following table shows the annual impact on the change in net assets resulting from operations of changes in interest rates, which assumes no changes in our investments and borrowings:

	Investment			Interest			Change in Net			Investment			Interest		Change in Net
Change in basis points	Income			Expense			Assets(1)			Income			Expense		Assets(1)
	(In thousands)									(In thousands)
Up 300 basis points	$	19,440		$	456		$	18,984		$	19,026		$	—	$	19,026
Up 200 basis points	$	13,014		$	304		$	12,710		$	12,716		$	—	$	12,716
Up 100 basis points	$	6,556		$	152		$	6,404		$	6,407		$	—	$	6,407
Down 300 basis points	$	(18,326	)	$	(456	)	$	(17,870	)	$	(17,400	)	$	—	$	(17,400	)
Down 200 basis points	$	(12,740	)	$	(304	)	$	(12,436	)	$	(12,211	)	$	—	$	(12,211	)
Down 100 basis points	$	(6,389	)	$	(152	)	$	(6,237	)	$	(6,114	)	$	—	$	(6,114	)

While our 2027 Notes, our 2026 Notes, our 2019 Asset-Backed Notes and our 2022 Asset-Backed Notes bear interest at a fixed rate, our Credit Facilities have a floating interest rate provision. The Key Facility is subject to aan interest rate floor of 0.25% per annum, based on a prime rate index which resets monthly, and the interest payable on NYL Facility is based on the ~~three year USD mid-market swap~~Three Year I Curve rate plus a margin of ~~between 3.55% and 5.15%~~3.50% with an interest rate floor ~~depending~~and resets on ~~the rating of such notes at the time of issuance.~~any advance date. Any other credit facilities into which we enter in the future may have floating interest rate provisions. We have used hedging instruments in the past to protect us against interest rate fluctuations, and we may use them in the future. Such instruments may include caps, swaps, futures, options and forward contracts. While hedging activities may insulate us against adverse changes in interest rates, they may also limit our ability to participate in the benefits of lower interest rates with respect to the investments in our portfolio with fixed interest rates. Engaging in commodity interest transactions such as swap transactions or futures contracts on our behalf may cause our Advisor to fall within the definition of “commodity pool operator” under the Commodity Exchange Act (the “CEA”), and related Commodity Futures Trading Commission (the "CFTC"), regulations. On January 31, 2020, our Advisor claimed an exclusion from the definition of the term “commodity pool operator” under the CEA and the CFTC regulations in connection with its management of us and, therefore, is not subject to CFTC registration or regulation under the CEA as a commodity pool operator with respect to its management of us.

Because we currently fund, and expect to continue to fund, our investments with borrowings, our net income is dependent upon the difference between the rate at which we borrow funds and the rate at which we invest the funds borrowed. Accordingly, there can be no assurance that a significant change in market interest rates will not have a material adverse effect on our net income. In periods of rising interest rates, our cost of funds could increase, which would reduce our net investment income.

Economic activity has continued to accelerate across sectors and regions. Nevertheless, due to global supply chain issues, geopolitical events, a rise in energy prices and strong consumer demand as economies continue to reopen, inflation is showing signs of acceleration in the U.S. and globally. Inflation is likely to continue in the near to medium-term, particularly in the U.S., with the possibility that monetary policy may tighten in response. Persistent inflationary pressures could affect our portfolio companies’ profit margins.

As of ~~March 31,~~June 30, 2023, we, including our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a‑15(e) under the Exchange Act). Based on that evaluation, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures were effective and provided reasonable assurance that information required to be disclosed in our periodic SEC filings is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. However, in evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of such possible controls and procedures.

There have been no material changes in our internal control over financial reporting (as defined in Rules 13a‑15(f) and 15d‑15(f) under the Exchange Act) during our most recently completed fiscal quarter, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

We are not currently subject to any material legal proceedings, nor, to our knowledge, are any material legal proceeding threatened against us. From time to time, we may be a party to certain legal proceedings in the ordinary course of business, including proceedings relating to the enforcement of our rights under contracts with our portfolio companies. Our business is also subject to extensive regulation, which may result in regulatory proceedings against us. While the outcome of any such future legal or regulatory proceedings cannot be predicted with certainty, we do not expect that any such future proceedings will have a material effect upon our financial condition or results of operations.

In addition to other information set forth in this quarterly report on Form 10-Q, you should carefully consider the factors set forth in “Item 1A Risk Factors” in our annual report on Form 10‑K for the year ended December 31, 2022, which could materially affect our business, financial condition and/or operating results. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially affect our business, financial condition and/or operating results. There have been no material changes during the ~~three~~six months ended ~~March 31,~~June 30, 2023 to the risk factors set forth in “Item 1A. Risk Factors” of our annual report on Form 10-K for the year ended December 31, 2022, except as set forth below.

We, our Advisor, and our portfolio companies may maintain cash balances at financial institutions that exceed federally insured limits and may otherwise be materially affected by adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties

Our cash and our Advisor’s cash is held in accounts at U.S. banking institutions that we believe are of high quality. Cash held by us, our Advisor and by our portfolio companies in non-interest-bearing and interest-bearing operating accounts may exceed the Federal Deposit Insurance Corporation (“FDIC”) insurance limits. If such banking institutions were to fail, we, our Advisor, or our portfolio companies could lose all or a portion of those amounts held in excess of such insurance limitations. In addition, actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems, which could adversely affect our, our Advisor’s and our portfolio companies’ business, financial condition, results of operations, or prospects.

Although we and our Advisor assess our and our portfolio companies’ banking relationships as we believe necessary or appropriate, our and our portfolio companies’ access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our respective current and projected future business operations could be significantly impaired by factors that affect us, our Advisor or our portfolio companies, the financial institutions with which we, our Advisor or our portfolio companies have arrangements directly, or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could involve financial institutions or financial services industry companies with which we, our Advisor or our portfolio companies have financial or business relationships, but could also include factors involving financial markets or the financial services industry generally.

In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us, our Advisor, or our portfolio companies to acquire financing on acceptable terms or at all.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Quarterly Report on Form 10‑Q to be signed on its behalf by the undersigned, thereunto duly authorized.

		Page
PART I
Item 1	Consolidated Financial Statements.	3

	Consolidated Statements of Assets and Liabilities as of ~~March 31,~~June 30, 2023 (unaudited) and December 31, 2022	3
	Consolidated Statements of Operations for the three and six months ended ~~March 31,~~June 30, 2023 and 2022 (unaudited)	4
	Consolidated Statements of Changes in Net Assets for the three and six months ended ~~March 31,~~June 30, 2023 and 2022 (unaudited)	5
	Consolidated Statements of Cash Flows for the ~~three~~six months ended ~~March 31,~~June 30, 2023 and 2022 (unaudited)	6
	Consolidated Schedules of Investments as of ~~March 31,~~June 30, 2023 (unaudited) and December 31, 2022	7
	Notes to the Consolidated Financial Statements (unaudited)	21
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	4445
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	5961
Item 4.	Controls and Procedures	6062

PART II
Item 1.	Legal Proceedings	6062
Item 1A.	Risk Factors	6062
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	6163
Item 3.	Defaults Upon Senior Securities	6163
Item 4.	Mine Safety Disclosures	6163
Item 5.	Other Information	6163
Item 6.	Exhibits	6163
	Signatures	6264
EX‑31.1
EX‑31.2
EX‑32.1
EX‑32.2

Ex-Dividend Date	*Record Date*	*Payment Date*	*Distributions Declared*
June 15, 2023	June 16, 2023	July 14, 2023	$	0.11
July 17, 2023	July 18, 2023	August 15, 2023	$	0.11
August 16, 2023	August 17, 2023	September 15, 2023	$	0.11

Ex-Dividend Date	*Record Date*	*Payment Date*	*Distributions Declared*
September 18, 2023	September 19, 2023	October 16, 2023	$	0.11
October 17, 2023	October 18, 2023	November 15, 2023	$	0.11
November 16, 2023	November 17, 2023	December 15, 2023	$	0.11

(14)	Debt investment sold to third party on July 3, 2023.
(15)	Entity is organized under the laws of Canada and has a principal place of business in Canada.

(13)	Debt investment is on non-accrual status as of December 31, 2022.
(14)	Entity is organized under the laws of Canada and has a principal place of business in Canada.

					Six months ended June 30, 2023
	*Fair value at*						*Transfers*				*Net*				*Fair value at*
Portfolio	*December 31,*				*Principal*		*in/(out) at*		*Discount*		*unrealized*		*Net realized*		*June 30,*
Company	*2022*		*Purchases*		*Payments*		*fair value*		*accretion*		*gain/(loss)*		*gain/(loss)*		*2023*
	(In thousands)
Cadrenal Therapeutics, Inc.	$	—	$	—	$	—	$	—	$	—	$	906	$	—	$	906
Total non-controlled affiliates	$	—	$	—	$	—	$	—	$	—	$	906	$	—	$	906

					*Six months ended June 30, 2022*
	*Fair value at*							*Transfers*				*Net*					*Fair value at*
Portfolio	*December 31,*				*Principal*			*in/(out) at*		*Discount*		*unrealized*		*Net realized*			*June 30,*
Company	*2021*		*Purchases*		*Payments*			*fair value*		*accretion*		*gain/(loss)*		*gain/(loss)*			*2022*
	(In thousands)
HESP LLC		—		—		(250	)		—		—		1,450		(1,200	)		—
Total controlled affiliates	$	—	$	—	$	(250	)	$	—	$	—	$	1,450	$	(1,200	)	$	—

	*Six months ended June 30, 2023*
	*Debt*			*Warrant*			*Equity*			*Other*
	*Investments*			*Investments*			*Investments*			*Investments*		*Total*
	(In thousands)
Level 3 assets, beginning of period	$	686,458		$	26,145		$	2,416		$	1,300	$	716,319
Purchase of investments		87,543			—			10			—		87,553
Warrants and equity received and classified as Level 3		—			656			89			—		745
Principal payments received on investments		(64,496	)		—			—			—		(64,496	)
Payment-in-kind interest on investments		2,154			—			—			—		2,154
Proceeds from sale of investments		(7,036	)		(1,470	)		—			—		(8,506	)
Net realized (loss) gain on investments		(17,665	)		1,146			(127	)		—		(16,646	)
Unrealized depreciation included in earnings		(2,448	)		(2,096	)		(1,118	)		—		(5,662	)
Transfer out of Level 3		—			—			(111	)		—		(111	)
Transfer out of debt investments		(3,095	)		(5	)		3,100			—		—
Other		1,894			—			—			—		1,894
Level 3 assets, end of period	$	683,309		$	24,376		$	4,259		$	1,300	$	713,244

	For the three months ended
	March 31,
Investment type:	2023			2022
Debt investments⁽¹⁾		16.3	%		12.4	%
All investments⁽¹⁾		15.5	%		11.8	%

Exhibit No.		Description
10.1		Amendment No. 4 to Sale and Servicing Agreement, dated as of May 24, 2023, by and among Horizon Funding I, LLC, the issuer, Horizon Secured Lending Fund I LLC, the originator and seller, Horizon Technology Finance Corporation, the servicer, U.S. Bank Trust Company, National Association and U.S. Bank National Association (Incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8‑K, filed on May 25, 2023).
10.2		Third Amended and Restated Note Funding Agreement, dated as of May 24, 2023, by and among Horizon Funding I, LLC, the issuer, and the Initial Purchasers (as defined therein) (Incorporated by reference to Exhibit 10.3 of the Company’s Current Report on Form 8‑K, filed on May 25, 2023).
10.3		Third Supplemental Indenture, dated as of May 24, 2023, by and among Horizon Funding I, LLC, the issuer, and U.S. Bank Trust Company, National Association (Incorporated by reference to Exhibit 10.5 of the Company’s Current Report on Form 8‑K, filed on May 25, 2023).
10.4		Underwriting Agreement, dated May 30, 2023, among Horizon Technology Finance Corporation, Horizon Technology Finance Management LLC and Morgan Stanley & Co. LLC, as representative of the several underwriters named on Schedule A thereto (Incorporated by reference to Exhibit 1.1 of the Company’s Current Report on Form 8‑K, filed on June 5, 2023).
10.5		Amendment No. 1 to Second Amended and Restated Loan and Security Agreement, dated as of June 29, 2023, by and among Horizon Credit II LLC, as borrower, the lenders that are signatories thereto, and KeyBank National Association, as arranger and agent for the lenders (Incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8‑K, filed on June 30, 2023).
10.6		Amendment No. 1 to Second Amended and Restated Sale and Servicing Agreement, dated as of June 29, 2023, by and among Horizon Credit II LLC, as buyer, the Company, as originator and servicer, Horizon Technology Finance Management LLC, as sub-servicer, U.S. Bank National Association, as collateral custodian and backup servicer, and KeyBank National Association, as agent for the lenders (Incorporated by reference to Exhibit 10.4 of the Company’s Current Report on Form 8‑K, filed on June 30, 2023).
10.7		Investment Management Agreement, effective as of June 30, 2023, by and between Horizon Technology Finance Corporation and Horizon Technology Finance Management LLC (Incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8‑K, filed on July 5, 2023).
31.1*		Certifications by Chief Executive Officer pursuant to Exchange Act Rule 13a‑14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as amended
31.2*		Certifications by Chief Financial Officer pursuant to Exchange Act Rule 13a‑14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as amended
32.1*		Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, as amended
32.2*		Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, as amended
101.INS		Inline XBRL Instance Document (the Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

	HORIZON TECHNOLOGY FINANCE CORPORATION

Date: ~~May 2,~~August 1, 2023	By:	/s/ Robert D. Pomeroy, Jr.
	Name:	Robert D. Pomeroy, Jr.
	Title:	Chief Executive Officer and Chairman of the Board

Date: ~~May 2,~~August 1, 2023	By:	/s/ Daniel R. Trolio
	Name:	Daniel R. Trolio
	Title:	Chief Financial Officer